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 1. Abstract 
1.1. Zusammenfassung 
 
Das FK506-bindende Protein (FKBP51) wurde als Risikofaktor für diverse psychiatrische Erkrankungen 
wie bespielsweise Depression und andere Erkrankungen wie Fettleibigkeit und chronischem Schmerz 
identifiziert. FKBP51 ist enzymatisch aktiv, seine FK1-Domäne ist eine Prolyl-peptidyl-isomerase. 
FK506, ein natürlicher und immunsuppressiver Ligand, bindet an diese Tasche. Mittlerweile wurden 
verschiedene neue Klassen an FKBP51-Liganden entwickelt. Diese Moleküle sind nicht mehr 
immunsuppressiv, besitzen eine höhere Affinität zu FKBP51 und sind teilweise selektiv gegenüber 
anderen FKBPs. Der „Selective Antagonist of FKBP51 by Induced Fit 1“ (SAFit1) ist hochselektiv für 
FKBP51 gegenüber seinem engen Homolog und in Teilen funktionellem Gegenspieler FKBP52. 
Liganden mit SAFit-Struktur wirken dem Effekt von FKBP51 entgegen, die Ausdifferenzierung 
neuronaler Zellen zu inhibieren. Außerdem zeigen sie diverse Effekte in verschiedenen Mausmodellen. 
Mäuse, die mit SAFit2 behandelt werden, passen sich besser an Stress an, bleiben schlanker bei 
fetthaltiger Ernährung und weisen abgeschwächte Symptome bei chronischem Schmerz auf. Die am 
besten beschriebene Aktivität auf molekularer und zellulärer Ebene von FKBP51 wird mit dem 
Glucocorticoid Rezeptor (GR) assoziiiert. Dieser ist ein zentraler Regulator der Reizweiterleitung bei 
Stress. Mutationen im fkbp5-Gen wurden mit erhöhter FKBP51-Expression und Glucocorticoidresistenz 
assoziiert. Neben dem GR wurden noch viele weitere Proteine als FKBP51-Interaktoren beschrieben, 
u.a. innerhalb des NF-κB und Akt-Signalweges. Obwohl FKBP51 ein attraktives Drugtarget von stetig 
steigendem Interesse ist, sind die zugrundeliegenden molekularen und zellulären Funktion von 
FKBP51-Liganden und des Proteins selbst kaum aufgeklärt. Diese Dissertation trägt dazu bei, die Kluft 
zwischen Molekularbiologie und klinischen Befunden zu schließen. In einem ersten Ansatz wird die 
Erforschung einer neuen Klasse von FKBP51-Liganden, entwickelt von Tianqi Mao in der Arbeitsgruppe 
Hausch, beschrieben. Diese FKBP51-PROTACs (proteolysis targeting chimeras) sollen einen 
chemischen Knockdown ihres Targets bewirken. Die PROTACs wurden gescreent. Eine 
vielversprechende Struktur, die die Menge an zellulär endogenem FKBP51 heruntersetzt, wurde mittels 
Western Blotting identifiziert. Dieser Befund wurde sowohl durch die reduzierte Aktivität eines FKBP51-
Luciferase-Konstrukts als auch durch die PROTAC-Wirkung in einem GR Reportergenassay bestätigt. 
Dieser Assay bestätigt zudem das Modell, dass FKBP51 den GR-Signalweg inhibiert und FKBP52 dem 
entgegenwirkt. Dennoch zeigten in diesem Assay konventionelle Liganden keinen Effekt. In einem 
zweiten Ansatz wurde die Interaktion von FKBPs und dem E3-Ligaseregulator Glomulin detailiert 
untersucht. FKBP12.6 wurde als neuer Bindepartner mittels HTRF-Methodik (Homogeneous Time 
Resolved Fluorescence) identifiziert. Dies ist der erste in-vitro-Assay, der die Bindung von FKBP51 an 
andere Proteine auf molekularbiologischer Ebene untersucht. Die Aminosäuren F67 und D68 sind 
essentiel, damit Glomulin an die FK1 Domäne von FKBP51 binden kann. Letztendlich beschreibt die 
Glomulin-FKBP51-Interaktion den allerersten Proteinkomplex, der sensitiv für verschiedene Klassen 
 von FKBP51 Liganden ist. Zusammenfassend deuten meine Ergebnisse darauf hin, dass FKBP51 zwei 
grundverschiedene Wirkungsweisen aufzeigt. Einer ist sensitiv für Liganden und abhängig von einer 
intakten PPIase-Domäne und der andere nicht. Diese Arbeit weist damit auf die Wichtigkeit der 
Erforschung definierter FKBP51-Protein-Interaktionen hin und unterstreicht das Ziel, Liganden zu 
entwickeln, die beide Wirkungsweisen von FKBP51 beeinflussen. 
 
 
 
 1.2. Abstract 
 
The FK506 Binding Protein 51 (FKBP51) is an identified risk factor for a variety of psychiatric disorders 
such as major depressive disorder as well as obesity and chronic pain. Enzymatically, FKBP51 exhibits 
prolyl-peptidyl-isomerase activity located within a pocket in its FK1 domain. The natural ligand and 
immunosuppressive drug FK506 binds to this pocket. Nowadays, several new classes of FKBP51 
ligands have been developed. These compounds that lack the immunosuppressive feature, show 
higher affinity for FKBP51 and partial selectivity towards other FKBP family members. The Selective 
Antagonist of FKBP51 by Induced Fit 1 (SAFit1) is highly selective for FKBP51 compared to FKBP52, 
a close homolog and partial functional counterplayer of FKBP51. Ligands of the SAFit class have been 
shown to reverse FKBP51 induced inhibition of neurite development of neuronal cells and are active in 
various mouse models. Mice treated with SAFit2 have an improved stress coping behavior, remain 
leaner during a high-fat diet and show decreased symptoms in a chronic pain state. The best described 
molecular and cellular activity of FKBP51 is linked to the Glucocorticoid Receptor (GR), a key player in 
the stress signaling cascade. Mutations of the fkbp5 gene were linked to increased FKBP51 levels and 
glucocorticoid resistance. Beside the GR, FKBP51 has been described as the interactor of many other 
proteins e.g. within the NF-κB and Akt signaling pathway. Although FKBP51 is an attractive drug target 
of continuous rising interest, the underlying molecular and cellular functions of FKBP51 ligands and the 
protein itself remain to be elucidated. This thesis contributes in closing the gap between molecular 
biology and clinical findings regarding FKBP51 and its ligands. The first approach was the investigation 
of a new class of FKBP51 ligands developed by Tianqi Mao in the Hausch lab. These FKBP51 
PROTACs (proteolysis targeting chimeras) aim to chemically knock down their target. These PROTACs 
were screened and a promising structure was identified, which resulted in decreased endogenous 
FKBP51 levels in cells detected through Western blotting. This finding was confirmed by a decreased 
FKBP51-Luciferase fusion protein signal and the PROTACs action in a GR reporter gene assay. The 
later assay supports the model of FKBP51 inhibiting and FKBP52 enhancing GR signaling. However, 
conventional ligands did not impact the FKBP51 effect. The second approach elucidated the interaction 
of FKBPs and the E3 ligase regulator Glomulin (Glmn) in detail. FKBP12.6 has been identified as novel 
interactor of this protein utilizing the HTRF (Homogeneous Time Resolved Fluorescence) methology. 
This is the first in-vitro assay, which addresses the binding of FKBP51 and a protein interactor on the 
molecular biological level. The amino acids F67 and D68 have been identified to be essential to 
establish the binding of Glmn to FKBP51s FK1 domain. At last, the FKBP51-Glmn complex is the first 
discovered interaction that is sensitive to multiple classes of FKBP51 ligands. In conclusion, my findings 
indicate two distinct modes of action of FKBP51. One is ligand-dependent and PPIase-domain-
dependent while the other is independent. My thesis points out the importance to increase the focus on 
the investigation on defined FKBP51 interactions and to raise the efforts to develop FKBP51 ligands 
that address both FKBP51 action modi. 
  
2. Introduction 
 
2.1. FK506 Binding Proteins 
FK506 binding proteins are clustered according to their ability to bind the immunosuppressive natural 
ligand FK506 and therefore, belong to the family of immunophilins along with cyclosporin-binding 
cyclophilins. Many members of both families are enzymatically active, exhibiting prolyl-peptidyl-
isomerase activity. The structures of FKBPs are versatile, but all members have at least one FK domain, 
a typical fold of five β-sheets palming an α-helix. The smallest family member, the archetypical FKBP12, 
comprises solely just this very domain.  The FKBP motif can be found in all kingdoms of life, 
FKBP51 itself is present in all mammals (as investigated thus far). Cellular functions and distribution of 
human FKBPs are various: FKBPs 12, 12.6, 51 and 52 can be localized in the cytoplasm; FKBP13 and 
65 can be found in the endoplasm and FKBP25 in the nucleus. This already points out the multitude of 
molecular processes involved: FKBP51 and 52 serve as cochaperones of Hsp90 and and modulate 
steroid receptor signaling (2.5.2), FKBP65 is involved in collagen folding [1] and calcium channels of 
the TRPC family are regulated by FKBP12 and 12.6 [2], just to name a few. 
 
2.2. FKBP51 – a disease relevant protein 
 
FKBP51 is a known interactor of the glucocorticoid receptor, a steroid hormone receptor and central 
player in stress procession and final attenuation of the hormonal stress reaction (see 2.5.2). It gained 
significant importance, as the correlation between single nucleotide polymorphisms (SNPs) and the 
recurrence of depressive episodes and rapid response to antidepressant treatment of major depressive 
disorder was discovered [3]. Some of those SNPs have been linked to altered methylation and 
expression patters of the fkbp5 gene [4], with an increasing number of associated psychiatric disorders 
[4-6]. There is indeed fundamental proof of the involvement of FKBP51 for the neuroendocrinology of 
stress and stress coping behavior in mice [7-11].  
The genetics of FKBP51 is furthermore reported to be associated with insulin resistance and 
energy metabolism [12,13] as well as trauma related chronic pain [14,15]. On the one hand, data 
obtained from fkbp5 -/- mice is widely supporting genetic findings and detrimental effects of this knockout 
have not been observed thus far [10]. On the other hand, a row of phenomenological benefits can be 
found: improved sleep profile [16], resistance towards diet induced obesity [17,18], resistance against 
artificially induced chronic pain [19,20] and resistance against glucocorticoid induced skin atrophy [21]. 
Treatment of wild type mice with SAFit2 (Selective Antagonist of FKBP51 by induced fit) enhanced 
feedback inhibition of the hypothalamus-pituitary-adrenal axis [22], various behavioral stress coping 
mechanism [22,23] and glucose tolerance [18]. It acted anxiolytic [23,24], protected from weight gain 
 [18] and positively dampened mechanical hypersensitivity in inflammatory, neuropathic and 
chemotherapy-induced pain states [19,20].  
Taken together, within the last 15 years FKBP51 emerged as an interesting and promising drug target. 
 
2.3. Structure of FKBP51 ligand development  
FKBP51 contains three domains: The N-terminal FK1 domain, the central FK2 domain and its C-
terminal tetratricopeptide repeat (TPR) domain, which serves as attachment site for Hsp90s MEEDV 
motif (Figure 1) [25]. The FK1 domain displays prolyl-peptidyl-isomerase (PPIase) activity and is 
capable of binding ligands, such as the name-giving FK506 (Ki = 100 ±10 nM) and the second natural 
compound, Rapamycin (Ki = 3.7 ±0.9 nM) [26]. It comprises five antiparallel β strands, which are 
wrapped around a central α helix. Although the FK2 domain exhibits a similar structure to the FK1 
domain, it is thought to neither be enzymatically active nor capable of ligand binding. The PPIase 
deficiency was justified by its structure [27]. The FK2 domain of FKBP52 was also found deficient 
[28,29]. The inability to bind ligand was thus far just shown for FKBP52s FK2 domain [30], where FK506 
could be detected in the binding pocket of the FK1 but not the FK2 domain (PDB-ID: 1LAX). 
 
  
Figure 1 Full length FKBP51 (PDB-ID: 1KT0) [27] bound to the MEEDV motif derived from the Hsp90 C-terminus (PDB-ID: 
5NJX) [31]. FK506 bound to the FK1 domain is superimposed from PDB-ID: 3O5R. Figure taken from [25]. 
FKBP51 shares 60% sequence identity and 78% similarity with its homologue FKBP52. Their overall 
structure is similar, but the relative orientation of FK1 and FK2 domain is twisted [32]. This could be a 
potential explanation for their differing effects on the glucocorticoid receptor [33,34] and non-identical 
interactomes. BioGRID.com (May 2019) lists 20 confirmed (≥ 2 independent methods and/or 
publications) interactors for FKBP52 and 69 for FKBP51.  
Most important for binding of small molecules such as FK506 are the H-bond donors tyrosine 
113 and isoleucine 87 within the FK1 domain [35,36]. Great efforts of ligand development were spent 
towards the development of selective ligands. Due to a highly conserved binding pocket shared with its 
close homologue FKBP52 ligands often exhibit similar binding affinities. Selectivity is important to 
achieve, since FKBP51 and FKBP52 act antagonistically in steroid hormone receptor signaling (see 
2.5.2) and neuritotrophic differentiation [22,37]. Additionally, FKBP52 knockout mice display a strongly 
impaired phenotype regarding their reproductive tissue development and fertility [38], making it an 
 antitarget. Gaali and Kirschner overcame this obstacle by serendipity in their discovery of SAFit 
(Selective Antagonist of FKBP51) class ligands [22]. 
 
Figure 2 FK1 domain bound to the selective ligand iFit4 (PDB-ID: 4TB7). The Phe67-in state is superimposed from PDB-
ID: 5OBK. Taken from [25]. 
The selectivity is achieved either by induced fit [22] or conformational selection [39][Jagtap et al. Angew 
Chem, 2019, in press] of a Phe67 out state, which is sterically possible for FKBP51 but not FKBP52 
(Figure 2 FK1 domain bound to the selective ligand iFit4 (PDB-ID: 4TB7). The Phe67-in state is 
superimposed from PDB-ID: 5OBK. Taken from [25]. The best binding was achieved by SAFit1, which 
binds to FKBP51 with Ki = 4 nM and 10,000 fold stronger than to FKBP52. Yet another class of FKBP 
ligands are [4.3.1]-aza-bicyclic sulfonamides, which are unable to discriminates between FKBP51 and 
FKBP52. However, their affinity reach high picomolar range for FKBP12 and low nanomolar range for 
FKBP51 and FKBP52, serving as more powerful tools for in vitro assays [40,41]. An overview on those 
ligands is given in Figure 3. 
  
Figure 3 FKBP ligands: The natural compounds FK506 and Rapamycin, SAFit series structure and [4.3.1]-aza-bicyclic 
sulfonamides, adapted from [42]. 
 
2.4. PROTACs 
 
The development of PROteolysis-TArgeting Chimeras (PROTACs) is a recently emerging concept of 
ligand development in order to achieve chemical knockdown of a target protein, which has yet to prove 
its applicability in drug development. The basic concept of PROTACs is the heterobifunctional 
connection of a target ligand (warhead) and an E3 ligase ligand connected via a linker (Figure 4 A).  
 
 
Figure 4 A) Action principle of PROTACs: By bringing target and E3 ligase into close proximity, polyubiquitination on the target 
followed by proteosomal degradation can be achieved. B) Overview on the limitations of conventional small molecular 
inhibitors. Inspired by [43]. 
 The PROTAC principle was firstly developed in 2001 targeting peptidases by linking a phosphopeptide 
moiety and a small molecule moiety binding TrCP leading to the ubiquitination and degradation of the 
peptidase MetAP-2 [44]. In 2008 the first non-peptide based, cell permeable PROTAC consisting of a 
non-steroidal androgen receptor ligand and nutlin, a ligand of the E3 ligase MDM2, successfully 
knocked down its target in HeLa cells [45]. Within the last years the E3 ligases Von-Hippel-Lindau (VHL) 
and cereblon (CRBN) [43] became most common to exploit. Example ligands, also used in our research, 
of both E3 ligases are (S,R,S)-AHPC or VH032 for VHL [46] and pomalidomide for CRBN [47], 
respectively.  
PROTACs have been shown to overcome certain limitations conventional ligands face (Figure 
4 B) in vitro. Since PROTACs can exhibit their catalytic function for the degradation of multiple targets, 
their potential efficacy can be exhibited sub-stoichiometrically [43,47,48]. On top of that, it was shown 
that some PROTACs have lower half-maximal values for target degradation (DC50) than the half-
maximal inhibitory effect of their corresponding target ligand moiety (IC50) [49,50]. A prominent readout 
in this field of research is the induction of apoptosis, due to the fact, that many cancers are caused by 
overexpression of certain factors. The inhibition of apoptosis via the bromodomain extraterminal protein 
(BETP) was with 16 nM for the PROTAC ARV-825 significantly higher than for the conventional inhibitor 
OTX015 with 398 nM [51]. Excitingly, the same study observed target overexpression induced by 
OTX015 treatment in Mino cells, which is a common escape mechanism of many cancer cell lines, 
which did not occur during PROTAC exposition. It was shown, that PROTACs can have both a quick 
onset (1 h) and long lasting effect up to 48 h, which could be even achieved by a single injection in a 
mouse xenograft model [52]. By developing conventional small molecules, drug discovery faces its 
limitations concerning certain proteins, which either lack an active site or contain an active site, which 
has no impact on its related pathology. Similar difficulties are encountered for multi-domain protein 
complexes, which serve as scaffolding platform for example in signal transduction, such as receptor 
tyrosine kinases (RTKs). In a recent case study, a PROTAC targeting the RTK epidermal growth factor 
receptor (EGFR), was introduced, which led to a more robust and rapid downstream inhibition and anti-
proliferative effect compared to the classical inhibitor [53]. Additionally, it was found that PROTACs can 
feature altered selectivity patterns [54,55], which is especially interesting in order to hit protein families 
with highly conserved binding pockets, such as kinases or FKBPs. It was even shown that PROTACs 
can have an improved efficacy against mutated targets [50], which is prominent escape mechanism in 
many cancers. 
The successful development of PROTACs usually requires an empirical approach and the 
synthesis of a small library to achieve the desired chemical-induced protein degradation. For the 
conception of PROTACs, one needs to address the following attributes: designated E3 ligase, 
constitution of the linker (length and chemical nature), chemical nature of warhead, attachment point of 
linker at the warhead (examples: [49,56,57]). Especially the nature and length of the linker is not 
predictable, as the only available crystal structure of the artificial ternary complex, finds it folded in 
 between target and E3 ligase (Figure 5)[46]. This indicates a potentially essential enhancement of a 
stable and cooperative complex by the linker, rather than a simple distance definition.  
 
Figure 5 Ternary structure of human VHL (blue), Brd4 (pink) and the PROTAC MZ1 (green). Linker describes a turn 
between both binding moieties. PDB: 5T35 
It has to be noted, that high throughput screening assays for PROTACs, especially with respect to 
concentration dependence and time course of the degradation, are hardly available so far, but first 
steps have been made by genetically labeling the protein of interest with a luciferase fragment tag [58]. 
Taken together, PROTACs are a promising concept of drug development. Besides conventional 
small molecules and monoclonal antibodies, PROTACs exhibit an often unpredictable difference 
regarding selectivity, efficacy and applicability compared to its small molecule warhead. Although they 
are proven to be powerful tools in molecular and cellular biology, clinical administration is in its earliest 
stage of development. Just recently, the first phase I study started by Arvinas to test in vivo degradation 
of the androgen receptor by their substance ARV-110 in stage 4 prostate cancer patients [59]. Due to 
the fact, that FKBP51 related pathologies are connected to elevated expression levels [3], the model of 
FKBP51 as scaffolding protein and a number of FKBP51 interactions, that have been found to be ligand 
insensitive [25], the research of FKBP51 PROTACs is promising to elucidate the biological role of this 
protein. 
 
2.5. Interactome of FKBP511 
 
FKBP51 has a rather vast interactome with more than 60 associated proteins reported (Figure 6). Many 
of the proposed interactors have been discovered through CoIP experiments and sometimes lack 
independent confirmation. Because FKBP51 binds to Hsp90, it is naturally part of large protein 
                                               
1 This content is taken from my review with slight changes “The Many Faces of FKBP51” 25. Hahle, A.; Merz, S.; Meyners, C.; 
Hausch, F. The Many Faces of FKBP51. Biomolecules 2019, 9, doi:10.3390/biom9010035. 
 complexes for example steroid hormone receptors [60]. Therefore, FKBP51 can be considered to be 
rather “sticky” and claims of interactors should be evaluated with caution. 
 
Figure 6 Overview of known FKBP51 interactors within their respective field of discovery. Stronger arrows indicate a 
larger data set of this specific interaction. Taken from [25]. 
2.5.1. Hsp90 
The heat shock protein 90 (Hsp90) is a highly abundant and ubiquitously expressed chaperone in 
most mammalian cells. It is a central player in protein folding, stabilization, mediator of protein complex 
formation and involved in protein degradation, with hundreds of client proteins and therefore involved 
in a plethora of cellular pathways and processes [61]. In early studies on steroid hormone receptors, 
FKBP51 and 52 (“p50/p54”) were successfully co-purified along with Hsp90 and the progesterone 
receptor [62] and later on identified as immunophilins of the FKBP family [63]. FKBP51 and Hsp90 
interact via their respective C-terminal domains. The FKBP51 TPR-domain binds the highly conserved 
MEEDV motif of Hsp90 [34]. The Hsp90 complex can be dissociated by the selective Hsp90 inhibitor 
Geldanamycin, which also interrupts the attachment of immunophilins to the complex [64]. 
About nine TPR domain-containing proteins have been identified and confirmed to bind to Hsp90, 
such as the Hsp70-Hsp90 Organizing Protein (HOP), the serine/threonine protein phosphates 5 (PP5) 
and the E3 ubiquitin ligase CHIP (C terminus of HSC70-Interacting Protein), which is explicitly reviewed 
 [61,65,66]. All of them share a 20 amino acid consensus sequence, which is required for Hsp90 
recognition [67,68]. Cochaperones are thought to compete for Hsp90 association which was shown to 
be important for the regulation of steroid receptor signaling [69]. The differences in binding affinity and 
concentration of various TPR-domain proteins [28] reflects one layer to regulate the action of FKBP51 
[60]. The dynamic association and dissociation of cochaperones, including PPIases, have been shown 
to be essential for the progression and fine-tuning of the conformational cycle of Hsp90 [61,70]. While 
it is clear that FKBP51 can associate with Hsp90, the involvement of Hsp90 as mediating factor in the 
action of FKBP51 within many pathways is often unclear.  
 
2.5.2. Steroid Hormone Receptors 
Both discovery and research motivation to study FKBP51 and other TPR-domain proteins is tightly 
connected to the investigation of steroid hormone receptors (SHR). The members of the SHR family 
are the Androgen Receptor (AR), the Estrogen Receptor (ER), the Mineralcorticoid Receptor (MR), the 
Progesterone Receptor (PR) and the Glucocorticoid Receptor (GR). SHRs are located in the cytosol 
and translocate into the nucleus upon hormone binding serving as transcription factors. Most SHR are 
clients of the Hsp90 chaperone machinery, which is essential for receptor maturation, hormone binding 
and translocation to the nucleus [71]. In a comprehensive study, Schülke et al. performed reporter gene 
assays and co-immunoprecipitations to investigate the impact of TPR proteins on SHRs [69]. GR and 
PR were shown to be most sensitive towards the presence of TPR proteins, including FKBP51, while 
AR was only mildly affected and MR and ER were found to be largely unresponsive to TPR proteins. 
Both FKBP51 and its PPIase-deficient mutant (FD67/68DV) are preferentially associated with PR and 
GR [72]. The fkbp5 gene itself is inducible by glucocorticoids [73-76], progesterone [75,77-79] and 
androgenic hormones [80-82] leading to both elevated mRNA and protein levels. The fkbp5 gene 
contains several glucocorticoid receptor response elements and GR attachment mediates PolII loading 
and DNA methylation [83]. Soon it became clear, that FKBP51 and especially the glucocorticoid 
receptor constitute an ultrashort negative feedback loop: Induced by steroid hormone receptors, 
elevated expression of FKBP51 reduces the transcriptional activity of those receptors. It was first shown 
in yeast, that FKBP51 blocks the FKBP52-induced potentiation of the GR [84]. In mammalian cells, 
FKBP51 reduces GR reporter activity, which was connected in part to a reduced dynein binding of the 
receptor-chaperone-complex and henceforth a dampened translocation rate of the GR into the nucleus 
[33]. The PPIase activity seems not to be required for this mode of action since the FD67/68DV mutant, 
that has no PPIase activity on peptide substrates, retains GR inhibitory activity. However, amino acid 
119 was found to be important in the different activity of FKBP51 and FKBP52. Pro119 as in FKBP52 
supported receptor activation whereas L119 as in FKBP51 displayed an inhibitory effect [85]. Mass 
spectrometry studies reveal similar complexes of GR/Hsp90/Hsp70/ATP with FKBP51 and FKBP52 as 
interchangeable factors in the early stages of complex formation. In those complexes, FKBP51 
 stabilizes the binding of the cochaperone p23, while FKBP52 leads to a release of p23, which primes 
the complex for nuclear translocation [86]. 
There might be other forms of GR and FKBP51 crosstalk. One study found that FKBP51 expression 
leads to GR subform α-mediated adipogenesis [87]. Regulation by posttranslational modification has 
also been described for FKBP51. The attachment of SUMO at lysine 422, which was shown in vitro, 
was claimed to be important for GR inhibition in a reporter gene readout in hippocampal neuronal cells 
[88]. Recently, benztropine was claimed to diminish the inhibitory effect of FKBP51 on GR, but the 
molecular mechanism of this remains to be elucidated [89]. GR itself is part of the hypothalamic pituitary 
adrenal (HPA) axis, which is the neuroendocrine stress response. Upon an external stimulus, the 
hypothalamus releases the corticotropin-releasing factor (CRF). Upon binding of CRF to CRF receptors 
on the anterior pituitary gland, adrenocorticotropic hormone (ACTH) is secreted. ACTH itself is 
perceived by the adrenal cortex and stimulates the release of cortisol. Cortisol finally activates the GR, 
which coordinates the final step of stress response and exerts a negative feedback on CRF and ACTH 
release, leading back to systemic homeostasis in the magnitude of hours. Several factors, such as 
repeating and continuous stress, certain drugs and age influence the sensitivity towards cortisol. Many 
patients suffering from major depressive disorder exhibit “cortisol resistance”, being unable to regain 
homeostasis (for recent reviews see [90-92]). Since FKBP51 is a negative regulator of the GR, its 
impact on various psychiatric disorders is mainly theorized to be GR-mediated.  
AR has largely been investigated in prostate cancer models. Contrary to GR, where FKBP51 has 
repeatedly been described as an inhibitory factor, two studies in 2010 reported an activation of AR by 
FKBP51 [93,94]. However, since those initial studies, no further confirmation of these findings has been 
published and the role of FKBP51 in prostate cancer biology remains controversial. The involvement of 
FKBP51 in steroid hormone signaling leads to numerous associations in physiological and pathological 
pathways involving a fine-tuned and cross-regulated interactome, intensively studied and reviewed [95]. 
 
2.5.3. Akt and NF κB 
 
Besides steroid hormone signaling, FKBP51 is described as actor in the important pathways of Akt and 
NF κB.  
The kinase Akt serves as a central node to regulate various signaling pathways in growth and 
proliferation. Akt activity strongly depends on the phosphorylation of its Serine 473, which is thought to 
be regulated by the PH domain and Leucine rich repeat Protein Phosphatases (PHLPP). FKBP51 is 
believed to serve as a scaffolding protein that recruits PHLPP to Akt to facilitate dephosphorylation 
[96,97]. In support for this model, overexpression of FKBP51 was shown to reduce phosphorylation of 
both Akt S473 [8,96-98] and the Akt downstream targets GSK3β and FOXO1. Conversely, FKBP51 
knockdown or knockout led to an enhanced S473 phosphorylation of Akt. Truncation studies suggest 
that the FK1 domain of FKBP51 is mainly required to recruit Akt [99] and the TPR domain to recruit 
 PHLPP [96]. Further investigations revealed that the FK1 domain alone can bind Akt, as well as their 
respective PPIase mutants without being impacted by the presence of FKBP ligands [18,99], suggesting 
a competitive binding model for several FKBPs towards Akt. Not all studies could confirm the impact of 
FKBP51 overexpression on Akt [99]. Another study found that FKBP51 overexpression enhanced 
GSK3β phosphorylation in HEK293 cells, which is counterintuitive to the suggested role FKBP51 on 
Akt/PHLPP [100]. In the context of Akt regulation, the ubiquitin specific peptidase 49 (USP49) could be 
co-purified with FKBP51. This deubiquitinase was claimed to stabilize FKBP51 and to enhance the 
dephosphorylation of Akt via PHLPP [97]. Moreover, the Akt-FKBP51-interaction was recently 
suggested to be regulated by acetylation of FKBP51 [98]. Six acetylation sites were reported, of which 
two are regulated by the deacetylase Sirtuin 7 (SIRT7). Acetylation on the sites K28 and K155 were 
proposed to enhance FKBP51-Akt interaction, S473 dephosphorylation of Akt reduced phosphorylation 
of Akt downstream targets such as GSK3β. In 2017, the Akt substrate 160 (AS160) was 
coimmunoprecipitated along with FKBP51, Akt and PHLPP [18]. Its phosphorylation status could be 
disrupted by the selective FKBP51 ligand SAFit2, both in vitro and in vivo.  
On the other hand, FKBP51 was also described as a regulator of NF-κB (nuclear factor binding 
near the κ light-chain in B cells) signaling in different cell types. For this reason, FKBP51 has been 
suggested as a drug target for the treatment of NF-κB-mediated inflammation and cancer [101-106]. 
NF-κB is a family of transcription factors affecting multiple cellular processes such as inflammation, 
proliferation, maturation, differentiation, survival and apoptosis [107-109]. As a key factor, NF-κB 
regulates the innate and adaptive immune response. In the last 15 years, several studies aimed to 
elucidate the role of FKBP51 in NF-κB pathways and the underlying mechanisms [101-106,110-113]. 
Different FKBP51 interaction partners involved in NF-κB pathways have been identified. Among them, 
members of the IKK complex, namely IKKα [101,102,104,111,113], IKKβ [102,104,113] and IKKγ 
[102,104,110,113] belong to the most prominent interaction partners shown in various cell lines. The 
FK1 and TPR domain of FKBP51 both appeared to be required for its interaction with IKKγ in HEK293 
cells [104]. Jiang et al. proposed that the FK1 domain is involved in the interaction with IKKα in human 
glioma cells (U87) [101]. The data indicated that the PPIase-inactive double-point mutation FD67DV of 
the FK1 domain reduced the interaction of FKBP51 with IKKα [101]. In contrast, Romano et al. did not 
observe any impact of the FD67DV mutation on either the FKBP51/IKKα/β or the IKKγ/IKKα/β 
interaction in HEK293 cells [104]. In accordance with these results, FK506, a FKBP51 isomerase 
inhibitor, did not affect the FKBP51/IKKα interaction [104]. Instead, a TPR domain mutant with 
diminished Hsp90 binding seemed to impair the interaction of IKKα/β with FKBP51 as well as with IKKγ 
in HEK293 cells [104]. The involvement of Hsp90 in FKBP51-mediated NF-κB signaling is still under 
discussion [102,112,113]. 
The effect of FKBP51 on NF-κB activation is also controversially discussed. On the one hand, 
various studies demonstrated that FKBP51 enhances NF-κB activation [104,105,111]. On the other 
 hand, Erlejman et al. described the opposite effect of FKBP51 and concluded that NF-κB activation is 
regulated by the FKBP51/FKBP52 ratio [112]. Reporter gene assays implicated that FKBP51 impaired, 
whereas FKBP52 enhanced, PMA (phorbol 12 myristate 13 acetate) as well as TNF α induced NF-κB 
activation in HEK293T cells overexpressing either FKBP51 or FKBP52, respectively. Both effects 
seemed to be reversed by the expression of the corresponding TPR peptide. A competition assay with 
FKBP51 and FKBP52 using the transcriptional activity of NF-κB as readout led to the conclusion, that 
FKBP52 could act as an FKBP51 antagonist, reversing its inhibitory effect on NF-κB activation. 
Taken together, it can be concluded that FKBP51 is connected to both pathways, but the extend 
and significance is unclear due to strong controversing findings.  
 
2.5.4. Glomulin 
 
Glomulin (Glmn) has been identified as a binding partner of FKBP12 and FKBP52 in a Y2H screen 
[114,115]. Initially, Glmn has been described as FKBP Associated Protein (called FAP48 or FAP68) 
[114,116]. More recently, a link between FKBP51 and Glmn was described in a high-throughput 
interactome network study [60]. 
Glmn has been discussed as E3 ligase regulator. Eukaryotic cells utilize a system of three 
enzymes (E1 to E3) and ubiquitin to prime proteins for proteosomal degradation. One of the most 
studied examples of the E3 ligase family is CRL1Fbw7 [117,118]. Glomulin (Glmn) binds to this complex 
by intercalating between Cullin1 (Cul1) and RING-box protein 1 (Rbx1) (Figure 7). Henceforth, Glmn 
masks the interaction surface of Rbx1 towards the E2 ubiquitin-conjugating enzyme Cdc34, leading to 
an inhibition of the ligase activity, because activated ubiquitin becomes unavailable [119,120]. This is 
also thought to prevent an overshooting ubiquitinylation reaction, which is mediated by Rbx1 binding to 
cullins and which would lead to a degradation of CRL1Fbw7 itself [120]. Later, an interaction of Glmn 
with cellular inhibitors of apoptosis proteins 1 and 2 (cIAP1 and cIAP2), which regulate E3 ligases, was 
discovered [121]. Additionally, most recently Glmn was associated with the infectious mechanism of 
Shigella [121,122], where Glmn was claimed to be hijacked by a bacterial E3 ligase to promote 
inflammation. Mutations in the Glomulin gene lead to Glomuvenous malformation [116,123,124]. Point 
mutants and truncation mutants lacking Prolin219 of Glomulin showed significantly reduced β-
galactosidase activity in a Y2H screen [115]. However, the detailed mechanism and regulation of this 
reaction is still poorly understood. A potential regulation by FKBPs in this context has not been 
investigated. 
  
Figure 7 Crystal structure of Glomulin (pink) with Cullin1 (green) and Rbx1 (blue). Proline219 is 
indicated in red. 
 
2.5.5. Other pathways and interactors associated with FKBP51 
 
FKBP51 has been associated with a great number of other proteins. In a comprehensive interactome 
study addressing the Hsp90 complex and its cochaperones, numerous interaction partners of FKBP51 
were described [60]. Among those findings are kinases such as the cyclin dependent kinases (CDK1, 
4, 9 and 11A) as well as kinases involved in cytoskeleton formation (Aurorakinase B, Fer). Furthermore, 
MYND-domain proteins, associated with transcriptional repression, minichromosome maintainance 
(MCM) complex proteins, helicase subunits and the argonaut proteins Ago1 and 2, essential 
components of the RNA-induced silencing complex (RISC) were identified as potential interactors. For 
CDKs, an antagonizing action mode of FKBP51 and 52 was described for their respective impact on 
DNA methylation [125]. Both immunophilins were copurified with the cyclin dependent kinase (CDK5) 
and its downstream target DNA methyltransferase 1 (DNMT1) [100,125]. Higher FKBP51 expression 
was linked to decreased DNMT1 phosphorylation levels and reduced methylation levels of the brain-
derived neurotrophic factor locus in human blood samples. Accordingly, FKBP52 was suggested to 
exhibit opposite effects [125]. In addition, FKBP51 was also found to bind to CDK4, a known oncogene, 
where FKBP51 knockdown led to decreased CDK4 expression [126].  
Although, the evidence of FKBP51 being involved in cytoskeletal processes accumulates, an 
overall model for its action mode is still lacking. The microtubule forming monomer Tau is linked to 
plague formation in Alzheimer’s Disease (AD). In 2010 it was claimed, that overexpression of FKBP51 
increases Tau concentration and FKBP51 knockdown reduces it. Both proteins could be copurified. 
 FKBP51 seemed to protect Tau from ubiquitination potentially acting as a chaperone, since Hsp90 was 
found in this complex as well. An active PPIase pocket was required for binding Tau [127]. In the same 
year, FKBP51 and its partial counter player FKBP52 were linked to another process involving 
microtubule arrangements. FKBP51 dampens while FKBP52 enhances neurite outgrowth during 
neuronal differentiation [22,37] which requires elevated expression of cytoskeletal proteins. The anti-
neuritotrophic activity of FKBP51 could be blocked by FKBP51 ligands which increases neurite 
outgrowth in neuroblastoma cell lines and in primary embryonic neurons [22,41,128]  
Interestingly, the connection of FKBP51 and microtubule formation via tau dephosphorylation 
was recently proposed to be PP5C mediated, a TPR-domain containing phosphatase [129]. 
Furthermore, expression levels of both proteins impact the store-operated calcium entry current in 
pulmonary artery endothelial cells and HEK293 cells. Additionally, store-operated channels have been 
reported to be desensitized by FKBP51. FKBP52 was shown to antagonize this effect [130]. 
Immunophilins, such as the FKBPs 52, 12, 25 and 38 have generally been associated with calcium ion 
channels especially of the TRPC family and effects of high concentrations of FK506 on calcium flux 
have been reported [2,131-133].  
The RISC protein complex shows elevated expression with increased FKBP51 and 52 levels in 
mural embryonal stem cells and is less abundant, if one or both immunophilins are knocked down. 
Interestingly, less Ago2 can be found if the cells are treated with FK506 [97,134]. 
It can be summarized that research on FKBP51 faces many (yet) loose ends and the findings are 
partially controversial or are lacking independent confirmations. A general concept bringing together all 
potential interactors and phenotypes has yet to be defined. 
 
2.6. Objectives of the work 
 
It becomes clear, that FKBP51 is an important protein factor in multiple cellular pathways and 
associated with many more other proteins. Side by side, there is continuous growing proof of FKBP51’s 
disease relevance in multiple fields, including psychiatric disorders, obesity, chronic pain and some 
cancers [25].  
The aim of this work was to contribute towards two goals, back to back: 
1. Elucidate the molecular and cellular mechanisms of FKBP51 ligands. 
2. Utilize FKBP51 ligands to create an improved understanding of FKBP51’s action modes itself. 
Selective FKBP51 ligands such as SAFit1 and SAFit2 have been shown to be active in various murine 
models for the previous named pathologies [18,20,23,24,104]. The underlying mechanisms are overall 
unclear. To address this problem, a first focus has been set to the action of FKBP51 in GR context. A 
reporter gene assay was established to research the effects of FKBP51 and its mutants overexpression 
on GR signaling strength, as well as the impact of FKBP51 ligands within this setup. In close 
cooperation with Tianqi Mao, a novel class of FKBP ligands – PROTACs – with the purpose to induce 
 chemical knockdown, were screened by Western Blotting and tested in the reporter gene assay. 
Besides the gain-of-function effects of FK506 and Rapamycin, no specific protein-protein interaction is 
described thus far which is altered by the presence of FKBP51 ligands. During the course of my work, 
some unpublished results indicated a tight and promising interaction of FKBP51 and Glmn. To 
investigate this interaction in vitro a HTRF setup was developed. Multiple FKBPs and FKBP51 mutants 
have been examined, as well as FKBP ligands.  
In this work, I present a new functional readout for GR signaling that confirms the FKBP action. 
Conventional ligands and a PROTAC exhibit different effects in this assay. Furthermore, two 
unprecedented protein-protein interactions are discovered and the very first ligand-sensitive interaction 
is described.  
  
 3. Materials 
All materials are listed with their name as indicated by their provider label, their provider and the 
providers catalog number. 
3.1. General Chemicals  
 
4-(6-methyl-1,3-benzothiazol-2-yl)aniline (dissolved in DMSO, Santa Cruz Biotechnology, sc-276812), 
Acetic acid 99-100% (C. Roth, 7332.2), Adenosin-5’-triphosphat disodium salt (C. Roth, HN35.1), Agar-
Agar, Kobe I (C. Roth, 5210.3), Albumin, Fluorescein isothiocyanate Conjugate bovine (Sigma, A9771), 
Ampicillin sodium salt (C. Roth, K09.5), Bovine Serum Albumin (Sigma, A7030), Brilliant Blue G250 (C. 
Roth, 9598.1), Charcoal Activated (C. Roth, X865.1), Carbachol (Alfa Aesar, L06674), Coelenterazine 
h (dissolved in Ethanol, AAT Bioquest, 21159), Coenzyme A free acid (AppliChem, A0812), cOmplete 
Mini Protease inhibitor cocktail (Roche, 11836153001), Coomasie Brilliant Blue R250 (C. Roth, 9598.1), 
D-Luciferin (C. Roth, CN24.1), Deoxyribonuclease I from bovine pancreas (DNAse I) (Sigma, DN25-
1G), Dexamethasone 21-phosphate disodium salt (dissolved in DMSO, Sigma, D1159), 
Dimethylsulfoxid (DMSO) (C. Roth, 4720.4), Dithiothreitol (DTT) (C. Roth, 6908.1), di-Potassium 
hydrogen phosphate (C. Roth, P749.1), Dual-Glo® Stop & Glo® Substrate (Promega, E313B), Ethanol 
70% pure (Krankenhaus Apotheke Schwabing, UN 1170), Ethanol denatured (C. Roth, K928.4), FK506 
Tacrolimus (Beta Pharma, 56-01267), Fluorescein-5-Maleimide (ThermoScientific, 62245), Glycerol 
86% (C. Roth, 4043.2), Glycine (C. Roth, 3908.2), Glutathione (reduced) (Merck, K46409890 514), 
Hepes (C. Roth, 9105.3), Hyperforin, Hyperforin derivatives, OAG (Friedland group, Universität Mainz), 
Imidazole (Fluka, 56750), Insulin solution from bovine pancreas (Sigma, I0516-5mL), IPTG (C. Roth, 
CN08.3), Kanamycin sulphate (C. Roth, T832.1), LB Broth (Luria/Miller) (C. Roth, X968.2), Lysozym 
(C. Roth, 8259.3), Magnesium chloride hexahydrate (Merck, Q649033 524), Magnesium sulphate 
heptahydrate (C. Roth, P027.2), mTNF-α aa80-235 E.coli derived (R&D Systems, 410-MT) Nano-Glo® 
Luciferase Assay (Promega, N112B), Nickel II Sulphate 6-hydrate (C. Roth, T111.1), Nonidet® P-40 
substitute (VWR Life Science, E109-50mL), Passive Lysis Buffer 5x (Promega, E194A), Phenymethyl 
suphonyl fluoride (C. Roth, 6367.2), Phorbol 12-myristate 13-acetate (Enzo, BML-PE 160), Ponceau S 
(C. Roth, 5938.2), Potassium dihydrogen phosphate (C. Roth, 3904.1), Potassium hydroxide (C. Roth, 
6751.1), Powdered mil (C. Roth, T145.3), Propan-2-ol (AppliChem, 603-117-00-0), Protein degrader 1 
hydrochloride (VHL ligand) (MedChemExpress, HY-101763A), Rapamycin (Alfa Aesar, J62473), 
Rotiophorese® Gel 30 (37.5:1) (C. Roth, 3029.1), SDS (C. Roth, 0183.3), Sodium Chloride (C. Roth), 
Sodium acetate anhydrous (Fluka, 71183), TECEP hydrochloride (trc Canada, 249283), TEMED (C. 
Roth, 2367.3), tetra-Sodium pyrophosphate decahydrate (Na4PPi) (Fluka, 71515), Trichloroacetic acid 
(C. Roth, 8789.2), TRIS (C. Roth, 4855.2), TRIS hydrochloride (C. Roth, 9090.3), Triton X-100 (C. Roth, 
3051.4), Tween 20 (C. Roth, 9127.2) 
 
 3.2. General Plastics and Materials 
 
Eppendorf Tubes 5.0 mL (Eppendorf, 0030119401), Micro tube 1.5 mL (Sarstedt, 72.690.001), 
Microtube 1.5 mL protein LB (Sarstedt, 72.706.600), Micro tube 2.0 mL (Sarstedt, 72.691), Micro tube 
2.0 mL LB (Sarstedt, 72.695.600), Pipette Tips – various volumes (Sarstedt), ProteinLoBind Tubes 
5.0 mL (Eppendorf, 003010832), white 96-well half-area plate (Greiner bio-one, 392-0287), gel drying 
frame and cellophane (C. Roth), Amersham™ Protran™ 0.2 µm Nitrocellulose (GE Healthcare Life 
Sciences, 10600001), Rotilabo®-Blottingpapiere, 0.35 mm (C. Roth, CL65.1),  
 
3.3. Cell Culture Plastics 
 
TC Dish 100 Standard (Sarstedt 83.3902), Combitips advanced 1.0 mL (Eppendorf BIOPUR 0030 
089.642), Combitips advanced 5 mL (Eppendorf BIOPUR 0030 089.669), CryoPure Tubes 1.8 mL 
white (Sarstedt, 72.379), TC Testplate 96F (TPP, 92096), TC Plate 24 Well Standard F (Sarstedt, 
83.3922.005), 12 Well Cell Culture Plate (Greiner bio-one, 665 180), TC – Plate sterile with lid single 
packed (Greiner bio-one, 657 160), Greiner CELLSTAR® 96 well plates wells V-bottom (with lid) 
(M9686 Sigma), Cell Culture Microplate 96 well PS, F-bottom (CHIMNEY WELL) µCLEAR® black 
cellstar® TC lid with condensation rings (Greiner Bio-one, 655090), Adhesive Black Light-Absorbing 
Film (VWR, 391-1291) 
 
3.4. HTRF Material 
 
384 well plate Assay Plate 384 Well No Lid Flat Bottom Low Flange Non-Binding-Surface Black 
Polystyrene (CORNING, 3575), Mab Anti GST-Tb cryptate (Cisbio, 61GSTTLA) 
 
 
3.5. Devices  
 
Biofuge Pico (Heraeus), Electrophorese Powersupply (EPS series, Amersham), CVC 3000 Vacuum 
pump (vacuubrand), DS11+ Spectrophotometer (Denovix), Duomax 1030 and Polymax 1040 
(Heidolph), EMB500-1 scale (KERN), IKA Kombimak REO stirring device, RM5 Rollenmischgerät, Light 
Microscope WILOVERT S (hund), Microwave (Samsung), Mixing Block MB-102 (BIOER) Multichannel 
Pipette 8 – 100µL (Eppendorf), Pipette Matrix Multichannel 16 – 125µL (Thermo Scientific), Pipettes – 
various volumes (Gilson), Reax 1 Vortexer (Heidolph), Rotilabo-Block-Heater H250 (Roth), RS-T170S 
Rollenmischgerät (PHOENIX Instrument), Sartorius Analytic Scale, Sprout Minifuge (Biozym), 
Waterbath-GFL-Typ-1002 
 
 3.6. Readers  
 
Genios Pro (Tecan), Infinite M1000 with dual injection module (Software: i-control 1.11), Berthold 
TriStar² LB 942 
 
3.7. Software  
 
Graphpad Prism6, ImageJ, Microsoft Office Suite 2016, Sigmaplot 11.0 
 
3.8. List of used group internal ligands 
 
Internal 
Nomenclature 
Published Name  Publication 
AV075 Unpublished Dissertation AV 
CK182 2b [26] 
MTQ238 16j [40] 
JK096 16g [40] 
MB53, THe10, SG770 SAFit1 [22] 
MTQ202 / MTQ416 unpublished Dissertation MTQ 
Other PROTACs unpublished Dissertation MTQ 
 
3.9. Primary Antibodies 
 
Name IgG Subtype, Species Dilution Manufacturer 
Flag(HRP), A8592 mono, mouse 1:10000, 5% milk in TBS Sigma-Aldrich 
FKBP51 A301-430A poly, rabbit 1:500, TBS Bethyl 
GAPDH A300-641A poly, rabbit 1:1000, 5% milk in TBS Bethyl 
Glomulin A304-940A poly, rabbit 1:1000, 5% milk in TBS Bethyl 
HA(HRP) 3F10 mono, rat 1:10000, 5% milk in TBS Roche 
Hsp90 PA5-27410 poly,rabbit 1:2500, 5% milk in TBS Thermofisher 
 
3.10. Secondary Antibodies 
 
Name IgG Subtype, Species Dilution Manufacturer 
Rabbit IgG A120-112P poly, goat 1:1000, 5% milk in TBS Bethyl 
 
3.11. Bacterial Strains 
 
 Two fundamental Escherichia coli strains were used, both purchased from Invitrogen (Karlsruhe).  
DH5α (Genotype: F’ Phi80dlacZ ΔM15 Δ(lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rK-mK+)phoA 
supE44 lambda- thi-1) for molecular cloning, site-directed mutagenesis and preparation of plasmid DNA.  
BL21(DE3)pLysS (Genotype:  F–, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3), pLysS, Cmr) for the 
heterologous production of protein. 
 
3.12. Expression Plasmids 
 
Proteintags are indicated ahead of the protein name if they are located N-terminally and after the protein 
name if they are located C-terminally of the protein sequence. 
 
3.12.1.  Bacterial expression 
 
Internal Reference 
Number 
Insert  Backbone  Created by 
HG 21 His-FKBP12 pProEx-HTA CKo, 08.09.2005 
HG 49 His-FKBP51FK1 (1-140) pProEx-HTA CKo, 09.03.2006 
HG 92 His-FKBP52FK1 (1-140) pProEx-HTA Andreas, 10.04.2006 
HG 116 His-FKBP51-Strep pProEx-HTA Steffen, 15.01.2008 
HG 118 His-FKBP52-Strep pProEx-HTA Steffen, 15.01.2008 
HG 156 His-FKBP12.6 pProEx-HTA ClS, 2005 
HG 306 His-FKBP51FK1 (1-140) 
F67V 
pProEx-HTA Bas 
HG 365 His-FKBP51FK1 (1-140) 
FD67/68DV 
pProEx-HTA Veronika Kupfer, 
19.07.2010 
HG 633 His-FKBP51FK1 (16-140), 
A19T 
pET30b ClS, 16.02.2015 
HG 653 His-FKBP51FK1-MonoCys 
(1-140, C103A, C107I, 
E140C)  
pET30b ClS, 02.09.2016 
HG 656 His-FKBP12-MonoCys 
(C23V, E108C)  
pET30b ClS, 07.09.2016 
HG 660 GST-Glmn pGex AHa, 08.07.2016 
obtained from Schulman 
group, Memphis) 
 HG 661 GST-Rbx1 pGex AHa, 08.07.2016 
obtained from Schulman 
group, Memphis) 
 
3.12.2.  Eukaryotic expression 
 
Internal Reference 
number 
Insert  Backbone  Created by 
HG 124 HA-GR pRK5 AHa, 13.07.2018 (AG 
Rein, MPIPsych) 
HG 206 FKBP52-Flag pRK5 AF, 2008 (AG Rein, 
MPIPsych) 
HG 207 FKBP51-Flag pRK5 AF, 2008 (AG Rein, 
MPIPsych) 
HG 302 FKBP51- Flag TPR* 
(K352A/R356A) 
pRK5 SC, 02.12.2009 (AG Rein, 
MPIPsych) 
HG 382 FKBP51-Flag PPIase 
(FD67/68DV) 
pRK5 AK, 23.11.2011 
HG 473 hRLuc/TK (pGL4.74) pGL4 AK, 23.08.2011 (Promega, 
9PIE692) 
HG 490 HA-FKBP51 pRK5 AK, 17.10.2011 
HG 498 MmFKBP51-HA pRK5 CKo, 3.11.2011 
HG 591 FKBP51-Flag (L119P) pRK5 ClS 
HG 598 RT-233-2/TRPC6-YFP pcDNA3.1 AG Leuner, FAU Erlangen 
HG 600 FKBP51-Flag Triple mut 
(K58T, K60W, F129V) 
pRK5 ClS, 25.06.2013 
HG 628, 
pGRE4luc2P 
Three copies of tandem GRE 
[135] 
pGL4.27 AHa, 01.09.2014 (Dvorak 
Group, University 
Olomouc) 
HG 644 3xFlag-Glmn pcDNA3.1 AHa, 11.01.2016 (Taipale 
Group, Toronto University) 
HG 645 Glmn-3xFlag pcDNA3.1 AHa, 11.01.2016 (Taipale 
Group, Toronto University) 
HG 658 TRPC6 YFP SDM C1 pcDNA3.1 AHa, 08.07.2016 
HG 680 Nluc-FKBP51 pNLF1 NGu, Master Thesis 
 HG813 p1242  Firefly-Reporterplasmid, 
canonical NF-κB pathway 
pGL2 Nils Gassen, MPIPsych, 
Promega product 
HG814 pNF-κB2  Firefly-Reporterplasmid, non-
canonical NF-κB pathway 
pGL2 Nils Gassen, MPIPsych, 
[136] 
 
3.13. Mammalian Cell Lines 
  
Name Description Origin Provided by  ATCC No. 
A375 malignant 
melanoma skin cells 
H. sapiens AG Boßerhoff 
(FAU Erlangen) 
CRL-1619 
HEK293-T Embryonic kidney 
cells 
H. sapiens Dr. T. Rein (MPI 
for Psychiatry, 
Munich) 
CRL-1573 
HEK TRPC6-HA 
#4 
Embryonic kidney 
cells, stable 
transfection with 
TRPC6 
H. sapiens Jana Demleitner 
(LMU Munich) 
 
HeLa Cervix 
adenocarcinoma 
cells 
H. sapiens Dr. T. Rein (MPI 
for Psychiatry, 
Munich) 
CCL-2 
Jurkat peripheral blood 
T Lymphocyte 
H. sapiens Anthony Zannas, 
Nils Gassen (MPI 
for Psychiatry, 
Munich) 
CRL-2899 
MEF Embryonic 
fibroblast cells 
M. musculus Dr. M. Cox 
(University of 
Texas, El Paso) 
CRL-2991 
Neuro2a Brain 
neuroblastoma cells 
M. musculus Dr. J. Deussing 
(MPI for 
Psychiatry, 
Munich) 
CCL-131 
PC12 Pheochromocytoma 
cell, adrenal gland 
R. norvegicus AG Friedland 
(Universität 
Mainz) 
CRL-1721 
 
3.14.  Cell Culture Media and Additives 
 
 Name Contents Used for Manufacturer  
Sterile Water Art.-
Nr. 3256.1 
 Plasmid Dilution, 
Plate coating 
C. Roth 
(Karlsruhe) 
Dulbecco’s 
Modified Eagle 
Medium 
C4207.0500 
4.5g/L glucose, L-
glutamine, 
sodium pyruvate, 
w/o phenol red, 
3.7g/L NaHCO3 
Reporter Gene 
Assays 
GENAXXON 
bioscience (Ulm) 
Dulbecco’s 
Modified Eagle 
Medium 41966-
029 
4.5g/L glucose, L-
glutamine, 
sodium pyruvate, 
phenol red 
Most cell lines Gibco-Invitrogen 
(Karlsruhe) 
Advanced RPMI 
1640 Medium, 
12633012 
glucose, non 
essential amino 
acids, sodium 
pyruvate, phenol 
red 
Jurkat, PC12  Gibco-Invitrogen 
(Karlsruhe) 
Dulbecco’s 
Phosphate 
Buffered Saline 
14190-094 
 All cell lines Gibco-Invitrogen 
(Karlsruhe) 
Heat Inactivated 
Fetal Bovine 
Serum 10500-064 
 All cell lines  Gibco-Invitrogen 
(Karlsruhe) 
Poly-L-Lysine 
P4707 
0.01%  PLL  Sigma 
LifeScience 
(Steinheim) 
Opti-MEM 
Reduced Serum 
Medium, 11058-
021 
L-Glutamine, 
HEPES, w/o 
phenol red 
All cell lines Gibco-Invitrogen 
(Karlsruhe) 
Pen Strep 
15140-122 
10,000 Units/mL 
Penicillin 
10,000 µg/mL 
Streptomycin 
All cell lines Gibco-Invitrogen 
(Karlsruhe) 
 Lipofectamine 
2000, 11668-019 
 All cell lines Invitrogen 
(Karlsruhe) 
0.25% Trypsin-
EDTA, 25200-056 
 All cell lines Gibco-Invitrogen 
(Karlsruhe) 
Trypan Blue Stain 
(0.4%), 15250-
061 
 All cell lines Gibco by Life 
Technologies 
 
  
 4. Methods  
 
4.1. Protein Purification 
 
4.1.1. His-tagged Proteins 
 
Proteins were expressed in E.coli BL21(DE3) cells. All incubation steps were performed at 
approximately 200 rpm in a heatable shaker. 3 mL LB media and the according antibiotic were 
inoculated with a scratch of glycerol stock by a steril pipette tipp to obtain the preculture and grown at 
37 °C overnight. The next day, 200 mL media + antibiotic were inoculated with 1 mL preculture and 
treated similar. 4 L of the main culture were inoculated with 120 mL of the second preculture and 
distributed into four time 1 L in a 2 L glass Erlmeyer flask. The cultures were grown to an OD600=0.5, 
induced with 600 µM IPTG (final) and grown for 4 h at 37 °C (Monocys variants 4 h 30 °C). The culture 
was spun down (4 °C, 6,000 g, 10 min, Sorvall RC5B), resuspended in lysis buffer (20 mM Hepes, 
200 mM NaCl, 200 mg/mL lysozyme, 2.5 mM PMSF, 0.1 mg/mL DNAse I, pH 8.0) and subjected to 
sonication (Branson SONIFIER cell disruptor B15, 20% output, 60% duty cycle, two times 5 min). After 
that, the lysis mixture was centrifuged (35,000 xg, 4 °C, 30 min, Sorvall RC5B). 6 mL Nickel-NTA bead 
slurry (Machery Nagel) were equilibrated in washing buffer (20 mM Hepes, 200 mM NaCl, 40 mM 
imidazole, pH 8.0, two times 10 mL), added to the lysis supernatant and incubated for 2h on a rolling 
device at 4°C. After that, the beads were spun down (100 xg, 2 min, Eppendorf Centrifuge 5804 R), the 
supernatant was removed, and the beads were washed two times with 30 mL washing buffer. The 
beads were added to a column (Biorad) and washed again. Elution was performed with elution buffer 
(20 mM Hepes, 200 mM NaCl, pH 8.0, 300 mM imidazole). Elution progress was monitored via 
qualitative Bradford assay (5 µL elution fraction added to 100 µL 1x Roti®-Nanoquant, C. Roth, in a 
transparent 96-well plate). Protein-containing fractions were pooled, centrifuged (14,000 xg, 4 °C, 
20 min, Eppendorf Centrifuge 5804 R), and the supernatant was subjected to size exclusion 
chromatography (FPLC buffer: 20 mM Hepes, 20 mM NaCl, 5%(v/v) glycerol, pH 8.0, HiLoad™ 26/600 
SuperDex™ 200pg on an ÄKTA Pure chromatography system by GE Healthcare). Resulting protein 
fractions were quantified, frozen in liquid nitrogen and stored at -80 °C. All buffers used for the 
purification of MonoCys mutants additionally contained 5 mM DTT.  
 
4.1.2. GST-tagged Proteins 
 
Proteins were expressed in E.coli BL21(DE3) cells. All incubation steps were performed at 
approximately 200 rpm in a heatable shaker. 3 mL LB media and the according antibiotic were 
inoculated with a scratch of glycerol stock by a steril pipette tipp to obtain the preculture and grown at 
37 °C overnight. The next day, 200 mL media + antibiotic were inoculated with 1 mL preculture and 
 treated similar. 4 L of the main culture were inoculated with 120 mL of the second preculture and 
distributed into four time 1 L in a 2 L glass Erlmeyer flask. The cultures were grown to an OD600=0.5, 
induced with 600 µM IPTG (final) and grown at 15 °C overnight). The culture was spun down (4 °C, 
6,000 g, 10 min, Sorvall RC5B), resuspended in lysis buffer (20 mM Hepes, 200 mM NaCl, 200 mg/mL 
lysozyme, 2.5 mM PMSF, 0.1 mg/mL DNAse I, 5mM DTT, pH 8.0) and subjected to sonication 
(Branson SONIFIER cell disruptor B15, 20% output, 60% duty cycle, two times 5 min). After that, the 
lysis mixture was centrifuged (35,000 xg, 4 °C, 30 min, Sorvall RC5B). 7 mL Gluthathion bead slurry 
(Glutathion Sepharose 4 FastFlow, GE Healthcare, 17-5132-01) were equilibrated in washing buffer 
(20 mM Hepes, 200 mM NaCl, 5 mM DTT, pH 8.0, two times 10 mL), added to the lysis supernatant 
and incubated for 2 h on a rolling device at 4 °C. After that, the beads were spun down (100 xg, 2 min, 
Eppendorf Centrifuge 5804 R), the supernatant was removed, and the beads were washed two times 
with 30 mL washing buffer. The beads were added to a column (Biorad) and washed again. Elution was 
performed with elution buffer (20 mM Hepes, 200 mM NaCl, 5 mM DTT, pH 8.0, 10 mM glutathione). 
Elution progress was monitored via qualitative Bradford assay (5 µL elution fraction added to 100 µL 
1x Roti®-Nanoquant, C. Roth, in a transparent 96-well plate). Protein-containing fractions were pooled, 
centrifuged (14,000 xg, 4 °C, 20 min, Eppendorf Centrifuge 5804 R), and the supernatant was 
subjected to size exclusion chromatography (FPLC buffer: 20 mM Hepes, 20 mM NaCl, 5% glycerol, 
5 mM DTT, pH 8.0, HiLoad™ 26/600 SuperDex™ 200pg on an ÄKTA Pure chromatography system by 
GE Healthcare). Resulting protein fractions were quantified, frozen in liquid nitrogen and stored at -
80 °C. Previous to size exclusion chromatography GST-Rbx1 was digested with TEV-protease to 
remove the GST-tag (20 U/µL = 3.5 µg/µL TEV Protease (MPI for Biochemistry, Munich, Dr. B. 
Suppmann) added to pooled Elution fractions, incubated at 4 °C overnight). 
 
4.1.3. Protein Labeling 
 
2 mL (up 2.5 mg protein) of FKBP51FK1-MonoCys and FKBP12-MonoCys were dialysed for 5 cycles 
(approximately 30 min / 1 / 2 / 4 h and overnight) at 4 °C in a Dialyse Slide-A-Lyzer 3.5k MWCO 
(ThermoFisher) in 20 mM Hepes, 20 mM NaCl, 5%(v/v) glycerol, 10 mM TCEP pH 8.0 with 45 mL buffer 
per cycle in order to remove DTT. The rebuffered protein was added to 500 µL equilibrated Ni-NTA 
slurry (4.1.1). After 2 h, a 20-fold molar excess of fluorescein-maleimide “5-MF” (TRC, F489500) was 
added and incubated for 2 h. The mix was transferred to a column (Biorad) and washed with buffer 
(20 mM Hepes, 20 mM NaCl, 5%(v/v) glycerol, pH 8.0, 5 mM DTT) until the flowthrough became 
colorless. Elution was performed with elution buffer (20 mM Hepes, 200 mM NaCl, pH 8.0, 300 mM 
imidazole, 5 mM DTT). The elution was ended as the eluate became colorless. In order to remove 
remaining unreacted fluorescein-maleimide, the first 3 mL of eluted, labeled protein were dialysed for 5 
cycles in a Dialyse Slide-A-Lyzer 3.5k MWCO (ThermoFisher, #88403) in 20 mM Hepes, 20 mM NaCl, 
 5% glycerol, 5 mM DTT as described before. The protein concentration was determined by measuring 
OD280 and OD495. Calculation protocol by ThermoFisher:  
 
cProtein = (OD280 – (OD495*0,3)) / εProtein 
Labeling efficiency = (OD495 / (εFluorescein x cProtein); εFluorescein = 68000 M-1 cm-1 
 
Washing and elution of FKBP12-MonoCys with 5-MF are visualized in Suppl. Fig. 63. 
 
4.1.4. Activity Assay of Labeled Proteins 
Compound FK[4.3.1]-16g [40] (Figure 8) was diluted in 15 one-to-one dilution steps ranging from 25 µM 
to 1.5 nM in DMSO. 1 µL of each dilution step was added to a black 384 well plate (Corning 3575). 
50 µL of a 5 nM 5-MF labeled protein dilution in FP-Assay buffer (20 mM Hepes, 0.002% Triton X-100, 
pH 8.0) were added to each tracer containing well. Fluorescence (Ex: 485±20 nm, Em: 520±10 nm) 
was measured with a Tecan Genios Pro plate reader. Data was processed with GraphPad Prism 6 and 
curves were fitted via a one-site-ligand depletion curve (Y= A / E * 0.5 *(X + E + 1 / K - sqrt ( sqrt ( X + 
E + 1 / K ) - 4 * E * X ))+B). 
 
 
Figure 8 Structure of FK[4.3.1.]-16g. 
The TAMRA fluorescence was not obtained. 
 
4.1.5. Active Site Titration of FKBPs 
 
All unlabeled FKBPs have been quantified by active site titration [26]. Proteins were diluted in 15 one-
to-one dilution steps in FP-assay buffer and equally mixed with a 100 nM solution of compound 
FK[4.3.1]-16 g in FP-Assay buffer (20 mM Hepes, 0.002% Triton X-100, pH 8.0) in a black 384 well 
plate (Corning 3575). Fluorescence polarization was measured with a Tecan Genios Pro plate reader 
(Ex: 485±20 nm, Em: 535±25 nm), plotted against the UV concentration (DevNovix, 
 D11+Spectrophotometer) and subjected to a four parameter fit using GraphPad Prism6: Y=Bottom + 
(Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). Concentration of active protein was calculated: cAST = 
((0.5x cTracer + KD) / EC50) x cUV. 
 
4.2. HTRF 
 
All components were diluted in HTRF-Assay-Buffer (20 mM Hepes, 20 mM NaCl, 5% Glycerol, 10 mM 
DTT, pH 8.0). The assay mix consists of four fractions of equal volume: binding partner I and II, Tb – 
cryptate coupled antibody and competitor. Therefore, 4x predilutions dilutions of all fractions were 
prepared (if not indicated differently) in low binding tubes: 120 nM Glmn-GST, 120 nM 
FKBP51FK1MonoCys-5MF, 40 ng /well Mab Anti GST-Tb cryptate monoclonal antibody (Cisbio) 
(approximate final concentration of 0.8 nM) and competitor as indicated. FKBP51FK1MonoCys-5MF, 
competitor and Glmn-GST (each 20 µL) were pre-incubated in a 384 well plate for 1 h at RT. Mab Anti 
GST-Tb cryptate (20 µL) was added and incubated for 2 h at. Fluorescence at Em: 340±10 nm / Ex: 
520±10 nm and Em: 340±10 nm / Ex 620±10 nm was measured sequentially for all wells in a Tecan 
Genios Pro Reader. The 520 nm signal of each well was normalized over its corresponding 620 nm 
signal. All assays were measured with the “Gain Optimal” setting, potentially leading to variations of 
absolute fluorescence values in between separate assays. Data was processed with GraphPad Prism6 
and competition curves fitted using a four parameter fit: Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-
X)*HillSlope)) 
 
4.3. Cell Culture 
 
All incubation steps took place in a HERAcell 160vi (ThermoFisher) at 37 °C and 5% CO2, if not 
indicated differently. All media and reagents are listed in section 3.14. All work was performed using 
sterility guidelines. Cell culturing and cellular assays were generally accompanied by the observation 
of the cells via light microscopy to assure confluency, cell shape, surface effects and the absence of 
contaminations. The adherent cell lines Neura2a (N2a), HEK293T and HeLa as well as Jurkat cells, 
which grow in suspension were used. Protocol deviations for Jurkat cells are described in 4.3.5. 
 
4.3.1.  Growth Conditions and Passaging 
 
Cells were grown in 10 cm TC-dishes for 3 to 5 days. After that, the cell culture media was aspirated 
and the cells were washed with 5 mL PBS. 1 mL of prewarmed Trypsin-EDTA solution was added and 
equally distributed on the surface. The dish was placed in the incubator for 5 min. Cells were removed 
from the surface by resuspension in 5 mL culture media and spun down for 2 min at 1000 rpm. The 
supernatant was removed and cells were resuspended with 5 mL culture growth media. For cells of 80 
 – 95% confluency, 250 µL of this suspension were added to 10 mL cell culture media in a fresh plate 
(1 to 20 passage). 
 
4.3.2. Surface Coating 
 
If indicated, cell culture dishes and multiwell plates used for assays were coated with poly-L-Lysine 
(PLL, 0.002%(v/v), 1:50 dilution in water). Half of the volume of the recommended culture volume was 
added to each cavity and placed in the incubator for 2 h up to 24 h. Afterwards, the solution was 
removed and all cavities were washed with an equal amount of water. Plates were dried in a sterile 
bank for 1 h and stored tape sealed at 4 °C until usage. Surface coating was performed for all cell 
culture assay experiments such as PROTAC treatment and reporter gene assays and to culture N2a 
and MEF cells. 
 
4.3.3. Storage 
 
In order to store cells, they were resuspended after passaging in cell culture media containing 10% (v/v) 
sterile filtered DMSO. The suspension was added to Cryo Pure tubes (Sarstedt, 72.379) and frozen to 
-80 °C in Cryo 1 °C Freezing Container (NALGENE). After 1 day, the tubes were transferred to a liquid 
nitrogen container (Locator 5 Plus, Thermo Scientific). In order to regain fresh cells, a 10 cm petri dish 
was filled with 20 mL media. An aliquoted cryotube of cells was removed from the liquid nitrogen tank 
and thawn in a 37 °C warm water bath under mild shaking. Cell suspension was then added to the 
prepared petri dish. After one day the media was exchanged and on the second day, cell passaged. 
Usally 30 to 100% of the cells were reseeded at this point, depending on their confluency. 
 
4.3.4. Cell Counting 
 
As the cells were passaged in order to transfer them to any assay, they were counted after 
resuspension. For this, 10 µL of cells and 10 µL Trypan Blue solution were mixed in a tube. 10 µL were 
then transferred to a Neubauer Counting Chamber (Marienfeld). All non-blue cells in the four major 
quadrants were counted. Cell count in resuspension was calculated: 1 Neubauer count ≙ 5,000 cells / 
mL in the primary resuspension. 
 
4.3.5. Jurkat Cell Culture 
 
Jurkat cells are a non-adherent T lymphocyte cell line. They are cultured in RPMI 1640 media, 
supplemented with 10% FBS. Passaging was performed by simply transferring 10% of the current 
 passage and add it to fresh media. In reporter gene assays non-coated, V-shaped well 96well plates 
were used. Each step, which required exchange of media, was preceded by a centrifugation step 
(1000 rpm, 2 min) and followed by mildly tapping the plate to assure resuspension. A successful 
centrifugation and resuspension of Jurkat cells in V-shaped wells can be monitored via light 
miscroscopy. 
 
4.4. Reporter Gene Assays 
 
4.4.1. Glucocorticoid Receptor Signaling 
 
Reporter gene assays were performed using media without phenol red and with 10% charcoal stripped 
FCS. 10,000 cells in media were seeded into a PLL-coated 96 well plate in a volume of 50 µL/well. 
Plates were incubated for 24 h. The transfection mix was prepared according to Lipofectamine 2000 
(Invitrogen) protocol: Plasmids (solved in sterile water) were diluted in Opti-MEM (45 ng/well 
pGRE4Luc2P, 5 ng/well pGL4.74, 0.5 ng/well HA-GR, different amounts of FKBP51, FKBP52 and 
Glmn). Maximum transfection doses varied from assay to assay but were equalized within an assay by 
the addition of mock plasmid (pRK5). Transfection doses always remained beneath 100 ng/well as 
recommended. A 1.67% (v/v) dilution of Lipofectamine in Opti-MEM was prepared and incubated for 
5 min at RT. After that, both Lipofectamine 2000 and plasmid dilutions were mixed equally and 
incubated for 20 to 25 min at RT. During that time, media was removed from the seeded cells and 80 µL 
of fresh media were added to each well. 20 µL of the final transfection mix were added to each well and 
the cells were incubated for 24 h. After that, each well was washed once with 50 µL media and 50 µL 
media were added to the wells. An incubation period of 30 to 60 min followed. Consecutively, the cells 
were treated with small molecules, which were added in a volume of 50 µL solved in media (4x 
concentration of the final concentration). All used compounds were dissolved and prediluted in sterile 
DMSO and the final DMSO content of the cell culture media remained below 0.2%. Treatment time 
extended up to 24 h. After that, the stimulation mix in a volume of 100 µL was added on top. This mix 
consisted of Dexamethasone dissolved and prediluted in sterile DMSO, diluted in cell culture media to 
a final concentration ranging from 0 to 100 nM. Here as well, the DMSO content in the cell culture media 
did not exeed 0.2% (v/v). Stimulation time extended up to 24 h. Subsequently, the cells were washed 
with 100 µL/well cold PBS and lysed in 50 µL 1× “Passive Lysis Buffer” (Promega, E1910) on ice for 
30 min. The plates with lysed cells were stored at - 20 °C. 
Preceding measurement, plates were thawn and 20 µL lysate of each well transferred to a white 96-
well half-area plate (Greiner bio-one, 392-0287). Measurement buffers were prepared as published in 
“ A protocol for combined Photinus and Renilla luciferase quantification compatible with protein assays” 
by Hampf, M. and Gossen, M., Anal Biochem, 2006 [137]. Measurement was performed with a Berthold 
TriStar² LB 942 (indicated in figure description) or a Tecan Infinite M1000 connected to a dual injection 
 module. Both lines were washed with 80% EtOH and water and primed with 0.5 mL of the corresponding 
substrate solution. 20 µL of firefly luciferase substrate solution (Photinus Buffer: 200 mM Tris-
HCl,15 mM MgSO4, 0.1 mM EDTA, pH 8, plus freshly added: 25 mM DTT, 1 mM ATP, 0.2 mM CoA, 
0. 2mM Luciferin) were injected to one well (speed: 200 µL/s) and luminescence measured for 5 s after 
a delay of 2 s. Afterwards, the same procedure was repeated in the same well with the gaussia 
substrate solution (Renilla Buffer: 25 mM Na4PPi,10 mM NaOAc, 15 mM EDTA, 500 mM Na2SO4, 
500 mM NaCl, pH 5, plus freshly added: 4 µM benzylcoelenterazine, 50 µL 4-(6-methylbenzothiazol-2-
yl)-aniline). Both buffers were prepared and stored at 4 °C without the components indicated as 
“freshly”. After the measurement of a single well, the measurement proceded to the next well. Data 
were processed as following: 1) Normalization of the firefly signal over the gaussia signal. 2) Averaging 
the quadruplicate or hexaplicate values of firefly, gaussia and normalized signal and calculation of the 
standard error of the mean using excel. Data was transferred to GraphPad Prism6 and graphically 
edited. 
 
4.4.2.  NF-κB-Signaling 
 
Reporter gene assays measuring the reporter activity of NF-κB-plasmids were generally performed in 
a similar fashion as GR reporter gene assays. Instead of pGRE4luc2P, the reporter plasmids p1242 for 
the canonical pathway and pNF-κB2 for the non-canonical NF-κB pathway were used at the 
concentration of 45 ng/well. A GR expression plasmid was not transfected. No experiment with ligand 
treatment was performed. Therefore, 24 h transfections were directly followed by stimulation with TNFα 
or PMA (phorbol 12-myristate 13-acetate) for 20 h. The stimulants were used up to a concentration of 
20 ng/µL for TNFα (stock dissolved in sterile PBS with 0.1% BSA) and 80 nM for PMA (stock dissolved 
sterile DMSO). For concentration equal and greater than 40 nM PMA massive cell death was observed 
(HEK293T and A375). Up to 15 nM PMA cells appeared to be fine in light microscopic observation. 
 
4.5. PROTAC Treatment of Cells 
 
Cells were seeded at a concentration of 35,000 per well in a 24 well TC-plate and incubated for 24 h. 
Medium was removed and 250 µL fresh medium were added to each well. PROTACs (Stock 1 to 5 mM 
in DMSO) were diluted in medium at 2x concentration. Usually a 1:1 dilution series was performed in 
DMSO containing medium to achieve a constant final DMSO content of 0.2% (v/v). 250 µL of the 
respective dilution was added to the according wells and incubated for the indicated time. After that, 
cells were lysed.  
 
 4.6. Cell Lysis 
 
To analyse expression levels of certain cellular proteins, medium was removed and cells were washed 
with with 4 °C cold PBS: 50 µL for reporter gene assay in 96 well format, 1 mL for a PROTAC in 24  well 
format. Then an appropriate amount (e.g. 70 µL for a single well of a 24 well plate) of NETN buffer 
(100 mM NaCl, 20 mM Tris-Cl pH 8.0, 0.5 mM EDTA, 0.5% (v/v) Nonidet P-40 (NP-40), 1% Protease 
inhibitor, 1 mM PMSF) was added. Cell plates were incubated for at least 30 min on ice on a shaking 
device. Cells were scratched off with a bended 100 µL pipette tipp (1 per well) and the fluid suspension 
was transferred to an Eppendorf tube. Lysates were centrifuged for 20 min at 16,000 xg at 4 °C 
(Eppendorf Centrifuge 5804 R) and the supernatants transferred to a fresh tube.  
 
4.7. Protein Quantification via BCA Assay 
 
In order to quantify protein amounts via Western Blot detection, the total protein content of lysates was 
normalized. The relative quantity of protein was obtained using a Pierce® BCA Protein Assay Kit 
(Thermo Scientific, 23227). 5 µL of centrifuged lysate sample were added to a transparent 96 well plate 
and 100 µL BCA reagent mix added. The plate was closed with a lid and incubated at 37 °C in a water 
bath above the water level for 30 min. The bottom of the plate was dried. The absorbance of each well 
at 590±20 nm was measured with a Tecan Genios Pro device. Data was processed using Excel. All 
samples which were going to be added to the same SDS-gel were normalized to an equal total protein 
concentration with 4xLämmli buffer of the sample of the least protein content: 15 µL of lysate mixed 
with at least 15 µL 4xLämmli buffer.  
 
4.8. SDS-PAGE  
 
SDS-PAGEs were performed using 1.0 mm disposable cassettes (Novex, NC2010) and mini gel tanks 
(Invitrogen by Thermo Fisher Scientific). In order to cast two gels, the separation gel was prepared as 
following: 
 
Amounts in mL  8% 10% 12% 14% 16% 
Acrylamide / 
Bisacrylamide 
30% / 0.6% 
3.80 4.75 5.70 6.65 7.60 
Aqua dest.  4.87 3.92 2.97 2.02 1.07 
Table 1 Variable components of acrylamide gels. Values are not rounded, since often a multitude of those amounts were 
calculated and pipetted 
 Independant of the acrylamide concentration: 5.34 mL 1 M Tris pH 8.8, 140 µL 10% SDS, 84 µL 10% 
APS, 17 µL TEMED. The mixture was poured into the cassettes (filling 3 / 4) and was overlayed with 
ca. 250 µL isopropanol. After polymerization, isopropanol was poured out and collection gel filled in to 
the top (for three gels: 5 mL stacking gel buffer containing, 25 µL 10% APS, 10 µL TEMED). 
 
Stacking Gel Buffer (250 mL):44 mL Acrylamide /Bisacrylamide 30% / 0,6%, 188.5 mL aqua dest, 
15 mL 1 M Tris-HCl pH 6.8, 2.5 mL 10% SDS. 
 
Gel combs were added right afterwards. After polymerization, gels were stored wrapped in wet tissue 
at in a plastic back at 4 °C.  
Protein samples were prepared with at least 25% 4xLämmli (amounts vary, especially since Lämmli 
buffer was used to normalize protein concentration) and boiled at 96 °C for at least 5 min. 1 L 4xLämmli 
buffer contains: 80 g SDS, 320 mL, 1 M Tris pH 6.8, 400 mL glycerol, 400 mg brom phenol blue, aqua 
dest add 1 L. Before usage 14 µL β-Mercaptoethanol were added per 1 mL Lämmli. Afterwards, the 
samples were spun down (13.000 rpm, 3 min) and added to the gel (3 to 15 µL). 3 µL marker solution 
were used (Page Ruler™, Prestained Protein Ladder, Thermo Scientific, #26616). 
Gels were run at 15 / 25 mA for the stacking phase and 25 / 45 mA for the separation phase, depending 
if one or two gels were loaded in a tank module using 1x SDS-Page buffer (500 mL 10x buffer contain: 
15 g Tris base, 72 g glycin, 5 g SDS, pH 8.3, in aqua dest). SDS-Pages performed for protein level 
quantification to analyse chemical knockdown by PROTACs were loaded with equal sample volume 
(15 µL) of equal total protein concentration. 
 
4.9. Coomassie Staining and Gel Drying 
 
SDS-page gels, which were not transferred for Western Blotting, were stained in Coomassie stainer 
(40% v/v ethanol, 10% v/v acetic acid, 1 g/L Coomasie Brilliant Blue R250) for at least 15 min. 
Destaining was performed in two steps: 1) at least 30 min in destaining solution (40% v/v ethanol, 10% 
v/v acetic acid) and 2) in water at 4 °C overnight. Additional steps in either liquid could be added for 
optimized contrast. Subsequently, gels were dried for at least two days in cellophane using a gel drying 
frame. 
 
4.10. Western Blotting 
 
Western blot sandwiches consisting of sponge, whatman paper, SDS-gel, nitrocellulose membrane, 
whatman paper and another sponge were prepared. All components were previously soaked in western 
blot buffer (1x SDS buffer, 20% (v/v) EtOH). The blotting sandwich was transferred to a blotting chamber 
and added to a mini gel tank (Invitrogen, various models). Transfer was performed at 30 V for one and 
 60 V for two sandwiches per chamber for 75 min. Afterwards, the nitrocellulose membrane was stained 
with Ponceau S solution (0.1%(w/v) Ponceau S in 5%(v/v) acetic acid) to verify transfer and 
subsequently destained in water. The membrane was blocked in 5% skimmed milk in TBS (50 mM Tris, 
150 mM NaCl, pH 7.4) for at least 30 min. The membranes were incubated with the primary antibody 
in the indicated dilution overnight at 4°C on a rolling device. Afterwards, the membrane was washed in 
TBS, TBS-T (0.1% Tween-20 added) and TBS for 5 min each under mild, constant swiveling. The 
membrane was added to the secondary antibody dilution and incubated for at least 1 h at room 
temperature on a rolling device. Washing procedure was repeated similarly. A mixture of equal parts 
HRP substrate solutions (“Immobilon Western”, Millipore) was prepared, added to the membrane 
placed in a transparent foil, equally distributed and measured until a decent chemiluminescence signal 
was detected (LAS-3000, Fujifilm).  
 
4.11. Westen Blot Data Procession for Signal Strength Analysis 
 
This procedure was developed by Thomas Geiger, during his research internship under my supervision 
in order to analyse chemiluminescence signals for chemical knockdown by PROTACs. 
Images of the blots were (colour) inverted using Paint (Version 1803). Afterwards, the FKBP51 and 
GAPDH band intensities were quantified using the “Analyze” tool of ImageJ. The area of interest was 
constant for all protein bands. The intensity of the FKBP51 band was normalized by the corresponding 
GAPDH intensities. The normalized intensities were divided by the normalized intensity of the according 
DMSO control (DMSO value is set to 1). This value indicates the endogenous FKBP51 level relative to 
the DMSO control. Data was processed using GraphPad Prism6.  
 
4.12. Degradation of Nanoluc-tagged FKBP51 
 
10,000 cells in media were seeded into each well of a polylysine coated 96 well plate in a volume of 
50 µL each. Plates were incubated for 24 h. The transfection mix was prepared according to the 
Lipofectamine 2000 (Invitrogen) protocol. Transfection was performed as described in 4.4 Reporter 
Gene Assays with HG 680 (N-terminally Nanoluc tagged FKBP51) in amounts indicated in the 
experiment. At the end of the transfection, the supernatant of each well was removed and fresh 50 µL 
media were added per well. Consecutively, the cells were treated with small molecules, which were 
added in a volume of 50 µL dissolved in media (2x concentration of the final concentration). All used 
compounds were dissolved and prediluted in sterile DMSO and the final DMSO content of the cell 
culture media remained below 0.2%. Treatment time extended up to 24 h. Subsequently, the cells were 
washed with 100 µL/well cold PBS and lysed in 50 µL 1× “Passive Lysis Buffer” (Promega, E1910) on 
ice for 30 min. The plates with lysed cells were stored at - 20 °C. 
 Preceding readout measurement, plates were thawn and 20 µL lysate of each well were transferred to 
a white 96-well half-area plate (Greiner bio-one, 392-0287). Nano-Glo® Luciferase Assay (Promega, 
N1120) was prepared by adding 45 µL substrate to 2250 µL assay buffer and 2250 µL PBS. 20 µL of 
this mixture were added to each lysate-containing well using a dispenser. These plates were incubated 
for 5 min at RT and measured in a Tecan Genious Pro (automatic signal reduction mode). Obtained 
data was processed using GraphPad Prism6. 
 
4.13. Calcium Influx Assays 
 
Calcium Influx Assays were performed using a Fluo-4 Direct Calcium Assay Kit (Invitrogen, F14201, 
containing assay buffer, calcium reagent and probenecid). In preparation one vial probenecid (77 mg) 
was dissolved in 1 mL assay buffer to obtain a 250 mM stock solution. The 2x calcium loading solution 
consisted of 10 mL assay buffer and 200 µL probenecid added to one bottle of calcium reagent. Cells 
were seeded at a densisty of 80,000 cells per 50 µL per well in a black 96 well plate with transparent 
bottom (655090) if no transfection step is indicated and 40,000 cells, if a transfection was performed 
prior to measurement. Transfection was performed as described in 4.4 Reporter Gene Assays with the 
plasmids indicated in the experiments. Cells were allowed to attach for 24 h. Afterwards, the assay was 
performed under non-tissue culture conditions and the bottom of the plate sealed with adhesive black 
light-absorbing film. 50 µL of 2x calcium loading solution were added to each well and incubated 30 to 
60 min at 37° C for dye loading. After that time, plates were kept at room temperature until measurement 
(Kit protocol notes assay stability up to 4 h at RT). Stimulation solutions containing OAG, Carbachol, 
Hyperforin, Hyp1 (stocks prepared in DMSO under excess of light) or DMSO were prepared in assay 
buffer. ATP served as positive control and was prepared as 10 mM stock in water. The Berthold TriStar² 
LB 942 injectors were primed with the solutions. The background of each well was measured (RLU0). 
50 µL were injected into three adjacent wells (medium speed setting). Plate was shaken by the device 
for 2 s. The wells were measured for up to 200 s, Ex: 530±15 nm and Em: 585±15 nm. Data was 
processed with SigmaPlot 11 and the fluorescence intensity (RLU) was corrected by the well 
background plotted against the time. 
  
 5. Results 
 
5.1. FKBP51 PROTACs 
 
Thus far, several series of PROTACs aimed to target endogenous FKBP51 were generated in the 
Hausch lab. Out of these, 62 different compounds [PhD Thesis Mao Tianqi] were tested in several cell 
lines (HeLa, HEK293T, N2a) and the levels of FKBP51 have been monitored via Western Blotting 
(Table 2). Yannick Kristiansen and Thomas Geiger contributed to this project as students under my 
supervision. The experiments performed by them are labeled with “Lab book: YK #” and “Lab book: 
TGe #”. 
 
  
Table 2 Overview of tested PROTACs. PROTACs are named as their respective "MTQ" number according to the following 
features: 1) SAFit-like or bicyclic structure, 2) linker length, 3) attachment point or substituent and 4) targeted E3 ligase (VHL 
or CRBN) 
 
5.1.1. Endogenous FKBP51 
 
The expression of GAPDH usually served as reference. Among the tested PROTACs only MTQ202 
and its second batch MTQ416 robustly decreased levels of FKBP51. The structure of this PROTAC is 
depicted in Suppl. Fig. 61. Western Blot figures of all other PROTACs can be found in 7.1. The PROTAC 
MTQ202 was able to knockdown the levels of FKBP51 in HEK293 cells after 24 h with maximum 
efficacy with concentration ranges between 63 and 500 nM (Figure 9).  
  
Linker Length
1
199 328 338 498 508 518
2 200 329 339 499 509 519
3 201 330 340 500 510 520
4 202 /  416 331 341 501 511 521
5 203 332 342 502 512 522
0 229
1 204 333 343 503 513 523
2 205 334 344 504 514 524
3 206 335 345 505 515 525
4 207 336 346 506 516 526
5 208 337 347 507 517 527
0 235
Atttachment Point 1 2 3 Substituent none X Y
SAFit based structure Bicyclic structure
V
H
L
C
R
B
N
  
 
Figure 9 Incubation of HEK293T cells with the PROTAC MTQ202, 35,000 cells per well in a 24 well format. Upper blot: 
Endogeneous FKBP51. Lower blot: GAPDH. Cells are treated with the compound for 24 h before lysis. All samples have 
exposed to a constant DMSO concentration. Lysate protein concentration was quantified via BCA assay and normalized with 
Lämmli buffer. Equal amounts of total protein were subjected to SDS-Page and Western Blot afterwards. Lab book: TGe13 
 
Figure 10 Quantification of Figure 9. Normalized Intensities of FKBP51 over GAPDH signal. Ration of the last lane (DMSO 
control) is set to 1. Intensities were analyzed using ImageJ. Masterthesis TGe 
The quantification of the same blot shows that FKBP51 levels go down to 40% (Figure 10) 
The very same compound is also active in HeLa cells with minimum FKBP51 concentrations after 24h 
of 250 nM (Figure 11). Since the antibody used for FKBP51 detection showed clearer signals in 
HEK293 lysats compared to HeLa cell lysats, I mainly focused on that cell line. The antibody was not 
reactive to mouse derived cell lines such as Neuro2a and MEF.  
   
Figure 11 Incubation of HeLa cells with the PROTAC MTQ202. 35,000 cells per well in a 24 well format. Upper blot: 
Endogeneous FKBP51. Lower blot: GAPDH. Cells are treated with the compound for 24 h before lysis. All samples have 
exposed to a constant DMSO concentration. Lysate protein concentration was quantified via BCA assay and normalized with 
Lämmli buffer. Equal amounts of total protein were subjected to SDS-Page and Western Blot afterwards. This blot shows 
duplicates. Lab book: AHa388 
During the course of this thesis, a second batch of MTQ202, MTQ416, was synthesized. This batch 
was tested as well and showed a strong chemical knockdown of FKBP51 after 48 h incubation in the 
range of 60 and 1000 nM (Figure 12). 
  
Figure 12 Incubation of HEK293T cells with the PROTAC MTQ416. 35,000 cells per well in a 24 well format. Upper blot: 
Endogeneous FKBP51. Lower blot: GAPDH. Cells are treated with the compound for 48 h before lysis. All samples have 
exposed to a constant DMSO concentration. Lysate protein concentration was quantified via BCA assay and normalized with 
Lämmli buffer. Equal amounts of total protein were subjected to SDS-Page and Western Blot afterwards. This blot shows 
duplicates. Lab book: AHa456 
 
To elucidate the time course of the chemical knockdown of MTQ202, a similar experiment was 
performed on several plates which were incubated with the PROTAC (Figure 14) or DMSO (Figure 13) 
for the indicated time prior to lysis.  
  
Figure 13 Incubation of HEK293T cells with DMSO. 35,000 cells per well in a 24 well format. Upper blot: Endogeneous 
FKBP51. Lower blot: GAPDH. Cells were seeded in separate 24well plates and treated with DMSO containing media. Cells 
were lysed after indicated incubation time ranging from 30 min to 48 h. Experiment shows duplicates for each point of time. 
Although there is an instable GAPDH signal, no effect of DMSO was observable in other experiments for the time points of 24 
and 48 h. Lab book: AHa428.  
 
Figure 14 Incubation of HEK293T cells with the PROTAC MTQ202. 35,000 cells per well in a 24 well format. Upper blot: 
Endogeneous FKBP51. Lower blot: GAPDH. Cells were seeded in separate 24 well plates and treated with DMSO containing 
media. Cells were lysed after indicated incubation time ranging from 30 min to 48 h. Experiment shows duplicates for each 
point of time. While the FKBP51 signal gradually decreases over time, the GAPDH signal remains rather stable. Lab book: 
AHa428. 
MTQ202 continuously decreases the levels of FKBP51 for up to 48h, while the DMSO control showed 
no effect over time. Although many PROTACs show a limited action window for intracellular chemical 
knockdown, MTQ202 remained active for 48 h. 
 In order to obtain more information on the the PROTACs activity time course, a lower amount of cells 
was seeded and incubated with MTQ416 up 72 h. After 24 h incubation, the media was exchanged in 
some wells to provide a PROTAC-free growth environment. 24 h incubation without PROTAC led to a 
recovery of the FKBP51 signal (Figure 15). 
 
Figure 15 Incubation of HEK293T cells with the PROTAC MTQ416. 15,000 cells per well in a 24 well format. Upper blot: 
Endogeneous FKBP51. Lower blot: GAPDH. Cells were seeded in separate 24 well plates (one per point of time) and treated 
with media containing 500 nM MTQ416. Cells were lysed after indicated incubation time ranging from 15 min to 72 h. For 
some wells liquid was exchanged after 24 h with compound free media, indicated with a *. The FKBP51 signal decreased for 
24 / 48 and 72 h, while media exchange leads to signal recovery. The GAPDH signal fluctuates. The quality of these blots are 
low due to low protein amount loaded. Protein concentrations were normalized to the first sample (15,000 cells, which grew 
for 24 h, instead of 35,000 cells growing for usually at least 48 h. Lab book: AHa490. 
Finally, a competition experiment was performed to investigate the chemical knockdown effect of 
MTQ416 in presence of either 2 µM SAFit1 or 2 µM VHL-ligand (Protein degrader 1 hydrochloride, 
dissolved in DMSO + 10% water). In the 24 h incubation blot the presence of both ligands seem to 
increase FKBP51 levels. At least for SAFit1 also GAPDH gives a stronger signal indicating a higher 
protein load for this sample. The FKBP51 levels after 48 h remain unaffected, neither did they dampen 
the chemical knockdown by MTQ416. Due to solubility limitations, an 8-fold excess of competitor 
(250 nM vs. 2 µM) was the highest possible (Figure 16). 
 
 
Figure 16 Incubation of HEK293T cells with the PROTAC MTQ416 (M), SAFit1/THe10 (S) or VHL-ligand (V). 35,000 cells 
per well in a one 24 well format. Upper blot: Endogeneous FKBP51. Lower blot: GAPDH. Cells were seeded in separate 
 24 well plates (one per point of time) and treated with media containing either 250 nM MTQ416, 2 µM SAFit1 or 2µM VHL-
ligand. Cells were lysed after indicated incubation time of either 24 or 48 h. All samples containing the PROTAC show a 
decreased FKBP51 signal independent of the presence of SAFit1 or VHL-ligand. SAFit1 and VHL-ligand alone have no impact 
on FKBP51 levels. The GAPDH signal is rather stable. Lab book: AHa491. 
  
 5.1.2. Exogenous FKBP51 
The detection of endogenous FKBP51 was limited to human FKBP51. Other antibodies tested showed 
no reactivity towards mouse FKBP51(data not shown, AHa375, AHa384). MTQ202 was capable to both 
knock-down mouse FKBP51 with a C-terminal HA-tag transfected in HeLa cells (Figure 17) and human 
FKBP51 with a N-terminal HA-tag in murine N2a cells (Figure 18). 
 
Figure 17 Incubation of HeLa cells with the PROTAC MTQ202. 35,000 cells per well in a 24 well format and transfected 
with 100 ng/well mouse FKBP51-HA (HG498) for 24 h. Upper blot: Hsp90. Lower blot: HA-tag. Cells were seeded in separate 
24 well plates and treated with DMSO containing media. Cells were lysed after 24 h. Experiment shows duplicates for each 
concentration. While the FKBP51 signal gradually decreases over time, the Hsp90 signal remains stable. Lab book: YK 
Bachelorthesis 
  
Figure 18 Incubation of murine N2a cells with the PROTAC MTQ202. 35,000 cells per well in a 24 well format and 
transfected with 100 ng/well human HA-FKBP51 (HG490). Upper blot: Hsp90. Lower blot: HA-tag. Cells were seeded in 
separate 24 well plates and treated with DMSO containing media. Cells were lysed after 24 h. Experiment shows duplicates 
for each concentration. While the FKBP51 signal gradually decreases over time, the Hsp90 signal remains stable. Lab book: 
AHa380 
 
5.1.3. Degradation of Nanoluc-FKBP51 
 
The screening of the PROTAC library via Western Blot required a high work and time load. In a side-
project a screening method was investigated featuring a higher throughput. In order to do so, HEK293T 
and N2a cells were seeded in a 96 well plate and transfected with an N-terminally Nanoluc®-tagged 
FKBP51 expression construct (HG 680). Transfected cells were treated with MTQ202 and the luciferase 
activity was read out after lysis. It was assumed that degradation of FKBP51 by MTQ202 also leads to 
degradation of the Nanoluc tag. It could be shown that, MTQ202 was capable to reduce luciferase 
 signal for the transfection amount of 1 ng/w HG 680 (Figure 19). Increasing amounts of transfected 
plasmid increased general signal strength from 104 RLU background to 108 for 10 ng/w. While no clear 
trend can be observed for 0 and 10 ng/w, the signal reduces with increasing amounts of MTQ202 on 
both cell lines by approximately 50% (125 nM for N2a and 500 to 1000 nM for HEK293T cells). The 
competition of 1000 nM MTQ202 with 1000 nM SAFit1 (MB53) did not lead to a significant change of 
the signal, likely because the lower plateau was already reached. High amounts of transfected plasmid 
could lead to an unaffected signal due to high expression levels. 
   
Figure 19 HEK293T (red) and N2a (blue) cells transfected with 0 (A), 1 (B) or 10 ng/w HG680 and treated with MTQ202. 
10,000 cells were seeded in a 96 well plate, settled for 24  
This assay system has not been persuded further. 
 5.2. FKBP51 in reporter gene assays 
 
5.2.1. Assay Setup 
 
Figure 20 Working principle of the GR reporter gene assay used here. Cell, which are exogenously transfected with a mix 
of plasmids including two reporters as well as GR and FKBP51 expression plasmids are stimulated with dexamethasone. The 
reporter plasmid containing GREs (triple tandem repeat) is expressed upon GR activation. The amount of transcribed firefly 
luciferase depends on the GR signaling strength, which might be impacted by the amount of FKP51 present and potentially 
by FKBP ligands. The second reporter transcribes renilla luciferase and is neither activated nor repressed by GR, FKBPs or 
ligands (herpes simplex virus thymidine kinase promotor – HSV-TK). Its expression levels serve as signal normalization tool. 
The GR is stimulated by Dexamethasone, inducing a reporter plasmid expressing the firefly luciferase. 
This induction might be dependent on the levels of FKBP51 present and its ligands. A second plasmid, 
expressing the Renilla luciferase is independent of external stimuli. The expression strength of both 
luciferases can be read out independently by the addition of their respective substrates and the 
measurement of the resulting luminescence. The assay principle is graphically depicted in Figure 20. 
It was observed that absolute luminescence value varied in between assays for various reasons. 
Therefore, stimulation controls were included. 
 
 5.2.2. Establishing the Assay Window and the Effect of Normalization 
 
  
Figure 21 Graph shows the normalized signal of N2a cells transfected with different amounts of HA-GR by increasing 
Dex concentrations. 10,000 cells per well in a 96well plate were used. Lower panels show the respective Firefly and Renilla 
signal. Each data point represents a quadruplicate and SEM. Lab book: AHa426 
During the establishment of the assay in N2a cells an insufficient assay window was observed. 
Therefore, a plasmid carrying HA-GR was cotransfected. 0.5 ng/well of this plasmid were sufficient to 
increase the signal from 0 to 4 nM Dex about 15-fold and with 100 nM Dex 30-fold (Figure 21). This 
effect is based on the signal change within the Firefly signal. The Renilla signal remains rather 
independent of Dexamethasone and serves as normalization basis to normalize occurring variables 
within and between assays, such as a fluctuating cell growth rate. All later described effects were 
observed at a stimulation of 4 nM Dexamethasone. 0 nM and 100 nM Dexamethasone served as 
stimulation control. 
 
 5.2.3. Overexpression of FKBP51 
 
 
Figure 22 Effect of increasing transfection amounts of FKBP51 on GR signaling stimulated by 4 nM Dex. Normalized 
signal of N2a cells transfected with different amounts of FKBP51 at constant Dex concentrations. 10,000 cells per well in a 
96well plate were used, transfected with plasmid mix (Firefly reporter, Renilla Reporter, GR, FKBP51) for 24 h. 0 and 100 nM 
Dex serve as controls. Dexamethasone stimulation started 24 h prior to lysis. DMSO concentration and total plasmid load are 
kept constant for all conditions. Lysates were transferred and handled as described in methods section 4.4.1 to be read out 
with a Tecan Infinite M1000. Each bar represents mean values of a quadruplicate and SEM. Lab book: AHa439 
At a constant stimulation of the N2a cells an increasing transfection dose of FKBP51 is lowering the 
read out signal indicating an active repression of GR signaling by FKBP51 (Figure 22). Each condition 
contained the same amount of plasmid to exclude transfection stress induced effects. The following 
assays used transfection amounts of either 3.3 or 10 ng/well FKBP51 plasmid (if not indicated 
differently: FKBP51-FLAG, HG207). 
 
 5.2.4. Effects of Different FKBP51 Mutants 
 
 
Figure 23 Effect of different FKBP51 mutants at 4 nM Dex stimulation: WT – wild type, PPIase mut = FD67/68DV; Triple 
= K58T/K60W/F129V, L119P, TPR mut = K352A/R356A. Normalized signal of N2a cells transfected with different mutants 
of FKBP51 at constant Dex concentrations. 10,000 cells per well in a 96well plate were used, transfected with plasmid mix 
(Firefly reporter, Renilla Reporter, GR, FKBP) for 24 h. Total plasmid load are kept constant for all conditions. Stimulation took 
place 24 h prior to lysis. Lysates were transferred and handled as described in methods section 4.4.1 to be read out with a 
Berthold TriStar² LB 942. Each bar represents mean values of a quadruplicate and SEM. Lab book: AHa125 
 
Different FKBP51 constructs have been cotransfected in a dose of 10 ng/well. Wild type FKBP51 
reduced the GR reporter strength at 4 nM Dex, as well as the PPIase deficient mutant (FD67/68DV) 
and the triple mutant, containing three amino acids of the homologues FKBP52 (K58T/K60W/F129V). 
The L119P mutant, another FKBP51-52 swap and especially the TPR mutant (K352A/R356A), which 
is unable to bind Hsp90 proved to be weaker inhibitors of the GR. 
 
 5.2.5.  FKBP52 in the Reporter Gene Assay 
 
  
Figure 24 Effect of the titration of FKBP52 with and without the cotransfection of FKBP51. Normalized signal of N2a 
cells transfected with different amounts of FKBP52 at constant Dex concentrations. 10,000 cells per well in a 96well plate were 
used, transfected with plasmid mix (Firefly reporter, Renilla Reporter, GR, FKBP) for 24 h. Total plasmid load are kept constant 
for all conditions. 0 and 100 nM Dex serve as controls. Stimulation took place for 8 h prior to lysis. Lysates were transferred 
and handled as described in methods section 4.4.1 to be read out with a Berthold TriStar² LB 942. Each bar represents mean 
values of a quadruplicate and SEM. Lab book: AHa126 
FKBP52 is described as functional counter player of FKBP51 in the GR context, enhancing GR 
signaling. An increasing amount of FKBP52 added to the transfection mix enhanced GR signaling both 
in the presence and absence of exogenous FKBP51. FKBP52 is able to completely overrule FKBP51 
inhibition. This effect was only observable after 8 h and not after 24 h stimulation time in the incubator 
(Figure 24). 
 
  
Figure 25 Effect of the titration of FKBP52 with and without the cotransfection of FKBP51. Normalized signal of N2a 
cells transfected with different amounts of FKBP52 at constant Dex concentrations. 10,000 cells per well in a 96well plate were 
used, transfected with plasmid mix (Firefly reporter, Renilla Reporter, GR, FKBP) for 24 h. Total plasmid load are kept constant 
for all conditions. 0 and 100 nM Dex serve as controls. Stimulation took place for 24 h prior to lysis. Lysates were transferred 
and handled as described in methods section 4.4.1 to be read out with a Tecan Infinite M1000. Each bar represents mean 
values of a triplicate and SEM. Lab book: AHa458 
After 24 h of stimulation, increasing amounts of FKBP52 expression plasmid transfected further 
reduced the luminescence, which could be caused by degradation of FKBP52 and increasing cellular 
translational stress (Figure 25). 
 5.2.6. Impact of FKBP51 Ligands in the Reporter Gene Assay 
  
Figure 26 Addition of two FKBP51 ligands at the indicated concentrations with and without overexpression of 
FKBP51. Normalized signal of N2a cells. 10,000 cells per well in a 96well plate were used, transfected with plasmid mix (Firefly 
reporter, Renilla Reporter, GR, FKBP51) for 24 h. Cells were treated for 8 h with MB53 (SAFit1) in blue or MTQ202 in green. 
Stimulation mix was added on top without removing treatment mix. 0 and 100 nM Dex serve as controls. Dexamethasone 
stimulation took 24 h prior to lysis. DMSO concentration and total plasmid load are kept constant for all conditions. Lysates 
were transferred and handled as described in methods section 4.4.1 to be read out in a Tecan Infinite M1000. Each bar 
represents mean values of a quadruplicate and SEM. Lab book: AHa453 
The effects of FKBP51 ligands present in the assay have been tested as well. After transfection, 
ligand containing-medium was added to the cells. Then, the cells were incubated for 8 h. After that, 
stimulation was performed without removing the ligand solution. Figure 26 shows three 
concentrations of MB53 (SAFit1 blue) and MTQ202 (green) added in the presence and absence of 
exogenous FKBP51. While MB53 seems to have a negative impact on GR signaling, MTQ202 
increases the signal under both conditions in a dose-dependent manner. The negative impact of 
SAFit not always occurred. Especially here, the highest concentration of SAFit has no effect in 
absence of exogenous FKBP, indicating an unspecific artifact. 
  
 5.2.7. Overexpression of Glomulin  
 
Due to the fact, that Glmn emerged as interesting interactor of FKBP51 during the course of this thesis, 
a similar reporter gene assay was performed to investigate any effect by the overexpression of Glmn. 
Two eukaryotic expression plasmids carrying Glmn tagged with three FLAG-peptides either N-
terminally (HG 644) or C-terminally (HG 645) were contransfected. Interestingly, 3x-FLAG-Glmn (N-
term.) overexpression shows no effect for both amounts (10 and 30 ng/well) (Figure 27), while Glmn-
3xFLAG (C-term) does increase reporter strength for the transfection load of 30 ng plasmid per well, 
but not for 10 ng/well. This effect is even stronger, if FKBP51 is co-overexpressed. How and if this effect 
is related to FKBP51 cannot be concluded, but Glomulin has a strong impact on GR signaling if its N-
terminus remains unlabeled. 
 
Figure 27 The effect of overexpression of 3xFLAG-Glmn in presence and absence of cotransfected FKBP51 at the 
stimulation of 4 nM Dex. Normalized signal of N2a cells transfected with two amounts of 3xFLAG-Glmn at constant Dex 
concentrations. 10,000 cells per well in a 96well plate were used, transfected with plasmid mix (Firefly reporter, Renilla 
Reporter, GR, FKBP, Glmn) for 24 h. 0 and 100 nM Dex serve as controls. Dexamethasone stimulation was performed for 
24 h prior to lysis. DMSO concentration and total plasmid load are kept constant for all conditions. Lysates were transferred 
and handled as described to be read out in methods section 4.4.1 in a Tecan Infinite M1000. Each bar represents mean values 
of a hexaplicate and SEM. Lab book: AHa464 
 
  
Figure 28 The effect of overexpression of Glmn-3xFLAG in presence and absence of cotransfected FKBP51 at the 
stimulation of 4 nM Dex. Normalized signal of N2a cells transfected with two amounts of 3xFLAG-Glmn at constant Dex 
concentrations. 10,000 cells per well in a 96well plate were used, transfected with plasmid mix (Firefly reporter, Renilla 
Reporter, GR, FKBP, Glmn) for 24 h. 0 and 100 nM Dex serve as controls. Dexamethasone stimulation took 24 h prior to lysis. 
DMSO concentration and total plasmid load are kept constant for all conditions. Lysates were transferred and handled as 
described in methods section 4.4.1 to be read out in a Tecan Infinite M1000. Each bar represents mean values of a hexaplicate 
and SEM. Lab book: AHa464 
The according Firefly and Renilla signals can be found in Suppl. Fig. 62. 
 
5.2.8. FKBP51 in NF-κB Signaling 
 
Via an internal cooperation within the MPI for Psychiatry, reporter gene assays were performed to 
investigate the effect of FKBP51 on NF-κB Signaling as a side project. Two different reporter plasmids 
were used: p1242 addressing the canonical and pNF-κB2 addressing the non-canonical pathway. The 
assay principle is depicted in Figure 29. 
  
Figure 29 Schematic depictution of the assay principle. A signaling cascade, which is induced by TNFα, leads to the 
release of IKKα from the IKK complex. IKKα phosphorylates the NF-κB precursors, which triggers proteolytic cleavage of the 
precursors and the formation of the transcription factor complexes. NF-κB can also be primed by PKC upon its activation by 
PMA. How PKC interacts with NF-κB2 is uncertain. The non-canonical pathway is stimulated by other signaling cascades as 
well, which are excluded here. This is a very strong simplification of the signaling pathway. 
 
Those firefly luciferase carrying reporters were transfected into different cell lines: the standard system 
HEK293T (Figure 30), the melanoma derived A375 line (Figure 31) and Jurkat T cells (Figure 32). 
A375 and Jurkat cells are commonly used to investigate the NF-κB pathway. Overall, experiments were 
performed similar to GR reporter gene assays. Stimulation was performed with either TNFα or PMA. It 
is speculated that PMA activates the non-canonical pathway via a limited set of PKC isoforms [138]. 
Optimal stimulation by PMA was reported for 15 nM [136,139,140]. Therefore, two concentrations higher 
and two concentrations lower have been choosen to stimulate the reporters as well. However, PMA 
treatment with 40 nM and more led to massive cell death of HEK293T and A375 cell (not tested for 
Jurkat). For lower PMA concentrations no detrimental effect was observed.  
 
   
Figure 30 The effect of overexpression of FKBP51 and the stimulation of the NF-κB Pathway in HEK293T cells. 
Normalized signal of HEK293T cells transfected with or without exogenous FKBP51 at increasing stimulant concentration. 
Two different reporter plasmids have been used: p1242 (A and C) and pNF-κB2 (B and D). Stimulation was performed either 
with TNFα (A and B) or PMA (C and D). 10,000 cells per well in a 96well plate were used, transfected with plasmid mix (NF-
κB reporter, Renilla Reporter, FKBP) for 24 h. Stimulation took 20 h prior to lysis. DMSO concentration and total plasmid load 
are kept constant for all conditions. Lysates were transferred and handled as described to be read out in a Berthold TriStar² 
LB 942. Each bar represents mean values of a hexaplicate and SEM. Lab book: AHa109 (analog in AHa94, 97, 103) 
   
Figure 31 The effect of overexpression of FKBP51 and the stimulation of the NF-κB Pathway in A375 cells. Normalized 
signal of A375 cells transfected with or without exogenous FKBP51 at increasing stimulant concentration. Two different 
reporter plasmids have been used: p1242 (A and C) and pNF-κB2 (B and D). Stimulation was performed either with TNFα (A 
and B) or PMA (C and D). 10,000 cells per well in a 96well plate were used, transfected with plasmid mix (NF-κB reporter, 
Renilla Reporter, FKBP) for 24 h. Stimulation took 20 h prior to lysis. DMSO concentration and total plasmid load are kept 
constant for all conditions. Lysates were transferred and handled as described to be read out in a Berthold TriStar² LB 942. 
Each bar represents mean values of a hexaplicate and SEM. Lab book: AHa117 
 
  
Figure 32 The effect of overexpression of FKBP51 and the stimulation of the NF-κB Pathway in Jurkat cells. Normalized 
signal of Jurkat cells transfected with or without exogenous FKBP51 at increasing stimulant concentration. Two different 
reporter plasmids have been used: p1242 (A and C) and pNF-κB2 (B and D). Stimulation was performed either with TNFα (A 
and B) or PMA (C and D). Bars indicated by with a * have been omitted due to cell death at those conditions. 10,000 cells per 
well in a 96well plate were used, transfected with plasmid mix (NF-κB reporter, Renilla Reporter, FKBP) for 24 h. Stimulation 
took 20 h prior to lysis. DMSO concentration and total plasmid load are kept constant for all conditions. Lysates were 
transferred and handled as described to be read out in a Berthold TriStar² LB 942. Each bar represents mean values of a 
hexaplicate and SEM. Lab book: AHa124 
The canonical pathway could be stimulated with TNFα in HEK293T and Jurkat cells and PMA in 
HEK293T cells. The non-canonical pathway responded to TNFα in Jurkat cells and weakly to PMA in 
A375 and HEK293T cells only. The overexpression of FKBP51 at 50 ng/well leads to a reduced signal 
for most stimulatable conditions. This assay has not been optimized with respect to transfection 
amounts and stimulation time. Further follow up would require and optimization of the assay window 
and address the issue if the FKBP51 overexpression effect is robust. 
  
 5.3. Glomulin – FKBP HTRF  
 
During the course of this PhD it several indicators (unpublished) arose, that FKBP51 might be an 
interactor of Glomulin. To address and quantify the Glmn – FKBP-Interaction a homogenous time-
resolved fluorescence (HTRF) assay was developed. The experiments were partly performed by 
Thomas Geiger, a master student under my supervision. His data is labeled with “Lab book: TGe #”. 
Over the time of the experiments two batches of Glmn have been purified and are indicated here as B1 
and B2. 
 
5.3.1. Assay Setup 
 
 
Figure 33 HTRF Setup. Binding of Glmn-GST and FKBP51FK1-5-MF brings both fluorophores (Terbium cryptate and 
Fluorescein) in close proximity and enables FRET. The disruption of this interaction by FKBP ligands or unlabeled FK1 
domains can be tested in a competitive setup. 
 
The constitution of the assay is depicted in Figure 33. For this assay, protein binding partners were 
heterogeneously expressed and purified. Purity was confirmed via SDS-Page (Suppl. Fig. 64). Size 
exclusion chromatograms can be found in Suppl. Fig. 65 to Suppl. Fig. 69. The Glmn construct contains 
a C-terminal GST-Tag. A C-terminal MonoCystein mutant of the FK1 domain of FKBP51 was covalently 
labeled with Fluoresceinmaleimide (5-MF). A Tb-cryptate conjugated antibody binds to the Glmn 
construct. If Glmn und FKBP51FK1 bind in close proximity excitation of the Tb will lead to emission of 
5-MF: Specificity and binding site can be probed with an excess of unlabeled FKBP51FK1 and FKBP51 
ligands.  
 
 5.3.2.  Assay development 
 
  
Figure 34 Establishing the HTRF (A) Activity test of labeled proteins by destructive FRET: Labeled proteins (5 nM) were 
incubated with the TAMRA based fluorescent tracer [4.3.1.]-16g /MTQ238. Fluorescence (Ex: 485±20 nm, Em: 520±10 nm) 
of 5-MF is quenched for higher tracer concentration. Data points (triplicates) are normalized to the “no tracer” value and fitted 
with a one-site-ligand depletion curve. Lab book: AHa485 (B) Assay window depending on Glmn concentration in presence of 
30 nM 5-MF labeled FKBP. Labeled FKBPs, increasing concentrations of Glmn B1 and 0.8 nM αGST-Tb-Cryptate are 
incubated together and FRET was measured. Data (triplicates) is normalized to the corresponding no FKBP control (first bar 
of each set). Suppl. Fig. 72 shows the same data plotted against the respective normalized fluorescence. Lab book: 
AHa382+407.  
In order to check the activity of the 5-MF labeled proteins, an activity assay was performed. An 
increasing amount of fluorescent tracer [4.3.1.]-16g quenched the signal of the conjugated 5-maleimide 
fluorescein in a dose-dependent manner via a destructive FRET (Figure 34 A). This can only be 
achieved, if the tracer binds to the fluorescein labeled protein, indicating that its binding pocket is still 
active and no denaturation of the pocket took place during the labeling. 30 nM of the respective FKBP 
was incubated with increasing concentrations of Glmn. It was possible to observe a FRET signal with 
FKBP51FK1-5-MF to a factor of three above background. This could not be achieved with FKBP12-5-
MF (Figure 34 B).  
 
5.3.3. Active site titrations of FKBPs 
 
The concentration of each unlabeled FKBP used in the HTRF assay was validated via active site 
titration (AST). This is an almost stoichiometric titration since the tracer concentration used is 10 to 100 
times higher than its respective KD. ASTs show a steep hillslope. At their EC50s (half rise to maximum), 
50% of the tracer molecules are equimolar bound to protein. Suppl. Fig. 70 shows the ASTs of FKBP12 
 and FKBP12.6 which exhibit a very different binding affinity towards Glmn. ASTs confirm the determined 
affinities within the HTRF by excluding inactive or denatured proteins within the batch. Since the tracer 
concentration is defined, the protein concentration can be calculated. Proteins were prepared and 
quantified by different people in the lab. An overview of all used FKBPs is given in Table 3. ASTs have 
been performed by different people in the lab, as the reference indicates. The structure of MTQ238 can 
be found in Suppl. Fig. 71. 
 
 
Table 3 Overview of FKBPs used in HTRF assays. All FKBPs were characterized via active site concentration with the 
indicated tracer in the indicated experiment. CK97 is a rapamycin derived tracer. 
Protein Tracer [Tracer]  /  nM cUV /  µM cAST  /  µM Ref
FKBP51FK1 (16-140) MTQ238 50 102 120 AHa463
FKBP51FK1 (1-140) CK97 50 223 456 AHa186
FKBP51FK1 (1-140) F67V CK97 50 113 167 AHa186
FKBP51FK1 (1-140) FD67/ 68DV CK97 50 141 106 AHa186
FKBP52FK1 CK97 50 136 209 ClS231
FKBP12 B1 CK97 50 600 498 ClS203
FKBP12 B2 MTQ238 50 150 130 CMe291
FKBP12.6 B1 CK97 50 88 16 ClS238
FKBP12.6 B2 MTQ238 50 20 17 CMe362
FKBP51FL MTQ238 50 41 136 AHa405
FKBP52FL MTQ238 50 9 25 AHa401
 5.3.4. Binding site specificity 
 
  
Figure 35 Four FKBP51 ligands compete with the interaction of Glmn and FKBP51FK1. 30 nM FKBP51-5-MF, increasing 
amounts of compounds (up to 40 µM), 30 nM Glmn B2 and 0.8 nM αGST-Tb-Cryptate are incubated together and FRET was 
measured. Data (triplicates) is normalized, plotted in GraphPad Prism6 and fitted to a non-linear regression curve. Lab book: 
AHa487 
FKBP51 ligands were tested for their potential to compete with Glmn binding to FKBP51FK1. Figure 
35 shows four competition curves of the ligands SG770 (SAFit1), JK96, FK506 and AV075 which are 
capable to quench the FRET signal. All curves are fitted with a four parameter fit. The half maximal 
inhibitory concentration (IC50) is the high nanomolar for JK96 and FK506 respectively and low 
micromolar range for SG770. The value for AV075 is extrapolated. Higher concentrations for this ligand 
could not be tested due to solubility limitations. 
A similar experiment was performed using a different a different batch Glmn and SAFit1 (MB53) (Figure 
36). Although JK96 binds weaker by a factor of 2 and SAFit by a factor of 4 in that assay under slightly 
different conditions (10 nM Glmn), it confirms the difference of competitive potential of both ligands. 
  
Figure 36 Two FKBP51 ligands compete with the interaction of Glmn and FKBP51FK1. 30 nM FKBP51-5-MF, increasing 
amounts of compounds (up to 10 µM), 10 nM Glmn B1 and 0.8 nM αGST-Tb-Cryptate are incubated together and FRET was 
measured. Data (triplicates) is normalized, plotted in GraphPad Prism6 and fitted to a non-linear regression curve. Lab book: 
AHa387 
 5.3.5. Comparision of different FKBPs 
 
 
Figure 37 Competition of several FKBPs with FKBP51FK1-5-MF for Glmn binding. 30 nM FKBP51-5-MF, increasing 
amounts of the competing proteins FKBP51FK1, FKBP51-FL, FKBP12 (B2) and FKBP12.6 (B2) (up to 10 µM), 30 nM Glmn 
B2 and 0.8 nM αGST-Tb-Cryptate are incubated together and FRET was measured. Data (triplicates) is normalized, plotted 
in GraphPad Prism6 and fitted to a non-linear regression curve. Lab book: TGe71 
The same setup was used to investigate the competitive capabilities of other FKBPs and their potential 
to sequester Glmn and henceforth, lower the FRET signal (Figure 37 and Figure 38). The FK1 domains 
of FKBP51 and 52 showed comparible affinities (400 nM, 470 nM). Although, FKBP12 is the best 
described interactor of Glmn [114,115] it exhibited the weakest competitive capabilities with IC50s in 
micromolar range. On the other side, its close homologue FKBP12.6 proofed to bind rather strong with 
around 140 nM. Interesting as well is the fact, that both full-length proteins show improved binding 
compared to their respecitive FK1 domains. FKBP51 is three-times stronger and FKBP52 almost by a 
factor 50. 
  
Figure 38 Competition of several FKBPs with FKBP51FK1-5-MF for Glmn binding. 30 nM FKBP51-5-MF, increasing 
amounts of the competing proteins FKBP52FK1, FKBP52-FL, FKBP12 (B2) and FKBP12.6 (B2) (up to 10 µM), 30 nM Glmn 
B2 and 0.8 nM αGST-Tb-Cryptate are incubated together and FRET was measured. Data (triplicates) is normalized, plotted 
in GraphPad Prism6 and fitted to a non-linear regression curve. Lab book: TGe76 
These findings were confirmed a another set of experiments, where the assay was performed with a 
different batch of Glmn, in the concentration of 10 nM final instead of 30 nM, and different batches of 
FKBP12 and 12.6 (Figure 39). This assay showed comparable results in the respective IC50 values: 
400 vs. 240 nM for FKBP51FK1, 470 vs. 560 nM for FKBP52FK1, 9,000 vs. 10,000 nM for FKBP12 
and 140 vs. 72 nM for FKBP12.6. This points out a general robustness of this assay towards changes 
of protein batches and Glmn concentration. 
  
Figure 39 Competition of several FKBPs with FKBP51FK1-5-MF for Glmn binding, control with different batches Glmn, 
FKBP12 and FKBP12.6. 30 nM FKBP51-5-MF, increasing amounts of the competing proteins FKBP51FK1, FKBP52FK1, 
FKBP12 (B1) and FKBP12.6 (B1) (up to 1 µM), 10 nM Glmn B1 and 0.8 nM αGST-Tb-Cryptate are incubated together and 
FRET was measured. Data (triplicates) is normalized, plotted in GraphPad Prism6 and fitted to a non-linear regression curve. 
Lab book: AHa393 
 
The differences of competitive binding capability of full length and their respective FK1 domains was 
also confirmed with this batch of Glmn (Figure 40). The IC50s of all tested proteins were about a factor 
3 higher but for FKBP51FL, it still confirms the general trend seen so far: FKBP52FL >FKBP51FL > 
FKBP51FK1 >FKBP52FK1. 
  
Figure 40 Competition of several FKBPs with FKBP51FK1-5-MF for Glmn binding, control with different batches Glmn. 
30 nM FKBP51-5-MF, increasing amounts of the competing proteins FKBP51FK1, FKBP51-FL, FKBP52FK1 and FKBP52-FL 
(up to 1 µM), 10 nM Glmn B1 and 0.8 nM αGST-Tb-Cryptate are incubated together and FRET was measured. Data 
(triplicates) is normalized, plotted in GraphPad Prism6 and fitted to a non-linear regression curve. Lab book: AHa406 
 
5.3.6. Characterization of FKBP51FK1 F67D and FD67/68DV mutants 
 
In order to investigate potential binding sites within the FK1 domain of FKBP51, two mutants showing 
decreased (F67V) and completely blunted PPIase activity (FD67/68DV) were purified. The KD of the 
low affine tracer CK182 (Structure: Suppl. Fig. 71) of wild type and mutant FK1 domains is in the same 
order of magnitude (Figure 41) indicating that the binding pocket remains intact and capable to bind 
small molecular ligands.  
  
Figure 41 Binding curves of the three different FKBP51FK1 domains with the low affine tracer 20 nM CK182. 
FKBP51FK1 (1-140) and mutants F67V and FD67/68DF bind to the tracer with similar affinity in fluorescence binding assay. 
KDs are obtained using GraphPad Prism6 and an one-site depletion fit: Y= A / E * 0.5 *(X + E + 1 / K - sqrt ( sqr ( X + E + 1 / 
K ) - 4 * E * X ))+B. 
Lab book: AHa187 
 5.3.7. Competition of other FKBP51 contructs 
 
  
Figure 42 Competition of various FKBP51FK1 constructs. 30 nM FKBP51-5-MF, increasing amounts of the competing 
proteins FKBP51FK1 (16-140), FKBP51FK1 (1-140), FKBP51FK1 (1-140) F67V and FKBP51FK1 (1-140) FD67/68DV (up to 
1 µM), 10 nM Glmn B1 and 0.8 nM αGST-Tb-Cryptate are incubated together and FRET was measured. Data (triplicates) is 
normalized, plotted in GraphPad Prism6 and fitted to a non-linear regression curve. Lab book: AHa397 
Similar to previous results different FK1 domains of FKBP51 were investigated for their competitive 
binding capability (Figure 42). The N-terminal shortened construct (aa 16-140, red circles) exhibits a 
slightly increased binding compared to the whole FK1 domain. Furthermore, the single respectively 
double point mutations of the FK1 domain of FKBP51 are not or just hardly able to break up the 
bound complex. 
 
5.3.8. Impact of Rbx1 in this HTRF setup 
Under my supervision Thomas Geiger performed competitive HTRF assays also testing Rbx1. Rbx1 
did not show any competition for Glmn binding up to a concentration of 40 µM (Figure 43), while 
FKBP52FK1 did. 
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Figure 43 Competition of Rbx1 with the interaction of Glmn and FKB51FK1. FKBP52FK1 serves as control. 30 nM 
FKBP51-5-MF, 30 nM Glmn, increasing amounts of competing protein (up to 40 µM) and 0.8 nM αGST-Tb-Cryptate are 
incubated together and FRET was measured. Data (triplicates) is normalized, plotted in GraphPad Prism6 and fitted to a non-
linear regression curve. Data was obtained in the same assay as Figure 38. The shown FKBP52FL is identical Lab book: 
TGe76 
We then tested, if the presence of Rbx1 has an impact on the competition of the FKBP51 ligand SAFit 
1 (Figure 44). The addition of 30 and 60 nM respectively, did not alter the IC50 of SAFit1 significantly. 
Intererstingly, the IC50 in this experiment was with 1 to 2 µM way lower than in previous experiment. A 
dilution error has to be assumed. 
  
Figure 44 Competition of the FKBP51 ligand SAFit1 with the interaction of Glmn and FKB51FK1. 30 nM FKBP51-5-MF, 
30 nM Glmn, increasing amounts of SAFit1 (up to 10 µM), 0.8 nM αGST-Tb-Cryptate and 0 / 30 / 60 nM Rbx1 are incubated 
together and FRET was measured. Data (triplicates) is normalized, plotted in GraphPad Prism6 and fitted to a non-linear 
regression curve. Lab book: TGe78 
  
 5.4. FKBP51 and Calcium Influx  
 
FKBPs are descriped as regulators of calcium channels such as RyR1 and TRPC6 [2,141]. Hyperforin, 
a small molecule found in the popular herbal St. Johns wort, which is claimed to be mood enhancing, 
was described both as activator of TRCP6 calcium channels and neurite outgrowth regulator [142-144]. 
In order to investigate a potential impact of FKBP51 on TRPC6, it was tried to set up a calcium uptake 
assay utilizing the Fluor4 assay kit by Invitrogen. In all assays, fluorescence increased upon injection 
independent of the injected solution, which might be due to the chemical shift around the cells and 
detachement from the surface. Stably transfected HEK293 cells expressing TRPC6 and PC12 cells, 
which endogenously express this channel, were stimulated with ATP, DMSO, Hyperforin and the 
Hyperforin derivative Hyp1 (Figure 45). Only the positive control, ATP, which is an unspecific stimulator 
of Ca2+-channels, lead to a quick exponential rise followed by a slow sigmoidal decay. All others 
remained at a rather constant level. 
 
  
Figure 45 Calcium influx into HEK293 cells expressing TRPC6 and PC12 cells. Baseline-corrected fluorescence intensity 
(RLU-RLU0) over time. Time course of 3 min, six wells measured simultaneously, measurement per well every 2.13s. 50,000 
cells per well seeded 24 h prior to measurement and loaded with Fluor-4 dye. Stimulation solution either contained 100 µM 
ATP, DMSO, 10 µM Hyperforin or 20 µM Hyp1. 1st and 3rd row represent each three wells of TRPC6 stable transfected HEK. 
2nd and 4th row represent three wells of PC12 cells. Lab book: AHa160 
 
To verify the functionality of the assay, a similar experiment was performed injecting a 5% SDS solution 
into dye loaded HEK-TRPC6 and PC12 cells. Two conditions have to be met in order to constitute an 
active fluorophore: 1) intracellular cleavage and 2) binding of Ca2+. SDS leads to cell lysis and the 
 exposure of the dye to elevated calcium concentrations in the surrounding media. If the dye was taken 
up by the cells and cleaved, SDS would lead to a signal increase. The addition of EDTA will complex 
Ca2+ and inactived the dye again. Such an assay was performed (Figure 46) and the principal 
functionality of the assay proven. 
 
 
Figure 46 Calcium influx into HEK293 cells expressing TRPC6 and PC12 cells. Baseline-corrected fluorescence intensity 
(RLU-RLU0) over time. Time course of 16 min, six wells measured at once, measurement per well every 2.13s. 50,000 cells 
per well seeded 24 h prior to measurement and loaded with Fluor-4 dye. Instead of stimulant, 50 µL 5% SDS solution was 
added. After 8 min 50 µL of a 60 mM EDTA solution were injected on top (200 µL final volume). Labbok: AHa161 
 
Since the reported TRPC6 stimulants did not show the expected effect in the mentioned cell lines, 
additional substances, namely the activator of phospholipid-dependent protein kinase C 1-oleoyl-2-
acetylglycerol (OAG) and the cholinergic agonist carbachol were tested. HEK293T cells were transiently 
transfected with either TRPC6 or mock plasmid and treated with OAG and Carbachol (Figure 47). While 
 ATP served as robust positive control, OAG did not show any effect at the two used concentrations. 
Using Carbachol, it was possible to stimulate both TRPC6 overexpressing and Mock transfected cells.  
 
Figure 47 Calciuminflux into transient TRPC6 (green) or mock (red) transfected HEK293T. Baseline-corrected 
fluorescence intensity (RLU-RLU0) over time. Time course of 2 min, measurement interval of 0.1 s. 50,000 cells per well 
seeded 24 h prior to transfection with 100 ng/w (HG598 or HG30) for 24 h. Afterwards, cells were loaded with Fluor-4 dye. 
Stimulation solution either contained 100 µM ATP, DMSO, 25 µM OAG, 250 µM OAG, 20 µM Carbachol or 100 µM Carbachol. 
Lab book: AHa180 
 
To exclude artifacts introduced by the transfection and in order to check other stimulants as well, 
HEK293T cells were transfected with either TRPC6 or TRPC6 mutant (Leuner group, FAU Erlangen), 
which is expressed but uncapable of Ca2+ transport. The cells have been subjected to a Calcium-Uptake 
Assay using ATP, DMSO, Hyperforin, Hyp1 and OAG (Figure 48). Again, only ATP lead to Ca2+ influx. 
  
Figure 48 Calcium influx into transient TRPC6 (upper row) or TRPC6 mutant (lower row) transfected HEK. Baseline-
corrected fluorescence intensity (RLU-RLU0) over time. Time course of 3 min, measurement interval of 0.5 s. 50,000 cells per 
well seeded 24 h prior to transfection with 100 ng/w (HG598 or HG658) for 24 h. Afterwards, cells were loaded with Fluor-4 
dye. Stimulation solution either contained 100 µM ATP, DMSO, 20 µM Hyperforin, 20 µM Hyp1 or 20 µM OAG. Lab book: 
AHa210 
  
 6. Discussion 
 
6.1. Summary 
 
In this thesis I present data that further elucidates both the action modes of FKBP51 and the effects of 
FKBP51 ligands. With MTQ202, I identified a PROTAC which robustly knocks down FKBP51 
expression levels in three different cell lines (HEK293, HeLa and N2a), both endogenous and transiently 
overexpressed. Using Western Blot protein detection, MTQ202 shows activity in concentrations higher 
than 60 nM which is confirmed by a reduced luminescence signal of an overexpressed Nanoluc-
FKBP51 fusion protein. The effect of MTQ202 is strongest after 48 h treatment. A competition of 250 nM 
MTQ202 with an 8-fold excess of either SAFit1 or VHL-ligand did not show a reduction of PROTAC 
activity. 
 In order to investigate FKBP51 in its role as cochaperone and regulator of glucocorticoid 
signaling, I successfully established a dual-luciferase-flash reporter gene assay in N2a cells. This assay 
required the cotransfection of a small amount GR in order to establish a sufficient assay window. The 
overexpression of FKBP51 reduced the expression of firefly luciferase in a dose-dependant manner 
without impacting the second luciferase signal. Several mutants of FKBP51 have been tested. A major 
impact was only exhibited by the TPR mutation but not by its active site mutations. The overexpression 
of FKBP52 increased GR signaling after 8 h stimulation but not 24 h. The reporter activity remained 
unaltered by the addition of SAFit1 but could be increased by MTQ202.  
 To investigate the FKBP-Glmn interaction, I developed a competitive HTRF binding setup. This 
HTRF assay confirmed the previously described binding of Glmn towards FK1 domains. Excitingly, 
other FKBPs and FKBP constructs were identified as interactors as well, discovering the novel 
interaction of Glmn and FKBP12.6. The known binder FKBP12 was shown to be a very weak interactor 
within this setup. Full-length FKBP51 and FKBP52 bind stronger than their respective FK1 domains. 
Within the FK1 domains two amino acids, F67 and D68, were identified, which are essential for the 
FKBP51-Glmn interaction. At last, I could demonstrate that this interaction is ligand sensitive, showing 
the very first biochemical activity of synthetic FKBP51 ligands. 
 
 6.2. FKBP51 PROTACs 
 
Testing 62 different PROTACs for FKBP51 revealed a single compound (MTQ202/MTQ416) which 
induced a chemical knockdown in the range of 60 to 2000 nM after 6 h as long as 72 h down to 40% 
compared to FKBP51 levels in untreated cells. This effect was confirmed by the PROTACs action in 
the knockdown of a Nanoluc-FKBP51 construct and its effect in a GR reporter gene assay. Although, 
all SAFit and most bicyclic PROTACs are binding FKBP51 in the low nanomolar range (unpublished, 
PhD Thesis MTQ), their target affinity clearly cannot be translated into knockdown efficacy [43]. This 
phenomenon is commonly seen during the development of PROTACs, which often requires the 
synthesis of a small library to obtain a successful lead compound. The PROTACs developed by Tianqi 
Mao vary in linker length and linker attachment point. The formation of the trimeric complex is thus far 
unpredictable, but the linker is likely involved in mediating contacts instead of just a simple space keeper 
[46]. Therefore, the crystallization of the trimeric FK1-PROTAC-VHL complex might give valuable 
insights into the future development of FKBP-PROTACs.  
Although, HEK293T cells have been treated with up to 2 µM PROTAC, no hook effect was 
observable. The hook effect describes the phenomenon of decreased chemical knockdown at high 
PROTAC concentrations which is believed to be caused by the prefererred formation of dimeric 
complexes (Figure 49). The absence of the hook effect is not unpreceded and some PROTACs are 
only able to knock down their target at relatively high concentration in µM-range (see for example [145]).  
 
 
Figure 49 Hook effect of PROTACs. The excess of PROTACs leads to an increased formation of dimeric complexes, where 
the PROTAC binds either its target or the E3 ligase. The dimeric complexes  
In order to obtain decent Western Blot results, I experienced the importance of the normalization of the 
samples according to their total protein concentration and a careful removal of media prior to lysis and 
 washing step, since leftover media distorts the BCA assay. Additionally, the solubiluty of many 
PROTACs have to be carefully observed during the experiment. Many of the here tested compounds 
precipitated at concentration >4 µM in cell media as they precipitated during the assay preparation. This 
limitation also prevented the observation of a competition effect by either free SAFit or VHL-ligand 
added. An 8-fold excess of both factors did not dampen the knockdown induced by 250 nM MTQ202, 
which is in line with the fact that at maximum tested PROTACs concentration of 2 µM no hook effect 
occurred. An overall challenge was the detection of the GAPDH control band. No systematic cause for 
partial altered GAPDH bands could be identified. The switch to another control would benefit the result 
quality, yet many of them run close FKBP51. In my experience, Hsp90 gives a decent control signal but 
is a rather uncommon loading control and also strongly associated with FKBP51. 
At last, I want to point out a certain possibility, that more than one PROTAC is active, but the 
chemical knockdown was not observable under the applied assay conditions. Recently, Riching, et. al. 
showed in their efforts to develop high-throughput PROTAC-screening methods that especially time 
and concentration will strongly effect knockdown strength [58]. They were able to lable target BRD 
proteins in cells. A newly constituted luciferase-tag provided a luminescence readout in presence of 
stabilized substrate. The indirectly measured protein concentration varied strongly depending on the 
assay condition and the time of the readout.  
Generally, the development of PROTACs would greatly benefit from high-throughput screening 
methods, enabling investigators to vary time, concentration and compounds within the same experiment 
without the workload of Western Blot detection.  
 
6.3. FKBP51 in Glucocorticoid Receptor Signaling 
 
In order to investigate the role of FKBPs and FKBP ligands in GR signaling a dual-luciferase-flash 
reporter gene assay was set up. The co-transfection of low amounts of a HA-GR construct (0.5 ng/well 
per 10,000 cells) was required to obtain a decent assay window, which underlines the low amount of 
endogenous GR present in N2a cells. This neuronal cell line was used for two reasons: On the one 
hand, stress-induced depression is linked to glucocorticoid resistance in the hypothalamus [146]. On 
the other hand, FKBP51-specific ligands showed an impact on the neurite formation of neuronal cells, 
including N2a cells [22]. Both firefly and normalized luciferase signal reached saturation as cells were 
stimulated with more than 100 nM Dexamethasone. The half-maximal signal was observed for 
concentrations around 4 nM. Henceforth, this concentration was used to investigate FKBP51 related 
effects. The titration of FKBP51 plasmid during the transfection led to a dose-dependant decrease of 
reporter signal saturated for concentrations > 10 ng/well per 10,000 cells. The overexpression of 
FKBP52 raised the signal and competed with the FKBP51-induced effect but only after 8 h stimulation 
time and not after 24 h. Those findings confirm the inhibitory model of FKBP51 in GR signaling and its 
functional counterplayer FKBP52. It can be speculated that FKBP52 overexpression raises intracellular 
 coping mechanisms, such as the induction of degradation of this protein, which level off its effects after 
24 h stimulation time.  
 The reporter gene assay setup was also used to transfect different FKBP51 mutants. The 
PPIase mutant (FD67/68DV) had the same inhibitory potency as the wild type as well as the triple 
FKBP51-FKBP52 swap mutant. The L119P is a FKBP51/FKBP52 swap, which is located in a proline-
rich loop on top of the active site. The position 119 is one of the few differences in the very conserved 
binding pocket. Still, this mutant inhibited GR signaling, only mildly weaker than the wild type. The TPR* 
mutant, which was shown not to bind Hsp90 [28], led only to a slightly decreased signal. Those 
observations indicated that an intact PPIase activity is not required for GR signaling and that Hsp90 
binding enhances FKBP51 activity in GR signaling. Nevertheless, the TRP* mutant effect, which only 
dampens but not obliterates FKBP51 inhibition might indicate the presence of more interaction sites 
throughout the protein, concurring with the the model of FKBP51 serving as protein complex scaffold.  
 The presence of SAFit1 did not reverse FKBP51-induced GR inhibition. On the contrary, it 
weakly increases GR inhibition, which might be due to an unspecific side reaction. It has to be noted 
that SAFit1 concentrations greater 5 µM lead to an artificial rise of the normalized signal, due to a 
decreased Renilla signal concomitant with observable cell rounding and detachment. The addition of 
the PROTAC MTQ202 antagonized FKBP51 inhibition independent of the presence of transient 
transfected FKBP51. This supports the hypothesis, that FKBP51 acts independent of its active site and 
the presence of ligands attached to it. I consider it very likely, that the action of FKBP51 selective ligands 
in mouse model studies and in neuronal differentiation might be either hardly GR dependent or not 
represented within this reporter gene assay performed in the murine neublastoma derived N2a cell line. 
This concurs with the observation that single mutations of FKBP51 swapping amino acids with FKBP52 
hardly showed an impact. The triple mutant is unable to bind SAFit1 because it cannot adopt the Phe67-
out confirmation. To confirm this scaffold model, a domain swap mutant (FKBP52FK1-FKBP51FK2-
TPR) should be tested in this assay.  
The FKBP51 PROTAC MTQ202 acts differently compared to SAFit. Instead of a mere binding 
site occupation, it leads to proteosomal degradation of the protein reversing its expression – ligand 
induced removal instead of epitope inhibition. Overall, this assay has the potential to address the 
investigation of the effects of FKBPs and FKBP mutants, but reaches its limitations to study FKBP 
ligands. In order to transfer this assay to other cellular systems, a certain amount of optimization efforts 
have to be invested with respect to transfection, treatment and stimulation conditions. Performing this 
assay in a human cell line would bear the advantage of creating a pure human system which might not 
require the overexpression of the GR. The FKBP constructs and GR used in my experimental setup are 
human and the ligands are generally tested for in-vitro affinity on human but not murine FKBPs. 
 
6.4. FKBP51 in NF-κB Signaling 
 
 While setting up a reporter gene assay using two reporter plasmids for either the canonical or non-
canonical NF-κB pathway, several observations did not concure with previous reports. The non-
canonical pathway was only inducible with TNFα in Jurkat cells providing a very limited assay window 
of a 3-fold induction. PMA proved to be a very weak, but toxic stimulant, only inducing the canonical 
pathway in HEK293 cells. The concentrations greater than 40 nM led to massive cell death of HEK293 
and A375 cells. Since the maximum induction by PMA occurred at 15 nM, it has to be questioned, if 
this stimulation might be unspecific and an overall cellular stressor. My findings indicate, that PMA is 
not a suitable stimulant, contradicting several reports [136,140]. A375 cells are derived from a human 
malignant melanoma, but the primary reporter remained unable to express the firefly reporter in 
presence of stimulants. Due to the fact, that the Renilla reporter showed a decent signal, the preceeding 
transfection was succesful. It has to be assumed, that a general issue with this cell line occurred. A375 
cells are a commonly used cancer cell line to investigate NF-κB signaling [103,104,147]. All data 
presented here, which showed a decent reporter induction, had the same feature in common: 
Overexpression of FKBP51 resulted in a reduced reporter activity. This is the contrary effect as Zannas 
et. al. found recently [148], which used the same cell line and reporter constructs. There are a couple 
of differences in the performance of the assay: 
 
 Hähle Zannas, et. al. 
Overall protocol 1) Seeding into 96 well plate 
2) Transfection in 96 well plate 
1) Transfection of the cell whole 
batch 
2) Seeding into 96 well plate 
Transfection amount of 
FKBP51 
50 ng/well per 105 cells 1 µg per 106 cells 
Stimulation  0 to 20 ng/mL TNFα 25 ng/ml PMA (40 nM) 
375 ng/ml Ionomycin 
 
The co-stimulation with PMA and Ionomycin is widely used to stimulate both NF- κB and NFAT pathway 
in order to study interleukin secretion. This was also represented in the paper for which the reporter 
gene assay was performed under similar stimulation conditions.  
To further confirm any FKBP51 effect, several controls should be introduced into the assay. 
Especially the effect of a PPIase-deficient mutant, a Hsp90 binding disabled TPR mutant and FKBP52 
should be cotransfected in order to exclude an assay artifact, such as translational stress.  
 
6.5. FKBP51 and Glomulin 
 
In my results, I show the binding of several FKBPs and Glmn in a HTRF setup. Variations in the 
respective IC50s occurred without altering the general trends of the different protein affinities. Those 
 shifts appear for all competing proteins or ligands indicating a general error. Generally, increased 
attention should be paid to the environmental conditions during the assay performance. Especially 
assays with purified proteins might be temperature and humidity sensitve if incubated in a lid closed but 
unsealed state at “room temperature”, which I experienced to vary between 12 and 40 °C. A higher 
temperature would affect the HTRF signal by altering the thermodynamics of the interaction. An 
increased concentration of labeled FKBP51FK1-5MF would bind to those competitors without a 
decrease of the HTRF signal. I identified FKBP12.6 as a novel interactor, while FKBP12 remained very 
weak. This novel example of difference can help to understand the difference of action modi those two 
proteins despite their homology for example in RyR1 regulation. It has previously been proposed that 
a limited number of point mutations can reverse binding affinities to the ryanodine receptor [149]. A 
similar test as the HTRF setup might help to identifiy more amino acid sites, which contribute to the 
interaction. Furthermore, the enzymatic essential sites Phe67 and Asp68 of FKBP51 were shown to be 
required to bind Glomulin. In order to identify an overall FKBP interaction surface, those mutations 
should additionally be incorporated into FKBP52FK1 and FKBP12.6. Since full length FKBP51 and 
especially FKBP52 are binding Glmn 3-fold, respectively 50-fold better, the ability to blunt the FK1 
domain might finally lead to an improved understanding of the function of the FK2 domain. If those 
mutated full-length proteins still bind Glmn, it is very likely that either the FK2 or the TPR domain 
positively contribute to the binding. This could also be verified by testing the competitive capability of 
the purified domains alone. Also the respective TPR domains which are overall less conserved as the 
FK1 domains might be of interest. Bracher et. al. showed that the linker between FK1 and FK2 domain 
is more flexible in FKBP52 than it is in FKBP51 [30]. They found two conformational orientations of both 
FKBP52 FK domains. One is “FKBP51-like” and the other one is twisted by 180° (Figure 50). It is 
possible that the twisted conformation makes the FK2 domain more accessable for interaction, which 
cannot occure in FKBP51 and leads to a strongly improved binding of FKBP52 compared to 
FKBP52FK1 and FKBP51. 
 
  
Figure 50 The interface between the FK1 and FK2 domains, overlay of FKBP51 (red) and two conformation of FKBP52: 
“FKBP51-like” (blue) and rotated by 180° (green). Taken from [30]. 
 
I hypothesize that FKBPs represent an additional layer of E3 regulation and propose that FKBPs affect 
Cul/Rbx1-type E3 ligases through sequestration of the Glmn and therefore affecting E3 ligase target 
levels. The overexpression of Glmn was shown to led to an increase of Fbw7 E3 ligase targets such as 
Cyclin E and c-Myc [119]. If Glmn sequestration by FKBPs would prevent Glmn from binding to the E3 
complex, it should impact the target degradation. According to my results such sequestration might be 
FKBP ligand sensitive. 
 
FKBP Inhibitors ┤FKBP ┤Glmn ┤Cul/Rbx1 → Fbw7 self-ubiquitination and degradation → Cyclin E/c-
Myc abundance. 
  
I propose that FKBP inhibitors, which disrupt the FKBP-Glmn complex, will restore the regulatory role 
of Glmn on E3 ligases counteracting the effect of the known Glmn mutants. Investigating this hypothesis 
will improve our understanding of E3 regulation and might foster a novel therapeutic approach to target 
Glmn-associated disorders. 
 
 
6.6. FKBP51 in Calcium Signaling 
 
 FKBPs are associated to calcium channels such as TRPC6 and RyR1. Therefore, a calcium influx 
assay was set up to test a potential impact. The calcium agonists are listed in Table 4. ATP treatment, 
which activates P2X and P2Y receptors, led to an increase of nucleosolic calcium concentrations, as 
did Carbachol, which leads to a release of intracellular stored calcium. 
 
Stimulant Mechanism Reference 
ATP Activates P2X receptors for external influx 
Activates P2Y receptors for stored release 
[150] 
[151] 
Hyperforin and its derivatives Specifically activates TRPC6 [142,143,152] 
OAG Derivative of DAG, both directly bind TRPC6 [153-155] 
Carbachol Agonist for muscarinic acetylcholine receptors, 
release of intracellular stored calcium 
[156,157] 
Table 4 Overview of tested stimulants 
Cells treated with the DAG derivative OAG, Hyperforin and its derivative Hyp1 did not show a 
measurable calcium increase in the reported range of 10 to 30 µM. There is a possibility, that the used 
drugs were degraded as Hyperforin and OAG is light and heat sensitive. Since the literature claimed 
stimulation was not observed, this assay was not pursued further. 
 
6.7. The FKBP51 interactome 
 
In this thesis, my results indicate that FKBP51 exhibits two different action modi. While FKBP51s 
binding to Glmn is mediated via Phe67 and Asp68 in its FK1 domain, their absence does not impact 
FKBP51s inhibitory effect on GR signaling. This concurs with the ligand sensitivity of the FKBP51FK1-
Glmn interaction, while the presence of SAFit shows no major impact within the GR reporter gene 
assay. In order to elucidate the molecular mechanisms of FKBP51 more knowledge of the protein-
protein-interaction sites needs to be acquired. Thus far, no cocrystal structure of FKBP51 with a 
potential client is available (except with Hsp90s MEEDV motif). Here, the homology with the FKBP 
family might be a guide for inspiration.  
All published dimeric crystal structure of FKBPs in complex with client proteins are listed in Table 
5. The two available trimeric complexes of FKBP12 with the FRB of mTOR mediated by Rapamycin 
and Calcineurin mediated by FK506 are excluded. Interestingly, all four structures show a proline close 
to either FKBP12 or FKBP12.6s concording phenylalanin and aspartic acid (Figure 51 to Figure 54). 
Even the trimeric complex of FKBP12, Calcineurin and FK506 finds a proline at that position. I raise the 
hypothesis that those three amino acids might define a common FKBP-client interaction motif. The F-
D sequence is present in many FK1 domains: FKBP51 Pos. 67-68, FKBP52 Pos. 67-68, FKBP12 37-
38, FKBP12.6 Pos. 37-38, FKBP13 66-67, FKBP25 145-146, FKBP65 Pos. 79-80. 
  
 
FKBP Client Remarks Proline 
present near 
Phe - Asp 
PDB 
FKBP12 RyR1 Dimeric complex YES 3J8H [158] 
FKBP12 TGFβ Dimeric complex YES 1B6C [159] 
FKBP12 ACVR1 Dimeric complex YES 3H9R [160] 
FKBP12.6 ACVR1 Dimeric complex YES 4C02 
[10.2210/pdb4C02/pdb] 
Table 5 Overview on published FKBP-client cocrystalstructures 
 
Figure 51 Cocrystalstructure of FKBP12 (blue) and RyR1 (green). Phe and Asp within the FKBP binding pocket are 
depicted in orange. Client prolines close to that pocket are depicted in red. PDB: 3J8H 
  
Figure 52 Cocrystalstructure of FKBP12 (blue) and TGFβ (green). Phe and Asp within the FKBP binding pocket are 
depicted in orange. Client prolines close to that pocket are depicted in red. PDB: 1B6C 
 
Figure 53 Cocrystalstructure of FKBP12 (blue) and ACVR1 (green). Phe and Asp within the FKBP binding pocket are 
depicted in orange. Client prolines close to that pocket are depicted in red. PDB: 3H9R 
  
Figure 54 Cocrystalstructure of FKBP12.6 (blue) and ACVR1 (green). Phe and Asp within the FKBP binding pocket are 
depicted in orange. Client prolines close to that pocket are depicted in red. PDB: 4DRI 
 
An important follow-up towards the shown FKBP-Glmn interaction would be crystallization efforts, which 
not only give more insight into the interaction surface, but have direct implications for drug development 
aiming for a disruption of the interaction. 
 
6.8. Perspectives for ligand development 
 
In summary, I described two different potential modes of action for FKBP51 ligands: The FKBP51-Glmn 
interaction can be interupted in vitro with different classes of ligands – the SAFit class ligand SAFit1, 
the bicyclic compound JK96, and the natural ligand FK506. In this kind of in-vitro assay using purified 
proteins, the addition of the PROTAC MTQ202 would not bear any benefit, since the assay mix does 
not contain the degradation-catalyzing enzymes. The inhibitory effect of FKBP51 in GR signaling could 
neither be obstructed by SAFit1 nor a blunted PPIase pocket. Here, FKBP51 likely serves as a part of 
a multi-protein complex exhibiting scaffold function which is independent enzyme pocket related activity. 
Nevertheless, MTQ202 impacted the reporter activity by degrading FKBP51. An overview can be found 
in Figure 55. 
 
  
Figure 55 Summary of found FKBP51 ligand action in GR signaling and the FKBP-Glmn interaction 
PROTACs and “conventional” ligands do not only distinguish from one another in their way of target 
inhibition but also in their chemical features. 
Especially the development of in-vitro assays would benefite by overcoming the 4 µM limitation. 
More hydrophilic compound derivatives could be applied to both cellular and purified protein utilizing 
assays. With respect to the addition of ligands to cultured cells an increase hydrophiliscity can cause a 
decreased uptake into the cytosol. A competitive BRET setup would be able to observe such a 
drawback. The use of more hydrophilic compounds in purified protein assays bears several advantages: 
1) Higher concentrations of soluble compound has the benefit to allow a more accurate quantification 
by obtaining both plateaus within the compound titration series as shown in my HTRF setup. 2) Any 
assay based on a pulldown or fishing approach will benefit from better soluble ligands, since the HTRF 
setup e.g. identified the IC50 of SAFit1 in the low micromolar range in order to disrupt the Glmn-
FKBP51FK1-5MF binding. In order to identify interaction partners of either FKBPs or FKBP ligands in 
cell lysates, it might occure that ligands thus far are too weak to quantitatively disrupt an already 
established FKBP-protein interaction.  
Table 6 lists the measured HTRF IC50s and their FP-Assay KDs on FKBP51FK1: 
 
 HTRF IC50 in µM FP-Assay KD in nM #-fold difference 
SAFit1 9; 35 20 [40] 1000 
JK96 0.16; 0.37 20 [40] 10 
FK506 0.31 400 [40] similar 
Table 6 Comparision of compound affinities (rounded) in Glmn-HTRF setup and competitive FP-Assay on FKBP51FK1 
It is obvious, that the values of both assays do not correlate. It has to be noted, that both assays utilize 
different FKBP51FK1 contructs: aa 1-140 C103A / C107I / E140C, 5-MF labeled (HTRF) and aa 16-
 140 A19T (FP-Assay). Those different constructs unlikely impact ligand binding since the alterations 
are outsite of the binding pocket and not conserved between FKBP51, FKBP52 and FKBP12. Still, a 
single mutation and especially the fluorescein maleimide labeling procedure can impact the overall 
structure. For this reason, we choose to label the C-terminus which is of greater distance from the 
binding pocket and more likely avoids structural interference. While the values for FK506 are in the 
same order of magnitude, synthetic ligands compete worse in the HTRF. The HTRF assay incubated 
at least for one hour and also overnight ligand affinities tend to get weaker. Therefore, a model of a 
kinetic inert FKBP51FK1-Glmn complex, which cannot be disrupted by ligands seems unlikely. It is 
more likely that the KD of Glmn towards the FK1 domain is much lower than of the tested ligands, which 
would contradict the findings of FK506. To overcome this obstacle, simply more data is required, 
including the testing of more ligands and a similar HTRF with a different FKBP client protein. Different 
FK1 domains should also be utilized and fluorophore labeled as well as FK2 domains, as the respective 
Cysteins are not conserved within the FKBP family and usually not close to the ligand binding pocket. 
The creation of a labeled full-length FKBP51 or 52 might prove more sophisticated, as the greater 
number of Cysteins to mutate can affect the protein structure. The labeling position is of importance as 
well, as the FRET effect is strongly distance depending. 
 This is the first shown FKBP51-protein interaction disruptable by conventional ligands. Although 
those ligands did not impact GR signaling, their respective effects on neurite outgrowth and multiple 
mouse model phenotypes might be effected by one or more direct interactions. A promising target to 
follow up my findings seems to comprise components of the IKK complex. Despite the confusion on 
FKBP51s action within the NF-κB pathway, the increasing amount of publications linked to it urgently 
require a revision via a clear breakdown into single interactions.  
All in all, those findings encourage the development of conventional ligands striving for high-
affinity and selectivity profiles. Nethertheless, relying on FP-Assay data to justify their investigation in 
cellular or even mouse models should be backed up by other in-vitro assays such as my HTRF. 
Despite the conventional ligands, I showed the activity of the FKBP51 PROTAC MTQ202. 
PROTACs acts completely different by the induction of target degradation. This enables MTQ202 to 
decrease intracellular FKBP51 concentration and even target its PPIase pocket and conventional ligand 
insensitive functions, such as a scaffold providing platform. Henceforth, MTQ202 was active in my GR 
reporter gene assay. MTQ202 can serve as a great tool for any kind of cellular assay, since it provides 
the answer to a simple but important question: Do FKBP51 levels matter within a certain context? 
Therefore, PROTACs provide a potent and easy applicable alternative to gene editing and RNAi 
knockdown. The PROTAC is simply added to the cell media and the cells do not need to undergo a 
stressful transfection step, keeping their genome unaltered. MTQ202 seems especially promising, due 
to its long lasting effect. The concept of PROTACs always carried the flaw of being non-adaptive to 
mouse model studies for their comparable large molecular size and predicted ADME profile. This belief 
slowly changes. Some PROTACs carry the potential serving as more than “just” a chemical knockdown 
 tool. Recently, the first PROTAC went into clinical trial phase I [59] and a FKBP12 degrader was shown 
to be active in multiple tissues in mouse – after oral administration [161]. Parallel to the development of 
CRISPR and RNAi technology, PROTACs might have a future in clinics (Figure 56). Further increasing 
the lab internal PROTAC library might lead to a better PROTAC as MTQ202, although the outcome is 
not predictable. Discovery of PROTACs acting on other FKBPs could be a potential side effect.  
 
Figure 56 The schematic illustration of various strategies to inactivate an oncogene or other disease-causing genes 
at the DNA, RNA or protein level by CRISPR, RNAi or PROTAC, respectively. Adopted from [162]. 
 
 
 7. Supplemental Information 
 
7.1. Chemical Knockdown of FKBP51 library 
 
The first set of figures covers 11-point dilution series of the indicated compound. Upper panel 
FKBP51, lower panel GAPDH. Incubation time: 24h. 
 
 
 
Suppl. Fig. 2 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ200. Lab book: TGe14 
 
Suppl. Fig. 3 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ201. Lab book: TGe15 
 
  
Suppl. Fig. 4 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ203. Lab book: TGe21 
 
Suppl. Fig. 5 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ204. Lab book: TGe18 
 
Suppl. Fig. 6 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ205. Lab book: TGe18 
 
Suppl. Fig. 7 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ206. Lab book: TGe19 
 
 
  
Suppl. Fig. 8 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ207. Lab book: TGe19 
 
Suppl. Fig. 9 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ208. Lab book: TGe19 
 
Suppl. Fig. 10 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ229. Lab book: TGe19 
 
Suppl. Fig. 11 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ235. Lab book: TGe18 
The next set of figures covers 11-point dilution series of the indicated compound. Upper panel 
FKBP51, lower panel GAPDH. Incubation time: 48h. 
  
Suppl. Fig. 12 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ328. Lab book: AHa447 
 
Suppl. Fig. 13 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ329. Lab book: AHa442 
 
Suppl. Fig. 14 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ330. Lab book: AHa447 
 
Suppl. Fig. 15 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ331. Lab book: AHa447 
  
Suppl. Fig. 16 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ332. Lab book: AHa447 
 
Suppl. Fig. 17 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ333. Lab book: AHa448 
 
Suppl. Fig. 18 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ334. Lab book: AHa448 
 
Suppl. Fig. 19 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ335. Lab book: AHa442 
  
Suppl. Fig. 20 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ336. Lab book: AHa448 
 
Suppl. Fig. 21 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ337. Lab book: AHa448 
 
Suppl. Fig. 22 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ338. Lab book: AHa450 
 
Suppl. Fig. 23 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ339. Lab book: AHa450 
  
Suppl. Fig. 24 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ340. Lab book: AHa455 
 
Suppl. Fig. 25 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ341. Lab book: AHa450 
 
Suppl. Fig. 26 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ342. Lab book: AHa452 
 
Suppl. Fig. 27 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ343. Lab book: AHa452 
  
Suppl. Fig. 28 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ344. Lab book: AHa344 
 
Suppl. Fig. 29 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ345. Lab book: AHa452 
 
Suppl. Fig. 30 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ346. Lab book: AHa452 
 
Suppl. Fig. 31 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ347. Lab book: AHa442 
  
Suppl. Fig. 32 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ498. Lab book: AHa474 
 
Suppl. Fig. 33 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ502. Lab book: AHa474 
 
Suppl. Fig. 34 Western Blot of HEK293T cell lysates treated with different concentrations of MTQ521. Lab book: AHa474 
The next set of figures shows a “quicktest” of PROTACs of the second series. Upper panel 
FKBP51, lower panel GAPDH. Incubation time: 48h. 
 
Suppl. Fig. 35 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ328 and MTQ329 
  
Suppl. Fig. 36 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ330 and MTQ331 
 
Suppl. Fig. 37 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ332 and MTQ333 
 
Suppl. Fig. 38 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ334 and MTQ335 
  
Suppl. Fig. 39 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ336 and MTQ337 
 
Suppl. Fig. 40 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ338 and MTQ339 
 
Suppl. Fig. 41 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ340 and MTQ341 
  
Suppl. Fig. 42 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ342 and MTQ343 
 
Suppl. Fig. 43 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ344 and MTQ345 
 
Suppl. Fig. 44 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ346 and MTQ347 
The next set of figures shows a “quicktest” of PROTACs of the third series. Upper panel 
FKBP51, lower panel GAPDH. Incubation time: 48h. 
 
  
Suppl. Fig. 45 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ498 and MTQ499 
 
Suppl. Fig. 46 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ500 and MTQ501 
 
Suppl. Fig. 47 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ502 and MTQ508 
  
Suppl. Fig. 48 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ202 and MTQ503 
 
Suppl. Fig. 49 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ504 and MTQ202 
 
Suppl. Fig. 50 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ505 and MTQ506 
  
Suppl. Fig. 51 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ507 and MTQ513 
 
Suppl. Fig. 52 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ509 and MTQ510 
 
Suppl. Fig. 53 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ511 and MTQ512 
  
Suppl. Fig. 54 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ514 and MTQ515 
 
Suppl. Fig. 55 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ516 and MTQ517 
 
Suppl. Fig. 56 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ518 and MTQ519 
  
Suppl. Fig. 57 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ520 and MTQ521 
 
Suppl. Fig. 58 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ522 and MTQ523 
 
Suppl. Fig. 59 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ524 and MTQ525 
  
Suppl. Fig. 60 Western Blot of HEK293T cell lysates treated with three concentrations (duplicates) of MTQ526 and MTQ527 
 
 
 
  
 7.3. Reporter Gene Assays 
 
 
Suppl. Fig. 62 Firefly and Renilla signal for Figure 27 and Figure 28. 
 7.4. HTRF 
 
 
 
  
Suppl. Fig. 63 Labeling of FKBP12-MonoCys with 5-MF on Ni-NTA-Agarose. First row shows the fractions during the column 
wash. Second row shows the elution fractions. 
 
 
Wash fractions 
W1 – W8 
Elution fractions 
E1 – E4 
  
Suppl. Fig. 64 Purified proteins used in the HTRF Assay. Upper panel depicts the Coomassie staining of the indicated proteins. 
Lower panel shows the same SDS-Page gels in GFP-detection mode of LAS-3000, Fujifilm, detecting 5-MF label of 
FKBP51FK1 and FKBP12. Rbx1 is not visible in this scan but a clean band was observable by eye. Lab book: AHa483 
  
 
Suppl. Fig. 65 SEC of Glmn B2 
  
Suppl. Fig. 66 SEC of Glmn B1 
  
Suppl. Fig. 67 SEC of FKBP52FL 
  
Suppl. Fig. 68 SEC of FKBP51FK1 (16-140) A19T 
  
Suppl. Fig. 69 SEC of TEV cleaved Rbx1 
  
 
Suppl. Fig. 70 Active Site Titrations of (A) FKBP12 and (B) FKBP12.6 Assays were performed in triplicates with 50 nM MTQ238 
/FK[4.3.1]-16g tracer. Active protein concentrations were calculated by cAST = ((0.5x cTracer + KD) / EC50) x cUV. Lab book: 
SMe88 and CMe362. Data gratefully taken from Stephanie Merz and Christian Meyners. 
 
 
 
Suppl. Fig. 71 (A) Structure of FK[4.3.1]-16g / MTQ238 and (B) 2b / CK182 
  
 
Suppl. Fig. 72 Titration of Glmn in the presence of labelled FKBP and Tb-αGST. Norm Fluorescence of 520/620 plotted. The 
two sets have been performed in two different experiments using the “Gain Optimal” setting that leads to different overall 
values in between different measurements 
  
 8. Abbrevations 
 
5-MF 
ADME 
AF 
APS 
Fluorescein 5-Maleimide 
Absorption, distribution, metabolism, and excretion 
Anne Fabian 
Ammonium persulfate 
ATP 
BCA 
BRET 
Adenintriphosphat 
Bicinchoninic Acid 
Bioluminescence Resonance Energy Transfer 
Ca2+ 
CKo 
Calciumions 
Christian Kozany 
ClS 
CRISPR 
Claudia Sippel 
Clustered regularly interspaced short palindromic repeats 
C-terminus 
DAG 
Carboxy-terminus 
Diacylglycerol 
DMSO Dimethylsulfoxid 
DTT Dithiothreitol 
EC50 Concentration at which the effect is half maximal 
EDTA Ethylendiamintetraacetat 
EtOH Ethanol 
Em Emission  
Ex Excitation 
FCS Fetale Calf Serum 
FKBP 
FL 
FK506 binding Protein 
Full Length 
FRET Förster Resonance Energy Transfer 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Glmn Glomulin 
GR Glucocorticoid Receptor 
GST Glutathion S-Transferase 
HEK Human embryonal kidney cells 
HTRF Homogenous Time Resolved Fluorescence 
Hsp90 Heat shock protein HSP 90 
IC50# 
IKK 
Concentration at which the inhibition is half maximal 
I-κB kinase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
MB Compounds synthesized by Michael Bauder 
 MEF Mouse embryonal fibroblasts 
MTQ 
N2a 
Compounds synthesized by Tianqi Mao 
Neuro-2a (ATCC® CCL-131™) 
NaAc Sodium acetate 
NaPPi sodium pyrophosphate 
NMR Nuclear magnetic resonance spectroscopy 
N-terminus 
OAG 
Amino-terminus 
1-oleoyl-2-acetyl-sn-glycerol 
PBS 
PKC 
PLL 
PMA 
Phosphate-buffered saline 
Protein kinase C 
poly-L-Lysine 
Phorbol 12-myristate 13-acetate 
PMSF Phenylmethylsulfonylfluorid 
PROTAC proteolysis targeting chimera 
SDS Sodium dodecyl sulfate 
Tb Terbium 
TBS(-T) 
TC 
Tris-buffered saline (-Tween) 
Tissue Culture 
TEMED 
TNFα 
TNFR 
Tetramethylethylenediamine 
tumor necrosis factor α 
tumor necrosis factor receptor 
TRPC6 
Y2H 
Transient Receptor Potential Cation Channel Subfamily C Member 6 
Yeast2Hybrid 
  
 
 
 
 9. Bibliography 
 
 “FKBP51 and FKBP12.6 – novel and tight interactors of Glomulin” Hähle, A., Geiger, T., Merz, 
S., Meyners C., Mao, T., Kolos, J., Hausch, F., in revision  
 
 “Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-kappaB-driven 
inflammation and cardiovascular risk” Zannas, A. S., Jia, M., Hafner, K., Baumert, J., 
Wiechmann, T., Pape, J. C., Arloth, J., Kodel, M., Martinelli, S., Roitman, M., Roh, S., Hähle, 
A., Emeny, R. T., Iurato, S., Carrillo-Roa, T., Lahti, J., Raikkonen, K., Eriksson, J. G., Drake, A. 
J., Waldenberger, M., Wahl, S., Kunze, S., Lucae, S., Bradley, B., Gieger, C., Hausch, F., Smith, 
A. K., Ressler, K. J., Muller-Myhsok, B., Ladwig, K. H., Rein, T., Gassen, N. C., Binder, E. B., 
PNAS., 2019  
 
 “The Many Faces of FKBP51” Hähle, A., Merz, S., Meyners C., Hausch, F. Biomolecules, 2019  
 
 “Chemogenomic Profiling of Human and Microbial FK506-Binding Proteins” Pomplun, S., 
Sippel, C. Hähle, A., Tay, D., Shima, K., Klages, A., Unal, C. M., Riess, B., Toh, H. T., Hansen, 
G., Yoon, H. S., Bracher, A., Preiser, P., Rupp, J., Steinert, M., Hausch, F. J. Med. Chem., 2018  
 
 “Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists 
of the FK506-Binding Protein 51” Gaali S., Feng X., Hähle A., Sippel C., Bracher, A., Hausch, 
F., J. Med. Chem., 2016  
 
 “Crystal structures of the free and ligand-bound FK1-FK2 domain segment of FKBP52 reveal a 
flexible inter-domain hinge.” Bracher, A., Kozany, C., Hähle, A., Wild, P., Zacharias, M., Hausch, 
F., Journal of Molecular Biology, 2013  
  
 10. Acknowledgements 
 
First and foremost, I am grateful to have been surrounded by so many kind, nice and caring people on 
both Munich and Darmstadt, both at work and in my off-time.  
My family, especially my mother Kathrin, my father Jürgen and my dear sister Sabine deserve 
all my gratitude for their continuous support. Although it was difficult for them, to understand what I am 
doing, they helped me moving, listened to me and counselled me during my many fights for quality in 
teaching, lab management and opportunities for international students. Special thoughts are to my 
sister Sarah-Loreen. May my defeats and victories benefit her life. 
I am thankful to my supervisor Prof. Dr. Felix Hausch, who provided me with the opportunity to 
dive deep into science. Through him, I was able to overcome the limitations of my body, mind and soul. 
This gratitude will even grow, as I will treasure the loss of my naivity as I mature in the real world. 
Among my many colleagues, Stephanie Merz deserves the seat of honor in my heart: 
Friendship, shared laughter and tears, connected in winnings and losses, never rejecting, always 
caring. She has the greatest soul I was able to discover in those intense 5 years. Stephi, the world 
might be too heavy to move, but the good will continue pushing! 
Special thanks deserve Sebastian Pomplun, Xixi Feng, Claudia Sippel, Tianqi Mao, Christian 
Meyners, Asat Baischew, Christine Schröpfer and Andreas Voll. Sebastian, Xixi and Claudia guided 
me at the beginning of my work and never fell short of their senior and useful advice. Christian and Asat 
always kept a positive mood in the biochemistry lab and provided tremendously needed scientific 
exchange. Tianqi was the salt in our rather monocultural department broth. Andreas gave me exciting 
and valuable insights into a life and character, which is very different from mine. I am especially grateful 
for his friendship. May it be lasting. 
 A great share of my gratitude goes to Ms. Beslek, the early morning sunshine every Tuesday 
and Thursday, as well as the team of Mr. Schädler. Without his essential skills of fixing urgently required 
infrastructure, most of the presented experiments never could have taken place. 
I am grateful for Ms. Dr. Mada Mevissen, who gave me comfort, when as the situations became 
dire, over and over again. 
My heart reaches out to the men, who teach me humility and an up-site-down view of the world. 
God bless you my dear friends in Guishan Prison Taiwan. I shall not stop reaching out to you. 
The financial and intellectual this work was supported by the Hanns-Seidel Stiftung. 
Finally, I want to thank all the places outside of work where I met so many special, gifted, empathetic 
and passionate people: MPI for Psychiatry, Hochschulsportzentrum Darmstadt, Staatstheater 
Darmstadt, SMD International München, Internationaler Kreis Darmstadt, Bachchor Darmstadt und 
Münchenklang, Johanneskirche Darmstadt and Matthäusdienst München and especially my friends in 
mission in Taiwan. 
  Finally, to everybody who reads this, the most important question of all: What is love? The 
answer is more than “Baby, don’t hurt me”. 
 
 11. Curriculum Vitae 
 
Personal information: 
 
Name: Andreas Hähle 
Date and place of birth: July 6th 1987, Rochlitz 
Citizenship: German 
 
Professional Experience: 
 
Since 9/2014 – 06/2019 
PhD studies starting at the Max-Planck-Institute for Psychiatry later at Technical University Darmstadt 
Research Group Prof. Hausch; Development of cellular and in vitro assays to elucidate protein-protein-
interactions and protein-ligand-interaction 
 
Volunteer Experience: 
 
9/2013 – 7/2014  
Volunteer Internship with Stiftung Marburger Mission in Taiwan 
English- and German Teacher for students and migrant workers, as well as foreign inmate prison 
counselling 
 
08/2006 – 07/2007 
Volunteer Social Year (FSJ), CVJM Lüdenscheid-West 
 
University Education and School: 
 
7/2013 
Degree Master of Science  
 
10/2010 – 7/2013  
Master studies Biochemistry at Ludwig-Maximilians-University Munich and Uppsala University 
(Erasmus semester, 03 – 08/2011) 
 
10/2010  
Degree Bachelor of Science 
10/2007Studies of Chemistry and Biochemistry an der Ludwig-Maximilians-University Munich 
  
09/1998 – 07/2006 
Johann-Mathesius-Gymnasium Rochlitz, High School Diploma: Abitur  
 
Awards: 
 
Promotionsstipendium Hanns-Seidel-Stiftung 
Studienstipendium Konrad-Adenauer-Stiftung 
Auszeichung des Landes Sachsen „Abitur mit 1,0“ 
 
 12. References 
 
1. Gjaltema, R.A.; van der Stoel, M.M.; Boersema, M.; Bank, R.A. Disentangling mechanisms 
involved in collagen pyridinoline cross-linking: The immunophilin FKBP65 is critical for 
dimerization of lysyl hydroxylase 2. Proc Natl Acad Sci U S A 2016, 113, 7142-7147, 
doi:10.1073/pnas.1600074113. 
2. Sinkins, W.G.; Goel, M.; Estacion, M.; Schilling, W.P. Association of immunophilins with 
mammalian TRPC channels. J Biol Chem 2004, 279, 34521-34529, 
doi:10.1074/jbc.M401156200. 
3. Binder, E.B.; Salyakina, D.; Lichtner, P.; Wochnik, G.M.; Ising, M.; Putz, B.; Papiol, S.; Seaman, 
S.; Lucae, S.; Kohli, M.A., et al. Polymorphisms in FKBP5 are associated with increased 
recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 
2004, 36, 1319-1325, doi:10.1038/ng1479. 
4. Klengel, T.; Mehta, D.; Anacker, C.; Rex-Haffner, M.; Pruessner, J.C.; Pariante, C.M.; Pace, 
T.W.; Mercer, K.B.; Mayberg, H.S.; Bradley, B., et al. Allele-specific FKBP5 DNA demethylation 
mediates gene-childhood trauma interactions. Nat Neurosci 2013, 16, 33-41, 
doi:10.1038/nn.3275. 
5. Zannas, A.S.; Wiechmann, T.; Gassen, N.C.; Binder, E.B. Gene-Stress-Epigenetic Regulation 
of FKBP5: Clinical and Translational Implications. Neuropsychopharmacology 2016, 41, 261-
274, doi:10.1038/npp.2015.235. 
6. Matosin, N.; Halldorsdottir, T.; Binder, E.B. Understanding the Molecular Mechanisms 
Underpinning Gene by Environment Interactions in Psychiatric Disorders: The FKBP5 Model. 
Biol Psychiatry 2018, 83, 821-830, doi:10.1016/j.biopsych.2018.01.021. 
7. Touma, C.; Gassen, N.C.; Herrmann, L.; Cheung-Flynn, J.; Bull, D.R.; Ionescu, I.A.; Heinzmann, 
J.M.; Knapman, A.; Siebertz, A.; Depping, A.M., et al. FK506 binding protein 5 shapes stress 
responsiveness: modulation of neuroendocrine reactivity and coping behavior. Biol Psychiatry 
2011, 70, 928-936, doi:10.1016/j.biopsych.2011.07.023. 
8. Gassen, N.C.; Hartmann, J.; Zschocke, J.; Stepan, J.; Hafner, K.; Zellner, A.; Kirmeier, T.; 
Kollmannsberger, L.; Wagner, K.V.; Dedic, N., et al. Association of FKBP51 with priming of 
autophagy pathways and mediation of antidepressant treatment response: evidence in cells, 
mice, and humans. PLoS Med 2014, 11, e1001755, doi:10.1371/journal.pmed.1001755. 
9. Hartmann, J.; Wagner, K.V.; Liebl, C.; Scharf, S.H.; Wang, X.D.; Wolf, M.; Hausch, F.; Rein, T.; 
Schmidt, U.; Touma, C., et al. The involvement of FK506-binding protein 51 (FKBP5) in the 
behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 
2012, 62, 332-339, doi:10.1016/j.neuropharm.2011.07.041. 
10. Sabbagh, J.J.; O'Leary, J.C., 3rd; Blair, L.J.; Klengel, T.; Nordhues, B.A.; Fontaine, S.N.; Binder, 
E.B.; Dickey, C.A. Age-associated epigenetic upregulation of the FKBP5 gene selectively 
impairs stress resiliency. PLoS One 2014, 9, e107241, doi:10.1371/journal.pone.0107241. 
11. O'Leary, J.C., 3rd; Dharia, S.; Blair, L.J.; Brady, S.; Johnson, A.G.; Peters, M.; Cheung-Flynn, 
J.; Cox, M.B.; de Erausquin, G.; Weeber, E.J., et al. A new anti-depressive strategy for the 
elderly: ablation of FKBP5/FKBP51. PLoS One 2011, 6, e24840, 
doi:10.1371/journal.pone.0024840. 
12. Pereira, M.J.; Palming, J.; Svensson, M.K.; Rizell, M.; Dalenback, J.; Hammar, M.; Fall, T.; 
Sidibeh, C.O.; Svensson, P.A.; Eriksson, J.W. FKBP5 expression in human adipose tissue 
increases following dexamethasone exposure and is associated with insulin resistance. 
Metabolism 2014, 63, 1198-1208, doi:10.1016/j.metabol.2014.05.015. 
13. Sidibeh, C.O.; Pereira, M.J.; Abalo, X.M.; G, J.B.; Skrtic, S.; Lundkvist, P.; Katsogiannos, P.; 
Hausch, F.; Castillejo-Lopez, C.; Eriksson, J.W. FKBP5 expression in human adipose tissue: 
potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes. Endocrine 
2018, 62, 116-128, doi:10.1007/s12020-018-1674-5. 
14. Bortsov, A.V.; Smith, J.E.; Diatchenko, L.; Soward, A.C.; Ulirsch, J.C.; Rossi, C.; Swor, R.A.; 
Hauda, W.E.; Peak, D.A.; Jones, J.S., et al. Polymorphisms in the glucocorticoid receptor co-
chaperone FKBP5 predict persistent musculoskeletal pain after traumatic stress exposure. Pain 
2013, 154, 1419-1426, doi:10.1016/j.pain.2013.04.037. 
 15. Linnstaedt, S.D.; Riker, K.D.; Rueckeis, C.A.; Kutchko, K.M.; Lackey, L.; McCarthy, K.R.; Tsai, 
Y.H.; Parker, J.S.; Kurz, M.C.; Hendry, P.L., et al. A Functional riboSNitch in the 3' Untranslated 
Region of FKBP5 Alters MicroRNA-320a Binding Efficiency and Mediates Vulnerability to 
Chronic Post-Traumatic Pain. J Neurosci 2018, 38, 8407-8420, doi:10.1523/JNEUROSCI.3458-
17.2018. 
16. Albu, S.; Romanowski, C.P.; Letizia Curzi, M.; Jakubcakova, V.; Flachskamm, C.; Gassen, N.C.; 
Hartmann, J.; Schmidt, M.V.; Schmidt, U.; Rein, T., et al. Deficiency of FK506-binding protein 
(FKBP) 51 alters sleep architecture and recovery sleep responses to stress in mice. J Sleep 
Res 2014, 23, 176-185, doi:10.1111/jsr.12112. 
17. Stechschulte, L.A.; Qiu, B.; Warrier, M.; Hinds, T.D., Jr.; Zhang, M.; Gu, H.; Xu, Y.; Khuder, 
S.S.; Russo, L.; Najjar, S.M., et al. FKBP51 Null Mice Are Resistant to Diet-Induced Obesity 
and the PPARgamma Agonist Rosiglitazone. Endocrinology 2016, 157, 3888-3900, 
doi:10.1210/en.2015-1996. 
18. Balsevich, G.; Hausl, A.S.; Meyer, C.W.; Karamihalev, S.; Feng, X.; Pohlmann, M.L.; Dournes, 
C.; Uribe-Marino, A.; Santarelli, S.; Labermaier, C., et al. Stress-responsive FKBP51 regulates 
AKT2-AS160 signaling and metabolic function. Nat Commun 2017, 8, 1725, 
doi:10.1038/s41467-017-01783-y. 
19. Maiaru, M.; Tochiki, K.K.; Cox, M.B.; Annan, L.V.; Bell, C.G.; Feng, X.; Hausch, F.; Geranton, 
S.M. The stress regulator FKBP51 drives chronic pain by modulating spinal glucocorticoid 
signaling. Sci Transl Med 2016, 8, 325ra319, doi:10.1126/scitranslmed.aab3376. 
20. Maiaru, M.; Morgan, O.B.; Mao, T.; Breitsamer, M.; Bamber, H.; Pohlmann, M.; Schmidt, M.V.; 
Winter, G.; Hausch, F.; Geranton, S.M. The stress regulator FKBP51: a novel and promising 
druggable target for the treatment of persistent pain states across sexes. Pain 2018, 159, 1224-
1234, doi:10.1097/j.pain.0000000000001204. 
21. Baida, G.; Bhalla, P.; Yemelyanov, A.; Stechschulte, L.A.; Shou, W.; Readhead, B.; Dudley, 
J.T.; Sanchez, E.R.; Budunova, I. Deletion of the glucocorticoid receptor chaperone FKBP51 
prevents glucocorticoid-induced skin atrophy. Oncotarget 2018, 9, 34772-34783, 
doi:10.18632/oncotarget.26194. 
22. Gaali, S.; Kirschner, A.; Cuboni, S.; Hartmann, J.; Kozany, C.; Balsevich, G.; Namendorf, C.; 
Fernandez-Vizarra, P.; Sippel, C.; Zannas, A.S., et al. Selective inhibitors of the FK506-binding 
protein 51 by induced fit. Nat Chem Biol 2015, 11, 33-37, doi:10.1038/nchembio.1699. 
23. Pohlmann, M.L.; Hausl, A.S.; Harbich, D.; Balsevich, G.; Engelhardt, C.; Feng, X.; Breitsamer, 
M.; Hausch, F.; Winter, G.; Schmidt, M.V. Pharmacological Modulation of the Psychiatric Risk 
Factor FKBP51 Alters Efficiency of Common Antidepressant Drugs. Front Behav Neurosci 2018, 
12, 262, doi:10.3389/fnbeh.2018.00262. 
24. Hartmann, J.; Wagner, K.V.; Gaali, S.; Kirschner, A.; Kozany, C.; Ruhter, G.; Dedic, N.; Hausl, 
A.S.; Hoeijmakers, L.; Westerholz, S., et al. Pharmacological Inhibition of the Psychiatric Risk 
Factor FKBP51 Has Anxiolytic Properties. J Neurosci 2015, 35, 9007-9016, 
doi:10.1523/JNEUROSCI.4024-14.2015. 
25. Hahle, A.; Merz, S.; Meyners, C.; Hausch, F. The Many Faces of FKBP51. Biomolecules 2019, 
9, doi:10.3390/biom9010035. 
26. Kozany, C.; Marz, A.; Kress, C.; Hausch, F. Fluorescent probes to characterise FK506-binding 
proteins. Chembiochem 2009, 10, 1402-1410, doi:10.1002/cbic.200800806. 
27. Sinars, C.R.; Cheung-Flynn, J.; Rimerman, R.A.; Scammell, J.G.; Smith, D.F.; Clardy, J. 
Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a 
component of steroid receptor complexes. Proc Natl Acad Sci U S A 2003, 100, 868-873, 
doi:10.1073/pnas.0231020100. 
28. Pirkl, F.; Buchner, J. Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans 
isomerases FKBP51, FKBP52 and Cyp40. J Mol Biol 2001, 308, 795-806, 
doi:10.1006/jmbi.2001.4595. 
29. Chambraud, B.; Rouviere-Fourmy, N.; Radanyi, C.; Hsiao, K.; Peattie, D.A.; Livingston, D.J.; 
Baulieu, E.E. Overexpression of p59-HBI (FKBP59), full length and domains, and 
characterization of PPlase activity. Biochem Biophys Res Commun 1993, 196, 160-166. 
 30. Bracher, A.; Kozany, C.; Hahle, A.; Wild, P.; Zacharias, M.; Hausch, F. Crystal structures of the 
free and ligand-bound FK1-FK2 domain segment of FKBP52 reveal a flexible inter-domain 
hinge. J Mol Biol 2013, 425, 4134-4144, doi:10.1016/j.jmb.2013.07.041. 
31. Kumar, R.; Moche, M.; Winblad, B.; Pavlov, P.F. Combined x-ray crystallography and 
computational modeling approach to investigate the Hsp90 C-terminal peptide binding to 
FKBP51. Sci Rep 2017, 7, 14288, doi:10.1038/s41598-017-14731-z. 
32. Wu, B.; Li, P.; Liu, Y.; Lou, Z.; Ding, Y.; Shu, C.; Ye, S.; Bartlam, M.; Shen, B.; Rao, Z. 3D 
structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid 
receptor/Hsp90/immunophilin heterocomplex. Proc Natl Acad Sci U S A 2004, 101, 8348-8353, 
doi:10.1073/pnas.0305969101. 
33. Wochnik, G.M.; Ruegg, J.; Abel, G.A.; Schmidt, U.; Holsboer, F.; Rein, T. FK506-binding 
proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the 
glucocorticoid receptor in mammalian cells. J Biol Chem 2005, 280, 4609-4616, 
doi:10.1074/jbc.M407498200. 
34. Chen, S.; Sullivan, W.P.; Toft, D.O.; Smith, D.F. Differential interactions of p23 and the TPR-
containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress 
Chaperones 1998, 3, 118-129. 
35. Wilson, K.P.; Yamashita, M.M.; Sintchak, M.D.; Rotstein, S.H.; Murcko, M.A.; Boger, J.; 
Thomson, J.A.; Fitzgibbon, M.J.; Black, J.R.; Navia, M.A. Comparative X-ray structures of the 
major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in 
complex with FK506 and rapamycin. Acta Crystallogr D Biol Crystallogr 1995, 51, 511-521, 
doi:10.1107/S0907444994014514. 
36. Bracher, A.; Kozany, C.; Thost, A.K.; Hausch, F. Structural characterization of the PPIase 
domain of FKBP51, a cochaperone of human Hsp90. Acta Crystallogr D Biol Crystallogr 2011, 
67, 549-559, doi:10.1107/S0907444911013862. 
37. Quinta, H.R.; Maschi, D.; Gomez-Sanchez, C.; Piwien-Pilipuk, G.; Galigniana, M.D. Subcellular 
rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and 
neurite outgrowth. J Neurochem 2010, 115, 716-734, doi:10.1111/j.1471-4159.2010.06970.x. 
38. Cheung-Flynn, J.; Prapapanich, V.; Cox, M.B.; Riggs, D.L.; Suarez-Quian, C.; Smith, D.F. 
Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol 
2005, 19, 1654-1666, doi:10.1210/me.2005-0071. 
39. LeMaster, D.M.; Mustafi, S.M.; Brecher, M.; Zhang, J.; Heroux, A.; Li, H.; Hernandez, G. 
Coupling of Conformational Transitions in the N-terminal Domain of the 51-kDa FK506-binding 
Protein (FKBP51) Near Its Site of Interaction with the Steroid Receptor Proteins. J Biol Chem 
2015, 290, 15746-15757, doi:10.1074/jbc.M115.650655. 
40. Pomplun, S.; Sippel, C.; Hahle, A.; Tay, D.; Shima, K.; Klages, A.; Unal, C.M.; Riess, B.; Toh, 
H.T.; Hansen, G., et al. Chemogenomic Profiling of Human and Microbial FK506-Binding 
Proteins. J Med Chem 2018, 61, 3660-3673, doi:10.1021/acs.jmedchem.8b00137. 
41. Pomplun, S.; Wang, Y.; Kirschner, A.; Kozany, C.; Bracher, A.; Hausch, F. Rational design and 
asymmetric synthesis of potent and neurotrophic ligands for FK506-binding proteins (FKBPs). 
Angew Chem Int Ed Engl 2015, 54, 345-348, doi:10.1002/anie.201408776. 
42. Kolos, J.M.; Voll, A.M.; Bauder, M.; Hausch, F. FKBP Ligands-Where We Are and Where to 
Go? Front Pharmacol 2018, 9, 1425, doi:10.3389/fphar.2018.01425. 
43. An, S.; Fu, L. Small-molecule PROTACs: An emerging and promising approach for the 
development of targeted therapy drugs. EBioMedicine 2018, 36, 553-562, 
doi:10.1016/j.ebiom.2018.09.005. 
44. Sakamoto, K.M.; Kim, K.B.; Kumagai, A.; Mercurio, F.; Crews, C.M.; Deshaies, R.J. Protacs: 
chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and 
degradation. Proc Natl Acad Sci U S A 2001, 98, 8554-8559, doi:10.1073/pnas.141230798. 
45. Schneekloth, A.R.; Pucheault, M.; Tae, H.S.; Crews, C.M. Targeted intracellular protein 
degradation induced by a small molecule: En route to chemical proteomics. Bioorg Med Chem 
Lett 2008, 18, 5904-5908, doi:10.1016/j.bmcl.2008.07.114. 
46. Gadd, M.S.; Testa, A.; Lucas, X.; Chan, K.H.; Chen, W.; Lamont, D.J.; Zengerle, M.; Ciulli, A. 
Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat 
Chem Biol 2017, 13, 514-521, doi:10.1038/nchembio.2329. 
 47. Lu, J.; Qian, Y.; Altieri, M.; Dong, H.; Wang, J.; Raina, K.; Hines, J.; Winkler, J.D.; Crew, A.P.; 
Coleman, K., et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem 
Biol 2015, 22, 755-763, doi:10.1016/j.chembiol.2015.05.009. 
48. Olson, C.M.; Jiang, B.; Erb, M.A.; Liang, Y.; Doctor, Z.M.; Zhang, Z.; Zhang, T.; Kwiatkowski, 
N.; Boukhali, M.; Green, J.L., et al. Pharmacological perturbation of CDK9 using selective CDK9 
inhibition or degradation. Nat Chem Biol 2018, 14, 163-170, doi:10.1038/nchembio.2538. 
49. Ohoka, N.; Okuhira, K.; Ito, M.; Nagai, K.; Shibata, N.; Hattori, T.; Ujikawa, O.; Shimokawa, K.; 
Sano, O.; Koyama, R., et al. In Vivo Knockdown of Pathogenic Proteins via Specific and 
Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs). J Biol 
Chem 2017, 292, 4556-4570, doi:10.1074/jbc.M116.768853. 
50. Buhimschi, A.D.; Armstrong, H.A.; Toure, M.; Jaime-Figueroa, S.; Chen, T.L.; Lehman, A.M.; 
Woyach, J.A.; Johnson, A.J.; Byrd, J.C.; Crews, C.M. Targeting the C481S Ibrutinib-Resistance 
Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. Biochemistry 
2018, 57, 3564-3575, doi:10.1021/acs.biochem.8b00391. 
51. Sun, B.; Fiskus, W.; Qian, Y.; Rajapakshe, K.; Raina, K.; Coleman, K.G.; Crew, A.P.; Shen, A.; 
Saenz, D.T.; Mill, C.P., et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent 
lethal activity against mantle cell lymphoma cells. Leukemia 2018, 32, 343-352, 
doi:10.1038/leu.2017.207. 
52. Zhou, B.; Hu, J.; Xu, F.; Chen, Z.; Bai, L.; Fernandez-Salas, E.; Lin, M.; Liu, L.; Yang, C.Y.; 
Zhao, Y., et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal 
(BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. 
J Med Chem 2018, 61, 462-481, doi:10.1021/acs.jmedchem.6b01816. 
53. Burslem, G.M.; Smith, B.E.; Lai, A.C.; Jaime-Figueroa, S.; McQuaid, D.C.; Bondeson, D.P.; 
Toure, M.; Dong, H.; Qian, Y.; Wang, J., et al. The Advantages of Targeted Protein Degradation 
Over Inhibition: An RTK Case Study. Cell Chem Biol 2018, 25, 67-77 e63, 
doi:10.1016/j.chembiol.2017.09.009. 
54. Bondeson, D.P.; Mares, A.; Smith, I.E.; Ko, E.; Campos, S.; Miah, A.H.; Mulholland, K.E.; Routly, 
N.; Buckley, D.L.; Gustafson, J.L., et al. Catalytic in vivo protein knockdown by small-molecule 
PROTACs. Nat Chem Biol 2015, 11, 611-617, doi:10.1038/nchembio.1858. 
55. Bondeson, D.P.; Smith, B.E.; Burslem, G.M.; Buhimschi, A.D.; Hines, J.; Jaime-Figueroa, S.; 
Wang, J.; Hamman, B.D.; Ishchenko, A.; Crews, C.M. Lessons in PROTAC Design from 
Selective Degradation with a Promiscuous Warhead. Cell Chem Biol 2018, 25, 78-87 e75, 
doi:10.1016/j.chembiol.2017.09.010. 
56. Itoh, Y.; Ishikawa, M.; Naito, M.; Hashimoto, Y. Protein knockdown using methyl bestatin-ligand 
hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of 
cellular retinoic acid-binding proteins. J Am Chem Soc 2010, 132, 5820-5826, 
doi:10.1021/ja100691p. 
57. Okuhira, K.; Demizu, Y.; Hattori, T.; Ohoka, N.; Shibata, N.; Nishimaki-Mogami, T.; Okuda, H.; 
Kurihara, M.; Naito, M. Development of hybrid small molecules that induce degradation of 
estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci 2013, 104, 
1492-1498, doi:10.1111/cas.12272. 
58. Riching, K.M.; Mahan, S.; Corona, C.R.; McDougall, M.; Vasta, J.D.; Robers, M.B.; Urh, M.; 
Daniels, D.L. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC 
Mode of Action. ACS Chem Biol 2018, 13, 2758-2770, doi:10.1021/acschembio.8b00692. 
59. Mullard, A. First targeted protein degrader hits the clinic. Nat Rev Drug Discov 2019, 
10.1038/d41573-019-00043-6, doi:10.1038/d41573-019-00043-6. 
60. Taipale, M.; Tucker, G.; Peng, J.; Krykbaeva, I.; Lin, Z.Y.; Larsen, B.; Choi, H.; Berger, B.; 
Gingras, A.C.; Lindquist, S. A quantitative chaperone interaction network reveals the 
architecture of cellular protein homeostasis pathways. Cell 2014, 158, 434-448, 
doi:10.1016/j.cell.2014.05.039. 
61. Schopf, F.H.; Biebl, M.M.; Buchner, J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol 
2017, 18, 345-360, doi:10.1038/nrm.2017.20. 
62. Smith, D.F.; Faber, L.E.; Toft, D.O. Purification of unactivated progesterone receptor and 
identification of novel receptor-associated proteins. J Biol Chem 1990, 265, 3996-4003. 
 63. Smith, D.F.; Albers, M.W.; Schreiber, S.L.; Leach, K.L.; Deibel, M.R., Jr. FKBP54, a novel 
FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. J Biol 
Chem 1993, 268, 24270-24273. 
64. Smith, D.F.; Whitesell, L.; Nair, S.C.; Chen, S.; Prapapanich, V.; Rimerman, R.A. Progesterone 
receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 
1995, 15, 6804-6812. 
65. Mayer, M.P.; Le Breton, L. Hsp90: breaking the symmetry. Mol Cell 2015, 58, 8-20, 
doi:10.1016/j.molcel.2015.02.022. 
66. Rohl, A.; Rohrberg, J.; Buchner, J. The chaperone Hsp90: changing partners for demanding 
clients. Trends Biochem Sci 2013, 38, 253-262, doi:10.1016/j.tibs.2013.02.003. 
67. Cheung-Flynn, J.; Roberts, P.J.; Riggs, D.L.; Smith, D.F. C-terminal sequences outside the 
tetratricopeptide repeat domain of FKBP51 and FKBP52 cause differential binding to Hsp90. J 
Biol Chem 2003, 278, 17388-17394, doi:10.1074/jbc.M300955200. 
68. Scheufler, C.; Brinker, A.; Bourenkov, G.; Pegoraro, S.; Moroder, L.; Bartunik, H.; Hartl, F.U.; 
Moarefi, I. Structure of TPR domain-peptide complexes: critical elements in the assembly of the 
Hsp70-Hsp90 multichaperone machine. Cell 2000, 101, 199-210, doi:10.1016/S0092-
8674(00)80830-2. 
69. Schulke, J.P.; Wochnik, G.M.; Lang-Rollin, I.; Gassen, N.C.; Knapp, R.T.; Berning, B.; 
Yassouridis, A.; Rein, T. Differential impact of tetratricopeptide repeat proteins on the steroid 
hormone receptors. PLoS One 2010, 5, e11717, doi:10.1371/journal.pone.0011717. 
70. Li, J.; Richter, K.; Buchner, J. Mixed Hsp90-cochaperone complexes are important for the 
progression of the reaction cycle. Nat Struct Mol Biol 2011, 18, 61-66, doi:10.1038/nsmb.1965. 
71. Echeverria, P.C.; Picard, D. Molecular chaperones, essential partners of steroid hormone 
receptors for activity and mobility. Biochim Biophys Acta 2010, 1803, 641-649, 
doi:10.1016/j.bbamcr.2009.11.012. 
72. Barent, R.L.; Nair, S.C.; Carr, D.C.; Ruan, Y.; Rimerman, R.A.; Fulton, J.; Zhang, Y.; Smith, D.F. 
Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with 
progesterone receptor complexes. Mol Endocrinol 1998, 12, 342-354, 
doi:10.1210/mend.12.3.0075. 
73. Baughman, G.; Wiederrecht, G.J.; Chang, F.; Martin, M.M.; Bourgeois, S. Tissue distribution 
and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin 
inhibition. Biochem Biophys Res Commun 1997, 232, 437-443. 
74. Reynolds, P.D.; Roveda, K.P.; Tucker, J.A.; Moore, C.M.; Valentine, D.L.; Scammell, J.G. 
Glucocorticoid-resistant B-lymphoblast cell line derived from the Bolivian squirrel monkey 
(Saimiri boliviensis boliviensis). Lab Anim Sci 1998, 48, 364-370. 
75. Wan, Y.; Nordeen, S.K. Identification of genes differentially regulated by glucocorticoids and 
progestins using a Cre/loxP-mediated retroviral promoter-trapping strategy. J Mol Endocrinol 
2002, 28, 177-192. 
76. Vermeer, H.; Hendriks-Stegeman, B.I.; van der Burg, B.; van Buul-Offers, S.C.; Jansen, M. 
Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid 
expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin 
Endocrinol Metab 2003, 88, 277-284, doi:10.1210/jc.2002-020354. 
77. Kester, H.A.; van der Leede, B.M.; van der Saag, P.T.; van der Burg, B. Novel progesterone 
target genes identified by an improved differential display technique suggest that progestin-
induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J 
Biol Chem 1997, 272, 16637-16643. 
78. Hubler, T.R.; Denny, W.B.; Valentine, D.L.; Cheung-Flynn, J.; Smith, D.F.; Scammell, J.G. The 
FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates 
progestin responsiveness. Endocrinology 2003, 144, 2380-2387, doi:10.1210/en.2003-0092. 
79. Hubler, T.R.; Scammell, J.G. Intronic hormone response elements mediate regulation of FKBP5 
by progestins and glucocorticoids. Cell Stress Chaperones 2004, 9, 243-252. 
80. Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; 
Leysens, M.; Higgins, B., et al. Dysregulated expression of androgen-responsive and 
nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-
R1. Cancer Res 2000, 60, 6134-6141. 
 81. Mousses, S.; Wagner, U.; Chen, Y.; Kim, J.W.; Bubendorf, L.; Bittner, M.; Pretlow, T.; Elkahloun, 
A.G.; Trepel, J.B.; Kallioniemi, O.P. Failure of hormone therapy in prostate cancer involves 
systematic restoration of androgen responsive genes and activation of rapamycin sensitive 
signaling. Oncogene 2001, 20, 6718-6723, doi:10.1038/sj.onc.1204889. 
82. Zhu, W.; Zhang, J.S.; Young, C.Y. Silymarin inhibits function of the androgen receptor by 
reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. 
Carcinogenesis 2001, 22, 1399-1403. 
83. Paakinaho, V.; Makkonen, H.; Jaaskelainen, T.; Palvimo, J.J. Glucocorticoid receptor activates 
poised FKBP51 locus through long-distance interactions. Mol Endocrinol 2010, 24, 511-525, 
doi:10.1210/me.2009-0443. 
84. Riggs, D.L.; Roberts, P.J.; Chirillo, S.C.; Cheung-Flynn, J.; Prapapanich, V.; Ratajczak, T.; 
Gaber, R.; Picard, D.; Smith, D.F. The Hsp90-binding peptidylprolyl isomerase FKBP52 
potentiates glucocorticoid signaling in vivo. EMBO J 2003, 22, 1158-1167, 
doi:10.1093/emboj/cdg108. 
85. Riggs, D.L.; Cox, M.B.; Tardif, H.L.; Hessling, M.; Buchner, J.; Smith, D.F. Noncatalytic role of 
the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling. 
Mol Cell Biol 2007, 27, 8658-8669, doi:10.1128/MCB.00985-07. 
86. Ebong, I.O.; Beilsten-Edmands, V.; Patel, N.A.; Morgner, N.; Robinson, C.V. The interchange 
of immunophilins leads to parallel pathways and different intermediates in the assembly of 
Hsp90 glucocorticoid receptor complexes. Cell Discov 2016, 2, 16002, 
doi:10.1038/celldisc.2016.2. 
87. Stechschulte, L.A.; Hinds, T.D., Jr.; Khuder, S.S.; Shou, W.; Najjar, S.M.; Sanchez, E.R. 
FKBP51 controls cellular adipogenesis through p38 kinase-mediated phosphorylation of 
GRalpha and PPARgamma. Mol Endocrinol 2014, 28, 1265-1275, doi:10.1210/me.2014-1022. 
88. Antunica-Noguerol, M.; Budzinski, M.L.; Druker, J.; Gassen, N.C.; Sokn, M.C.; Senin, S.; Aprile-
Garcia, F.; Holsboer, F.; Rein, T.; Liberman, A.C., et al. The activity of the glucocorticoid receptor 
is regulated by SUMO conjugation to FKBP51. Cell Death Differ 2016, 23, 1579-1591, 
doi:10.1038/cdd.2016.44. 
89. Sabbagh, J.J.; Cordova, R.A.; Zheng, D.; Criado-Marrero, M.; Lemus, A.; Li, P.; Baker, J.D.; 
Nordhues, B.A.; Darling, A.L.; Martinez-Licha, C., et al. Targeting the FKBP51/GR/Hsp90 
Complex to Identify Functionally Relevant Treatments for Depression and PTSD. ACS Chem 
Biol 2018, 13, 2288-2299, doi:10.1021/acschembio.8b00454. 
90. Criado-Marrero, M.; Rein, T.; Binder, E.B.; Porter, J.T.; Koren, J., 3rd; Blair, L.J. Hsp90 and 
FKBP51: complex regulators of psychiatric diseases. Philos Trans R Soc Lond B Biol Sci 2018, 
373, doi:10.1098/rstb.2016.0532. 
91. DeMorrow, S. Role of the Hypothalamic-Pituitary-Adrenal Axis in Health and Disease. Int J Mol 
Sci 2018, 19, doi:10.3390/ijms19040986. 
92. Garabedian, M.J.; Harris, C.A.; Jeanneteau, F. Glucocorticoid receptor action in metabolic and 
neuronal function. F1000Res 2017, 6, 1208, doi:10.12688/f1000research.11375.1. 
93. Ni, L.; Yang, C.S.; Gioeli, D.; Frierson, H.; Toft, D.O.; Paschal, B.M. FKBP51 promotes assembly 
of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer 
cells. Mol Cell Biol 2010, 30, 1243-1253, doi:10.1128/MCB.01891-08. 
94. Periyasamy, S.; Hinds, T., Jr.; Shemshedini, L.; Shou, W.; Sanchez, E.R. FKBP51 and Cyp40 
are positive regulators of androgen-dependent prostate cancer cell growth and the targets of 
FK506 and cyclosporin A. Oncogene 2010, 29, 1691-1701, doi:10.1038/onc.2009.458. 
95. Caratti, G.; Matthews, L.; Poolman, T.; Kershaw, S.; Baxter, M.; Ray, D. Glucocorticoid receptor 
function in health and disease. Clin Endocrinol (Oxf) 2015, 83, 441-448, doi:10.1111/cen.12728. 
96. Pei, H.; Li, L.; Fridley, B.L.; Jenkins, G.D.; Kalari, K.R.; Lingle, W.; Petersen, G.; Lou, Z.; Wang, 
L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer 
Cell 2009, 16, 259-266, doi:10.1016/j.ccr.2009.07.016. 
97. Luo, K.; Li, Y.; Yin, Y.; Li, L.; Wu, C.; Chen, Y.; Nowsheen, S.; Hu, Q.; Zhang, L.; Lou, Z., et al. 
USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT 
signaling. EMBO J 2017, 36, 1434-1446, doi:10.15252/embj.201695669. 
 98. Yu, J.; Qin, B.; Wu, F.; Qin, S.; Nowsheen, S.; Shan, S.; Zayas, J.; Pei, H.; Lou, Z.; Wang, L. 
Regulation of Serine-Threonine Kinase Akt Activation by NAD(+)-Dependent Deacetylase 
SIRT7. Cell Rep 2017, 18, 1229-1240, doi:10.1016/j.celrep.2017.01.009. 
99. Fabian, A.K.; Marz, A.; Neimanis, S.; Biondi, R.M.; Kozany, C.; Hausch, F. InterAKTions with 
FKBPs--mutational and pharmacological exploration. PLoS One 2013, 8, e57508, 
doi:10.1371/journal.pone.0057508. 
100. Gassen, N.C.; Hartmann, J.; Zannas, A.S.; Kretzschmar, A.; Zschocke, J.; Maccarrone, G.; 
Hafner, K.; Zellner, A.; Kollmannsberger, L.K.; Wagner, K.V., et al. FKBP51 inhibits GSK3beta 
and augments the effects of distinct psychotropic medications. Mol Psychiatry 2016, 21, 277-
289, doi:10.1038/mp.2015.38. 
101. Jiang, W.; Cazacu, S.; Xiang, C.; Zenklusen, J.C.; Fine, H.A.; Berens, M.; Armstrong, B.; Brodie, 
C.; Mikkelsen, T. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin 
treatment by regulating NF-kappaB signaling pathway. Neoplasia 2008, 10, 235-243. 
102. Kastle, M.; Kistler, B.; Lamla, T.; Bretschneider, T.; Lamb, D.; Nicklin, P.; Wyatt, D. FKBP51 
modulates steroid sensitivity and NFkappaB signalling: A novel anti-inflammatory drug target. 
Eur J Immunol 2018, 48, 1904-1914, doi:10.1002/eji.201847699. 
103. Romano, S.; D'Angelillo, A.; Pacelli, R.; Staibano, S.; De Luna, E.; Bisogni, R.; Eskelinen, E.L.; 
Mascolo, M.; Cali, G.; Arra, C., et al. Role of FK506-binding protein 51 in the control of apoptosis 
of irradiated melanoma cells. Cell Death Differ 2010, 17, 145-157, doi:10.1038/cdd.2009.115. 
104. Romano, S.; Xiao, Y.; Nakaya, M.; D'Angelillo, A.; Chang, M.; Jin, J.; Hausch, F.; Masullo, M.; 
Feng, X.; Romano, M.F., et al. FKBP51 employs both scaffold and isomerase functions to 
promote NF-kappaB activation in melanoma. Nucleic Acids Res 2015, 43, 6983-6993, 
doi:10.1093/nar/gkv615. 
105. Srivastava, S.K.; Bhardwaj, A.; Arora, S.; Tyagi, N.; Singh, A.P.; Carter, J.E.; Scammell, J.G.; 
Fodstad, O.; Singh, S. Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, 
angiogenesis and metastasis. Br J Cancer 2015, 112, 1772-1781, doi:10.1038/bjc.2015.154. 
106. Romano, M.F.; Avellino, R.; Petrella, A.; Bisogni, R.; Romano, S.; Venuta, S. Rapamycin inhibits 
doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma 
cells. Eur J Cancer 2004, 40, 2829-2836, doi:10.1016/j.ejca.2004.08.017. 
107. Zhang, Q.; Lenardo, M.J.; Baltimore, D. 30 Years of NF-kappaB: A Blossoming of Relevance to 
Human Pathobiology. Cell 2017, 168, 37-57, doi:10.1016/j.cell.2016.12.012. 
108. Cildir, G.; Low, K.C.; Tergaonkar, V. Noncanonical NF-kappaB Signaling in Health and Disease. 
Trends Mol Med 2016, 22, 414-429, doi:10.1016/j.molmed.2016.03.002. 
109. Mitchell, S.; Vargas, J.; Hoffmann, A. Signaling via the NFkappaB system. Wiley Interdiscip Rev 
Syst Biol Med 2016, 8, 227-241, doi:10.1002/wsbm.1331. 
110. Akiyama, T.; Shiraishi, T.; Qin, J.; Konno, H.; Akiyama, N.; Shinzawa, M.; Miyauchi, M.; 
Takizawa, N.; Yanai, H.; Ohashi, H., et al. Mitochondria-nucleus shuttling FK506-binding protein 
51 interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated expression of 
type I IFN. PLoS One 2014, 9, e95992, doi:10.1371/journal.pone.0095992. 
111. Bouwmeester, T.; Bauch, A.; Ruffner, H.; Angrand, P.O.; Bergamini, G.; Croughton, K.; Cruciat, 
C.; Eberhard, D.; Gagneur, J.; Ghidelli, S., et al. A physical and functional map of the human 
TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004, 6, 97-105, 
doi:10.1038/ncb1086. 
112. Erlejman, A.G.; De Leo, S.A.; Mazaira, G.I.; Molinari, A.M.; Camisay, M.F.; Fontana, V.; Cox, 
M.B.; Piwien-Pilipuk, G.; Galigniana, M.D. NF-kappaB transcriptional activity is modulated by 
FK506-binding proteins FKBP51 and FKBP52: a role for peptidyl-prolyl isomerase activity. J Biol 
Chem 2014, 289, 26263-26276, doi:10.1074/jbc.M114.582882. 
113. Hinz, M.; Broemer, M.; Arslan, S.C.; Otto, A.; Mueller, E.C.; Dettmer, R.; Scheidereit, C. Signal 
responsiveness of IkappaB kinases is determined by Cdc37-assisted transient interaction with 
Hsp90. J Biol Chem 2007, 282, 32311-32319, doi:10.1074/jbc.M705785200. 
114. Chambraud, B.; Radanyi, C.; Camonis, J.H.; Shazand, K.; Rajkowski, K.; Baulieu, E.E. FAP48, 
a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. 
Prevention by the immunosuppressant drugs FK506 and rapamycin. J Biol Chem 1996, 271, 
32923-32929. 
 115. Neye, H. Mutation of FKBP associated protein 48 (FAP48) at proline 219 disrupts the interaction 
with FKBP12 and FKBP52. Regul Pept 2001, 97, 147-152. 
116. Brouillard, P.; Boon, L.M.; Mulliken, J.B.; Enjolras, O.; Ghassibe, M.; Warman, M.L.; Tan, O.T.; 
Olsen, B.R.; Vikkula, M. Mutations in a novel factor, glomulin, are responsible for glomuvenous 
malformations ("glomangiomas"). Am J Hum Genet 2002, 70, 866-874, doi:10.1086/339492. 
117. Pashkova, N.; Gakhar, L.; Winistorfer, S.C.; Yu, L.; Ramaswamy, S.; Piper, R.C. WD40 repeat 
propellers define a ubiquitin-binding domain that regulates turnover of F box proteins. Mol Cell 
2010, 40, 433-443, doi:10.1016/j.molcel.2010.10.018. 
118. Bashir, T.; Dorrello, N.V.; Amador, V.; Guardavaccaro, D.; Pagano, M. Control of the SCF(Skp2-
Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004, 428, 190-193, 
doi:10.1038/nature02330. 
119. Tron, A.E.; Arai, T.; Duda, D.M.; Kuwabara, H.; Olszewski, J.L.; Fujiwara, Y.; Bahamon, B.N.; 
Signoretti, S.; Schulman, B.A.; DeCaprio, J.A. The glomuvenous malformation protein Glomulin 
binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7. Mol Cell 2012, 46, 67-
78, doi:10.1016/j.molcel.2012.02.005. 
120. Duda, D.M.; Olszewski, J.L.; Tron, A.E.; Hammel, M.; Lambert, L.J.; Waddell, M.B.; Mittag, T.; 
DeCaprio, J.A.; Schulman, B.A. Structure of a glomulin-RBX1-CUL1 complex: inhibition of a 
RING E3 ligase through masking of its E2-binding surface. Mol Cell 2012, 47, 371-382, 
doi:10.1016/j.molcel.2012.05.044. 
121. Suzuki, S.; Suzuki, T.; Mimuro, H.; Mizushima, T.; Sasakawa, C. Shigella hijacks the glomulin-
cIAPs-inflammasome axis to promote inflammation. EMBO Rep 2018, 19, 89-101, 
doi:10.15252/embr.201643841. 
122. Suzuki, S.; Mimuro, H.; Kim, M.; Ogawa, M.; Ashida, H.; Toyotome, T.; Franchi, L.; Suzuki, M.; 
Sanada, T.; Suzuki, T., et al. Shigella IpaH7.8 E3 ubiquitin ligase targets glomulin and activates 
inflammasomes to demolish macrophages. Proc Natl Acad Sci U S A 2014, 111, E4254-4263, 
doi:10.1073/pnas.1324021111. 
123. Brouillard, P.; Boon, L.M.; Revencu, N.; Berg, J.; Dompmartin, A.; Dubois, J.; Garzon, M.; 
Holden, S.; Kangesu, L.; Labreze, C., et al. Genotypes and phenotypes of 162 families with a 
glomulin mutation. Mol Syndromol 2013, 4, 157-164, doi:10.1159/000348675. 
124. Brouillard, P.; Ghassibe, M.; Penington, A.; Boon, L.M.; Dompmartin, A.; Temple, I.K.; Cordisco, 
M.; Adams, D.; Piette, F.; Harper, J.I., et al. Four common glomulin mutations cause two thirds 
of glomuvenous malformations ("familial glomangiomas"): evidence for a founder effect. J Med 
Genet 2005, 42, e13, doi:10.1136/jmg.2004.024174. 
125. Gassen, N.C.; Fries, G.R.; Zannas, A.S.; Hartmann, J.; Zschocke, J.; Hafner, K.; Carrillo-Roa, 
T.; Steinbacher, J.; Preissinger, S.N.; Hoeijmakers, L., et al. Chaperoning epigenetics: FKBP51 
decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant 
paroxetine. Sci Signal 2015, 8, ra119, doi:10.1126/scisignal.aac7695. 
126. Jirawatnotai, S.; Sharma, S.; Michowski, W.; Suktitipat, B.; Geng, Y.; Quackenbush, J.; Elias, 
J.E.; Gygi, S.P.; Wang, Y.E.; Sicinski, P. The cyclin D1-CDK4 oncogenic interactome enables 
identification of potential novel oncogenes and clinical prognosis. Cell Cycle 2014, 13, 2889-
2900, doi:10.4161/15384101.2014.946850. 
127. Jinwal, U.K.; Koren, J., 3rd; Borysov, S.I.; Schmid, A.B.; Abisambra, J.F.; Blair, L.J.; Johnson, 
A.G.; Jones, J.R.; Shults, C.L.; O'Leary, J.C., 3rd, et al. The Hsp90 cochaperone, FKBP51, 
increases Tau stability and polymerizes microtubules. J Neurosci 2010, 30, 591-599, 
doi:10.1523/JNEUROSCI.4815-09.2010. 
128. Gaali, S.; Feng, X.; Hahle, A.; Sippel, C.; Bracher, A.; Hausch, F. Rapid, Structure-Based 
Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding 
Protein 51. J Med Chem 2016, 59, 2410-2422, doi:10.1021/acs.jmedchem.5b01355. 
129. Hamilton, C.L.; Abney, K.A.; Vasauskas, A.A.; Alexeyev, M.; Li, N.; Honkanen, R.E.; Scammell, 
J.G.; Cioffi, D.L. Serine/threonine phosphatase 5 (PP5C/PPP5C) regulates the ISOC channel 
through a PP5C-FKBP51 axis. Pulm Circ 2018, 8, 2045893217753156, 
doi:10.1177/2045893217753156. 
130. Kadeba, P.I.; Vasauskas, A.A.; Chen, H.; Wu, S.; Scammell, J.G.; Cioffi, D.L. Regulation of 
store-operated calcium entry by FK506-binding immunophilins. Cell Calcium 2013, 53, 275-285, 
doi:10.1016/j.ceca.2012.12.008. 
 131. Lopez, E.; Berna-Erro, A.; Hernandez-Cruz, J.M.; Salido, G.M.; Redondo, P.C.; Rosado, J.A. 
Immunophilins are involved in the altered platelet aggregation observed in patients with type 2 
diabetes mellitus. Curr Med Chem 2013, 20, 1912-1921. 
132. Lopez, E.; Berna-Erro, A.; Salido, G.M.; Rosado, J.A.; Redondo, P.C. FKBP52 is involved in the 
regulation of SOCE channels in the human platelets and MEG 01 cells. Biochim Biophys Acta 
2013, 1833, 652-662, doi:10.1016/j.bbamcr.2012.11.029. 
133. Lopez, E.; Berna-Erro, A.; Salido, G.M.; Rosado, J.A.; Redondo, P.C. FKBP25 and FKBP38 
regulate non-capacitative calcium entry through TRPC6. Biochim Biophys Acta 2015, 1853, 
2684-2696, doi:10.1016/j.bbamcr.2015.07.023. 
134. Martinez, N.J.; Chang, H.M.; Borrajo Jde, R.; Gregory, R.I. The co-chaperones Fkbp4/5 control 
Argonaute2 expression and facilitate RISC assembly. RNA 2013, 19, 1583-1593, 
doi:10.1261/rna.040790.113. 
135. Novotna, A.; Pavek, P.; Dvorak, Z. Construction and characterization of a reporter gene cell line 
for assessment of human glucocorticoid receptor activation. Eur J Pharm Sci 2012, 47, 842-
847, doi:10.1016/j.ejps.2012.10.003. 
136. Oswald, F.; Liptay, S.; Adler, G.; Schmid, R.M. NF-kappaB2 is a putative target gene of activated 
Notch-1 via RBP-Jkappa. Mol Cell Biol 1998, 18, 2077-2088, doi:10.1128/mcb.18.4.2077. 
137. Hampf, M.; Gossen, M. A protocol for combined Photinus and Renilla luciferase quantification 
compatible with protein assays. Anal Biochem 2006, 356, 94-99, doi:10.1016/j.ab.2006.04.046. 
138. Holden, N.S.; Squires, P.E.; Kaur, M.; Bland, R.; Jones, C.E.; Newton, R. Phorbol ester-
stimulated NF-kappaB-dependent transcription: roles for isoforms of novel protein kinase C. Cell 
Signal 2008, 20, 1338-1348, doi:10.1016/j.cellsig.2008.03.001. 
139. Hellweg, C.E.; Arenz, A.; Bogner, S.; Schmitz, C.; Baumstark-Khan, C. Activation of nuclear 
factor kappa B by different agents: influence of culture conditions in a cell-based assay. Ann N 
Y Acad Sci 2006, 1091, 191-204, doi:10.1196/annals.1378.066. 
140. Liptay, S.; Schmid, R.M.; Nabel, E.G.; Nabel, G.J. Transcriptional regulation of NF-kappa B2: 
evidence for kappa B-mediated positive and negative autoregulation. Mol Cell Biol 1994, 14, 
7695-7703, doi:10.1128/mcb.14.12.7695. 
141. Avila, G.; Lee, E.H.; Perez, C.F.; Allen, P.D.; Dirksen, R.T. FKBP12 binding to RyR1 modulates 
excitation-contraction coupling in mouse skeletal myotubes. J Biol Chem 2003, 278, 22600-
22608, doi:10.1074/jbc.M205866200. 
142. Leuner, K.; Li, W.; Amaral, M.D.; Rudolph, S.; Calfa, G.; Schuwald, A.M.; Harteneck, C.; Inoue, 
T.; Pozzo-Miller, L. Hyperforin modulates dendritic spine morphology in hippocampal pyramidal 
neurons by activating Ca(2+) -permeable TRPC6 channels. Hippocampus 2013, 23, 40-52, 
doi:10.1002/hipo.22052. 
143. Leuner, K.; Kazanski, V.; Muller, M.; Essin, K.; Henke, B.; Gollasch, M.; Harteneck, C.; Muller, 
W.E. Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. 
FASEB J 2007, 21, 4101-4111, doi:10.1096/fj.07-8110com. 
144. Heiser, J.H.; Schuwald, A.M.; Sillani, G.; Ye, L.; Muller, W.E.; Leuner, K. TRPC6 channel-
mediated neurite outgrowth in PC12 cells and hippocampal neurons involves activation of 
RAS/MEK/ERK, PI3K, and CAMKIV signaling. J Neurochem 2013, 127, 303-313, 
doi:10.1111/jnc.12376. 
145. Schiedel, M.; Herp, D.; Hammelmann, S.; Swyter, S.; Lehotzky, A.; Robaa, D.; Olah, J.; Ovadi, 
J.; Sippl, W.; Jung, M. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis 
Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). J Med Chem 
2018, 61, 482-491, doi:10.1021/acs.jmedchem.6b01872. 
146. Cohen, S.; Janicki-Deverts, D.; Doyle, W.J.; Miller, G.E.; Frank, E.; Rabin, B.S.; Turner, R.B. 
Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl 
Acad Sci U S A 2012, 109, 5995-5999, doi:10.1073/pnas.1118355109. 
147. Romano, S.; Mallardo, M.; Romano, M.F. FKBP51 and the NF-kappaB regulatory pathway in 
cancer. Curr Opin Pharmacol 2011, 11, 288-293, doi:10.1016/j.coph.2011.04.011. 
148. Zannas, A.S.; Jia, M.; Hafner, K.; Baumert, J.; Wiechmann, T.; Pape, J.C.; Arloth, J.; Kodel, M.; 
Martinelli, S.; Roitman, M., et al. Epigenetic upregulation of FKBP5 by aging and stress 
contributes to NF-kappaB-driven inflammation and cardiovascular risk. Proc Natl Acad Sci U S 
A 2019, 116, 11370-11379, doi:10.1073/pnas.1816847116. 
 149. Xin, H.B.; Rogers, K.; Qi, Y.; Kanematsu, T.; Fleischer, S. Three amino acid residues determine 
selective binding of FK506-binding protein 12.6 to the cardiac ryanodine receptor. J Biol Chem 
1999, 274, 15315-15319. 
150. Swanson, K.D.; Reigh, C.; Landreth, G.E. ATP-stimulated activation of the mitogen-activated 
protein kinases through ionotrophic P2X2 purinoreceptors in PC12 cells. Difference in 
purinoreceptor sensitivity in two PC12 cell lines. J Biol Chem 1998, 273, 19965-19971, 
doi:10.1074/jbc.273.32.19965. 
151. Dong, X.; Smoll, E.J.; Ko, K.H.; Lee, J.; Chow, J.Y.; Kim, H.D.; Insel, P.A.; Dong, H. P2Y 
receptors mediate Ca2+ signaling in duodenocytes and contribute to duodenal mucosal 
bicarbonate secretion. Am J Physiol Gastrointest Liver Physiol 2009, 296, G424-432, 
doi:10.1152/ajpgi.90314.2008. 
152. Muller, M.; Essin, K.; Hill, K.; Beschmann, H.; Rubant, S.; Schempp, C.M.; Gollasch, M.; 
Boehncke, W.H.; Harteneck, C.; Muller, W.E., et al. Specific TRPC6 channel activation, a novel 
approach to stimulate keratinocyte differentiation. J Biol Chem 2008, 283, 33942-33954, 
doi:10.1074/jbc.M801844200. 
153. Estacion, M.; Li, S.; Sinkins, W.G.; Gosling, M.; Bahra, P.; Poll, C.; Westwick, J.; Schilling, W.P. 
Activation of human TRPC6 channels by receptor stimulation. J Biol Chem 2004, 279, 22047-
22056, doi:10.1074/jbc.M402320200. 
154. Estacion, M.; Sinkins, W.G.; Jones, S.W.; Applegate, M.A.; Schilling, W.P. Human TRPC6 
expressed in HEK 293 cells forms non-selective cation channels with limited Ca2+ permeability. 
J Physiol 2006, 572, 359-377, doi:10.1113/jphysiol.2005.103143. 
155. Riazanski, V.; Gabdoulkhakova, A.G.; Boynton, L.S.; Eguchi, R.R.; Deriy, L.V.; Hogarth, D.K.; 
Loaec, N.; Oumata, N.; Galons, H.; Brown, M.E., et al. TRPC6 channel translocation into 
phagosomal membrane augments phagosomal function. Proc Natl Acad Sci U S A 2015, 112, 
E6486-6495, doi:10.1073/pnas.1518966112. 
156. Schmidt, M.; Bienek, C.; van Koppen, C.J.; Michel, M.C.; Jakobs, K.H. Differential calcium 
signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type. Naunyn 
Schmiedebergs Arch Pharmacol 1995, 352, 469-476. 
157. Carroll, R.C.; Peralta, E.G. The m3 muscarinic acetylcholine receptor differentially regulates 
calcium influx and release through modulation of monovalent cation channels. EMBO J 1998, 
17, 3036-3044, doi:10.1093/emboj/17.11.3036. 
158. Yan, Z.; Bai, X.; Yan, C.; Wu, J.; Li, Z.; Xie, T.; Peng, W.; Yin, C.; Li, X.; Scheres, S.H.W., et al. 
Structure of the rabbit ryanodine receptor RyR1 at near-atomic resolution. Nature 2015, 517, 
50-55, doi:10.1038/nature14063. 
159. Huse, M.; Chen, Y.G.; Massague, J.; Kuriyan, J. Crystal structure of the cytoplasmic domain of 
the type I TGF beta receptor in complex with FKBP12. Cell 1999, 96, 425-436. 
160. Chaikuad, A.; Alfano, I.; Kerr, G.; Sanvitale, C.E.; Boergermann, J.H.; Triffitt, J.T.; von Delft, F.; 
Knapp, S.; Knaus, P.; Bullock, A.N. Structure of the bone morphogenetic protein receptor ALK2 
and implications for fibrodysplasia ossificans progressiva. J Biol Chem 2012, 287, 36990-36998, 
doi:10.1074/jbc.M112.365932. 
161. Sun, X.; Wang, J.; Yao, X.; Zheng, W.; Mao, Y.; Lan, T.; Wang, L.; Sun, Y.; Zhang, X.; Zhao, 
Q., et al. A chemical approach for global protein knockdown from mice to non-human primates. 
Cell Discov 2019, 5, 10, doi:10.1038/s41421-018-0079-1. 
162. Guo, J.; Liu, J.; Wei, W. Degrading proteins in animals: "PROTAC"tion goes in vivo. Cell Res 
2019, 29, 179-180, doi:10.1038/s41422-019-0144-9. 
 
